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ABSTRACT
Brust, Tarsis F. Ph.D., Purdue University, August 2015. Functional Selectivity
Downstream of Gαi/o-coupled receptors. Major professor: Val J. Watts.
G protein-coupled receptors (GPCRs) are drug targets that often activate multiple
signaling pathways. The multiple GPCR responses provide opportunities for biased or
functionally selective ligands to preferentially modulate one signaling pathway over
another. Studies with several GPCRs have suggested that selective activation of signaling
pathways downstream of a GPCR may lead to safer and more effective drug therapies.
The dopamine D2 receptor is the main target in therapies for Parkinson’s disease and
schizophrenia. First and second generation antipsychotic drugs antagonize dopamine D2
receptor. Notably, both these classes of drugs may cause side effects associated with D2
receptor antagonism (e.g. hyperprolactemia and extrapyramidal symptoms). The novel,
“third generation” antipsychotic drug, aripiprazole is also used to treat schizophrenia,
with the remarkable advantage that its tendency to cause extrapyramidal symptoms is
minimal. In this work we studied the molecular pharmacology of aripiprazole and
showed that the compound displays ligand bias for modulation of G proteins, being a
partial agonist for Gαi/o and a robust antagonist for Gβγ signaling. We have also
examined the activation of immediate effectors of the dopamine D2 receptor (i.e. Gαi/o,
Gβγ, β-arrestin recruitment) and more complex signaling pathways (i.e., extracellular
signal-regulated kinase phosphorylation, heterologous sensitization, and dynamic mass
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redistribution) in response to a series of D2 receptor ligands. The most commonly used
methods to measure ligand bias were employed and compared. Functional selectivity
analyses were also employed as tools to explore the relative contribution of immediate
dopamine D2 receptor effectors for the activation of more complex signaling pathways.
We have further identified novel classes of AC1 inhibitors through both chemical library
screening and structure-activity relationship studies. The effects of our best inhibitor
(W001) on acute and chronic signaling through the µ-opioid receptor were also
examined, revealing an alternative method to induce functional selectivity (i.e. by
targeting signaling components that are downstream of GPCRs). Lastly, we showed that
W001, which is the most potent selective small molecule AC1 inhibitor described to date,
has analgesic properties in a mouse model of inflammatory pain.
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CHAPTER 1. INTRODUCTION

1.1

G protein-coupled receptors

G protein-coupled receptors (GPCRs – also termed seven-transmembrane domain
receptors) are membrane proteins whose main function is to transfer signals from the
extracellular space to the intracellular space. With nearly 1000 genes, GPCRs represent
the largest family of known proteins in the human genome (Fredriksson et al., 2003;
Hanson and Stevens, 2009). GPCRs are metabotropic receptors involved in a number of
physiological processes. From the autonomic sympathetic and parasympathetic nervous
systems to the fine motor control pathways in the basal ganglia, the roles of GPCRs
encompass virtually all neurological functions (Beaulieu and Gainetdinov, 2011;
Lefkowitz, 2004). Moreover, various different types of stimuli that include peptides,
proteins, ions, lipids, odorants, photons, nucleotides, and small molecules with diverse
chemical structures can activate GPCRs (Fredriksson et al., 2003).

1.1.1

Therapeutic relevance
Considering the diversity and prominent physiological relevance of GPCRs, it is

not surprising that this class of membrane proteins is heavily targeted for numerous
therapies. It is estimated that nearly 36% of all FDA (US Food and Drug
Administration)-approved drugs directly target GPCRs
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(Overington et al., 2006; Rask-Andersen et al., 2011). Drugs targeting GPCRs are
typically among the drugs with the highest sales. For instance, it has been reported that in
2006 approximately 32% of the drugs with the highest sales in the United States targeted
GPCRs (Rask-Andersen et al., 2011). Additionally, in 2010 30% of the drugs with the
highest sales in the world targeted GPCRs (Rask-Andersen et al., 2011). GPCRs are also
indirectly targeted in a number of other therapies. For example, the serotonin reuptake
inhibitors, commonly used in therapies for treating depressive disorders, increase the
amounts of serotonin in synapses, but the actions of this neurotransmitter are achieved
through activation of GPCRs (Belmaker and Agam, 2008; Svenningsson et al., 2013).
Similarly, angiotensin-converting enzyme (ACE) inhibitors indirectly inhibit GPCRs (i.e.
angiotensin receptors) through inhibition of the synthesis of its endogenous ligand (Li et
al., 2014).

1.1.2

Families of G protein-coupled receptors
The superfamily of GPCRs has been clustered according to several different

grouping methods (Attwood and Findlay, 1994; Fredriksson et al., 2003; Kolakowski,
1994). Structural features, physiological functions, and ligand binding mechanisms
represent systems used to classify GPCRs in different families. One of the most accepted
methods for classifying human GPCRs was described by Fredriksson and colleagues in
2003 (Fredriksson et al., 2003). Fredriksson et al. (2003) used similarities in GPCR
sequences from the human genome to perform multiple phylogenetic analyses. In their
system they described five main families of human GPCRs: adhesion (24 members),
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frizzled/taste2 (24 members), glutamate (15 members), rhodopsin (701 members), and
secretin (15 members) (Fredriksson et al., 2003).
The adhesion receptor family contains receptors with adhesion-like domains in
the N terminus. The frizzled/taste2 receptor family is composed of frizzled receptors and
TAS2 receptors. The glutamate receptor family encompasses metabotropic glutamate
receptors, GABA (γ-aminobutyric acid) receptors, a calcium sensing receptor, and taste
receptors. The rhodopsin receptor family, as the largest family of this classification
system, can be further divided into four main groups (i.e. α, β, γ, and δ). The α-group has
89 members that include prostaglandin receptors, amine receptors, opsin receptors,
melatonin receptors, and MECA (melanocortin, endothelial differentiation, cannabinoid,
and adenosine) receptors. The β-group is composed of 35 receptors and the known
ligands to all receptors in this group are peptides. The γ-group is composed of SOG
(somatostatin, opioid, and GPR7/GPR8) receptors, MCH (melanin-concentrating
hormone) receptors, and chemokine receptors. The δ-group contains MAS-related
receptors, glycoprotein receptors, purin receptors and olfactory receptors. The secretin
receptor family is composed of 15 receptors, and among others includes the secretin
receptor, the calcitonin receptor, growth hormone-releasing receptor, and the glucagonlike peptide receptor (Fredriksson et al., 2003). All GPCRs studied herein are in the
rhodopsin family. Dopamine receptors pertain to the amine cluster of the α-group, while
opioid receptors belong to the SOG cluster of the γ-group (Fredriksson et al., 2003;
Hanson and Stevens, 2009).

!
1.1.3

4
Structure of G protein-coupled receptors
GPCRs are membrane proteins composed of seven transmembrane helical

segments designated as TM I through TM VII (Hanson and Stevens, 2009; Katritch et al.,
2013). The first structural clues on GPCRs came in the 1980’s with the sequencing of
rhodopsin and the cloning of the β2-adrenergic receptor (Dixon et al., 1986; Nathans and
Hogness, 1984). These studies provided significant insights on the general structural
arrangement of GPCRs. Nearly a decade later, in 1997 the presence and arrangement of
the seven transmembrane α-helices were confirmed using two-dimensional crystals of
frog rhodopsin (Unger et al., 1997). The relative structural stability and abundant
expression in bovine retina made rhodopsin the ideal receptor for the initial GPCR
structural studies (Kobilka, 2013). And in 2000 the first high-resolution (i.e. 2.8 Å) threedimensional structure of a GPCR was solved by Palczewiski and colleagues for bovine
rhodopsin (Palczewski et al., 2000). Since then, the structures of 27 different GPCRs
were determined using X-ray crystallography (Chien et al., 2010; Dore et al., 2014; Geng
et al., 2013; Granier et al., 2012; Haga et al., 2012; Hanson et al., 2012; Hollenstein et al.,
2013; Jaakola et al., 2008; Kruse et al., 2012; Manglik et al., 2012; Palczewski et al.,
2000; Rasmussen et al., 2007; Rasmussen et al., 2011b; Shimamura et al., 2011; Siu et
al., 2013; Srivastava et al., 2014; Tan et al., 2013; Thompson et al., 2012; Wacker et al.,
2013; Wang et al., 2013a; Wang et al., 2013b; Warne et al., 2008; White et al., 2012; Wu
et al., 2010; Wu et al., 2012; Wu et al., 2014; Zhang et al., 2012; Zhang et al., 2014).
Most of the GPCR structures published to date reflect the inactive conformations
of the receptors, however, rhodopsin, the adenosine A2A receptor, and the β2-adrenergic
receptor have also been crystalized in active states (Rasmussen et al., 2011a; Standfuss et
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al., 2011; Xu et al., 2011). Moreover, the β2-adrenergic receptor has also been crystalized
in complex with a heterotrimeric G protein (Rasmussen et al., 2011b). These studies
together with biochemical and spectroscopy methods are being used to determine how the
extracellular interaction of the receptor with an agonist leads to intracellular signaling
events (Katritch et al., 2013; Venkatakrishnan et al., 2013). Despite the notable
differences among the distinct GPCRs, the structures of the receptors in the active state
reveal a few conformational changes that, although with different magnitudes, appear to
be shared by these (and perhaps most) GPCRs. One of them happens in the intracellular
side and is characterized by an outward movement of helix VI that happens
simultaneously with a motion in helix V (Katritch et al., 2013; Schwartz et al., 2006). The
intracellular portion of helix VII also undergoes a characteristic inward movement toward
the middle of the receptor axis. Helix III goes through an upward shift along its axis and a
small lateral movement (Katritch et al., 2013).
The GPCR structures also revealed that the region with the most notable structural
divergence is the extracellular loop region (Wheatley et al., 2012). This is not surprising
when considering that this region typically constitutes the ligand binding domains. The
variability in the extracellular loop region creates binding pockets with unique sizes,
electrostatic properties, and shapes, which account for the substantial diversity among the
ligands of GPCRs (Katritch et al., 2013; Wheatley et al., 2012).
The activation of GPCRs by their ligands results in a dynamic equilibrium of a
number of different conformational states that leads to the activation of several signaling
pathways (Katritch et al., 2013; Venkatakrishnan et al., 2013). Some ligands appear to
have higher affinities for a specific subset of receptor conformational states, which may
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lead to selective activation of certain signaling pathways (Katritch et al., 2013;
Venkatakrishnan et al., 2013). For instance, it was shown that for the β2-adrenergic
receptor, balanced ligands that equally activate G proteins and β-arrestin cause striking
conformational changes in helices VI and VII; in contrast, a biased ligand, that
selectively activates β-arrestin and does not cause G protein signaling, specifically shifts
helix VII to an active conformation, and leaves helix VI in its inactive conformation (Liu
et al., 2012b). This study suggests that conformational changes in helix VI are associated
with G protein activation and structural rearrangements in helix VII are linked to βarrestin recruitment (Katritch et al., 2013; Liu et al., 2012b; Venkatakrishnan et al.,
2013). These results are in agreement with the crystal structure of the β2-adrenergic
receptor-G protein complex, which shows that helix VII does not interact with the G
protein (Rasmussen et al., 2011b). Future studies of receptor dynamics using biophysical
and computational techniques should aid in identifying the different conformational states
that take place during receptor activation and how they relate to different signaling
outcomes. These studies will assist the design and development of functionally selective
ligands (see section 1.2 below).

1.1.4

Signaling properties of G protein coupled receptors

1.1.4.1 Signaling cycle
The interaction of an agonist with a GPCR leads to conformational changes in the
receptor that ultimately induce an active state of heterotrimeric G proteins through the
replacement of bound guanosine diphosphate (GDP) by guanosine triphosphate (GTP) in
the Gα subunit (Nygaard et al., 2013; Rasmussen et al., 2011b; Venkatakrishnan et al.,
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2013). G protein activation causes dissociation/rearrangement of the Gα subunit and Gβγ
subunits that lead to diverse signaling events through a variety of effectors (Khan et al.,
2013; Lefkowitz and Shenoy, 2005; Lefkowitz, 2004; Rasmussen et al., 2011b).
Following activation of G proteins, G protein-coupled receptor kinases (GRK) can
phosphorylate the receptor, allowing β-arrestin to be recruited to the GPCR (Katritch et
al., 2013; Lefkowitz and Shenoy, 2005; Lefkowitz, 2004). Recruitment of β-arrestin can
lead to receptor desensitization, as well as diverse β-arrestin-mediated signaling events
(figure 1.1) (Kenakin, 2014a; Lefkowitz and Shenoy, 2005).

GRK
ß-arrestin

Gα

β
γ

Signaling

Desensitization

Signaling

Figure 1.1 Signaling through GPCRs. Following receptor activation there is activation
of heterotrimeric G proteins, which can lead to signaling events through Gα and Gβγ
dependent mechanisms. Next, GRKs phosphorylate the receptor, thus allowing β-arrestin
recruitment, which can cause desensitization of the receptor and also signal transduction.
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1.1.4.2 Gα subunits
Heterotrimeric G proteins are composed of three different subunits denoted α, β,
and γ (Birnbaumer, 1992; Birnbaumer, 2007). There are four main classes of Gα subunits
that are grouped according to their signaling outcomes as Gαs, Gαi/o, Gαq/11, and Gα12/13
(table 1.1) (Birnbaumer, 2007; Moreira, 2014; Neubig and Siderovski, 2002; Worzfeld et
al., 2008). Gαs subunits activate adenylyl cyclases and, therefore, cause an increase in the
intracellular levels of cyclic adenosine monophosphate (cAMP), which binds to and
activates protein kinase A (PKA) (Birnbaumer, 2007; Rasmussen et al., 2011b; Suhara et
al., 2002). Conversely, Gαi/o subunits inhibit adenylyl cyclases and lead to a decrease in
the cAMP levels (Birnbaumer, 2007; Suhara et al., 2002; Watts et al., 1998). Gαq/11
subunits activate phospholipase C (PLC), which then cleaves phosphatidylinositol 4,5bisphosphate (PIP2) into diacylglycerol and inositol 1,4,5-trisphosphate (IP3) (SanchezFernandez et al., 2014). Diacylglycerol activates protein kinase C (PKC), and IP3
interacts with and activates calcium channels in the endoplasmic reticulum to increase
intracellular calcium levels (Birnbaumer, 2007; Sanchez-Fernandez et al., 2014). Gα12/13
subunits activate RhoGEF, which leads to the activation of the small GTPase RhoA
(Siehler, 2009; Worzfeld et al., 2008). The main focus of the work presented herein is on
the dopamine D2 receptor and the µ-opioid receptor, both of which couple to Gαi/o
subunits.
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Table 1.1 Classes of Gα subunits and their signaling outcomes.
Gα protein class

Class members

Signaling outcome

Gα s

Gαs, Gαolf

Activation of adenylyl cyclases

Gα i/o

Gαi1, Gαi2, Gαi3, Gαo, Gαz, Gαt

Inhibition of adenylyl cyclases

Gα q/11

Gαq, Gα11, Gα14, Gα16,

Activation of PLC

Gα 12/13

Gα12, Gα13

Activation of RhoGEF

1.1.4.3 Gβγ subunits
Activation of GPCRs promotes an exchange of GDP for GTP in the Gα subunit.
This results in the activation of Gα and Gβγ subunits (Khan et al., 2013; Nygaard et al.,
2013; Rasmussen et al., 2011b; Venkatakrishnan et al., 2013). Gβγ subunits were
originally thought to be involved solely with the inactivation of Gα subunits, leading to
reassociation with the GPCR for new signaling cycles (Dupre et al., 2009). And, thus,
Gβγ subunits were considered to be negative regulators of signaling through Gα subunits.
Notably, now it is well established that activation of Gβγ subunits can lead to a variety of
signaling outcomes, including conditional activation of glycine receptors, modulation of
adenylyl cyclase isoforms (e.g. AC1 and AC2), ERK (extracellular signal-regulated
kinase) phosphorylation, activation of phospholipase C β2/β3, activation of GIRK (G
protein-coupled inwardly rectifying potassium) and N-type calcium channels, activation
of phosphoinositide 3 kinase, and stabilization of microtubules (Cooper and
Crossthwaite, 2006; Dupre et al., 2009; Khan et al., 2013; Lin and Smrcka, 2011).
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In humans there are 5 isoforms of Gβ and 12 isoforms of Gγ subunits (Dupre et

al., 2009; Hurowitz et al., 2000; Khan et al., 2013), and there is evidence that Gβγ dimers
composed of specific isoforms of Gβ and Gγ may be associated with distinct signaling
outcomes and coupling to different GPCRs (Asano et al., 1999; Bigler Wang et al., 2011;
Khan et al., 2013; Richardson and Robishaw, 1999). For instance, it has been shown that
the Gγ7 subunit is required for dopamine D1 receptor-mediated activation of adenylyl
cyclases in the striatum (Schwindinger et al., 2003).
It has also been suggested that Gβγ subunits may be targeted for therapeutic
purposes. For instance, in heart failure there is a decrease in the cardiac reserve of βadrenergic receptors (Smrcka et al., 2008). The progression to heart failure results in
increased activation of β-adrenergic receptors, leading to Gβγ-mediated activation of
GRK2 (Hata and Koch, 2003; Smrcka et al., 2008). GRK2 phosphorylates the receptor
leading to receptor desensitization and retrieval from the membrane (Hata and Koch,
2003; Lefkowitz and Shenoy, 2005; Smrcka et al., 2008). In rodent models of heart
failure, inhibition of Gβγ subunits with βARK-CT (the C terminus of GRK2)
significantly rescued cardiac function (Iaccarino and Koch, 2003; Rockman et al., 1998;
Smrcka et al., 2008). Moreover, it has been hypothesized that inhibition of Gβγ-mediated
signaling may be a useful strategy to inhibit inflammation in conditions such as
rheumatoid arthritis, and to enhance the analgesic effects of opioids (Smrcka et al., 2008).
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1.1.4.4 β-arrestins
Activation of GPCRs results in receptor phosphorylation by GRKs, which allows
for the recruitment of β-arrestins to the GPCR (Lefkowitz and Shenoy, 2005; Lefkowitz,
2004). As highlighted by the nomenclature, recruitment of β-arrestin to the receptor can
lead to termination of the G protein signaling through three main processes. The first is
by sterically obstructing additional interactions between receptor and G proteins (Shenoy
and Lefkowitz, 2011). The second is by removing the receptor from the membrane in
clathrin-coated vesicles (Ferguson et al., 1996; Goodman et al., 1996). And the third is by
docking phosphodiesterases and diacylglycerol kinases (enzymes that degrade/inhibit
second messengers) to the cellular membrane (Nelson et al., 2007; Perry et al., 2002). βarrestins were initially linked to the termination of the GPCR signaling cycle, however, it
is now well established that β-arrestin can also mediate signaling events (Latapy and
Beaulieu, 2013; Lefkowitz and Shenoy, 2005; Shenoy and Lefkowitz, 2011; Shukla et al.,
2011).
It has been hypothesized that the isoform of GRK and the site of phosphorylation
in the GPCR will dictate the outcome of β-arrestin recruitment (Lefkowitz and Shenoy,
2005; Shenoy and Lefkowitz, 2011). According to this hypothesis, these two phenomena
create a phosphorylation “barcode” in the receptor that directs the recruitment of βarrestins to specific signaling or endocytic events (Shenoy and Lefkowitz, 2011). This
hypothesis is supported by studies that showed that phosphorylation of the angiotensin
AT1A and the vasopressin V2 receptors by GRK2 and GRK3 is associated primarily with
receptor internalization, whereas phosphorylation by GRK5 and GRK6 causes little
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receptor internalization, but is necessary for β-arrestin-mediated ERK phosphorylation
(Kim et al., 2005; Ren et al., 2005). Notably, GPCRs have a number of residues that can
be phosphorylated by GRKs, and the site of phosphorylation seems to be specific to
individual GRK isoforms (Busillo et al., 2010; Shenoy and Lefkowitz, 2011). Depending
on the isoforms of GRK expressed in the cells and the receptor identity, recruitment of βarrestin can lead to different signaling events. For instance, in the basal ganglia,
recruitment of β-arrestin 2 to the dopamine D1 receptor leads to ERK phosphorylation,
while β-arrestin 2 recruitment to the dopamine D2 receptor leads to dephosphorylation of
Akt (Del'guidice et al., 2011).
It seems that β-arrestins mediate signaling events by acting as scaffolds, which
bring together several components of the signaling cascade (Lefkowitz and Shenoy,
2005; Shenoy and Lefkowitz, 2011). In the β-arrestin-mediated signaling events
following activation of the dopamine D2 receptor, for example, β-arrestin interacts with
Akt and phosphatase 2A (PP2A) (Beaulieu et al., 2005; Beaulieu et al., 2007a; Beaulieu
et al., 2007b). This signaling complex brings PP2A in close proximity to Akt, and
facilitates the dephosphorylation of Akt by PP2A (Beaulieu et al., 2005; Beaulieu et al.,
2007a; Beaulieu et al., 2007b; Del'guidice et al., 2011). Similarly, for β-arrestin-mediated
ERK phosphorylation, β-arrestin forms a complex with cRaf-1, MEK1, and ERK, thus
grouping the necessary components for the mitogen-activated protein kinase (MAPK)
signaling cascade (DeFea et al., 2000; Luttrell et al., 2001; Shenoy and Lefkowitz, 2011).
Because of the multiple possible outcomes of the recruitment of β-arrestins to GPCRs, it
has been suggested that for several therapies targeting GPCRs the selective
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activation/inhibition of β-arrestin signaling may lead to improved clinical effects
(Rominger et al., 2014; Violin et al., 2014; Whalen et al., 2011).

1.1.5

Adenylyl cyclases
Adenylyl cyclases are important integrators of signaling through GPCRs.

Adenylyl cyclases are enzymes that catalyze the formation of cAMP from ATP
(adenosine triphosphate). Structurally, the membrane-bound adenylyl cyclases share an
overall similar arrangement (Cooper and Crossthwaite, 2006). They are composed of two
transmembrane clusters (M1 and M2), each containing six transmembrane helices, and
three intracellular domains: a short N terminus, a large cytoplasmic domain (C1 domain)
that separates the two transmembrane clusters, and a large C terminus denoted C2 domain
(figure 1.2) (Cooper and Crossthwaite, 2006; Sadana and Dessauer, 2009; Sunahara et al.,
1996; Wang et al., 2009a).
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Figure 1.2 Topology of adenylyl cyclases. Membrane-bound adenylyl cyclases share an
overall similar arrangement. They are composed of two transmembrane clusters (M1 and
M2), each containing six transmembrane helixes and three intracellular domains: a short
N terminus (NT), a large cytoplasmic domain (C1 domain) that separates the two
transmembrane clusters, and a large C terminus denoted C2 domain.

There are nine different isoforms of membrane-bound adenylyl cyclases and one
soluble adenylyl cyclase described to date (Cooper and Crossthwaite, 2006; Sadana and
Dessauer, 2009). The different isoforms of membrane-bound adenylyl cyclases can be
grouped into four main groups according to their regulatory properties (table 1.2) (Patel
et al., 2001; Sunahara and Taussig, 2002). Group 1 adenylyl cyclases include AC1, AC3,
and AC8. These adenylyl cyclases are activated by calcium in a calmodulin-dependent
manner. AC2, AC4, and AC7 comprise group 2 adenylyl cyclases, and these adenylyl
cyclases are conditionally activated by Gβγ subunits. Group 3 adenylyl cyclases
encompass AC5 and AC6, which are inhibited by calcium. Group 4 adenylyl cyclases is
composed solely of AC9, which is separated from the other isoforms due to its relative
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insensitivity to the small molecule activator of adenylyl cyclases, forskolin (Cooper and
Crossthwaite, 2006; Hacker et al., 1998).

Table 1.2 Regulatory properties of groups of adenylyl cyclases. ! = stimulation, " =
inhibition.
Group and members

Gα s

Gα i/o

Gβγ

Ca2+

Forskolin

1 – AC1, AC3, AC8

!

"

"

!

!

2 – AC2, AC4, AC7

!

3 – AC5, AC6

!

4 – AC9

!

!

!*
"

"

!

"

* Conditional activation.

1.1.5.1 Physiological functions of adenylyl cyclases
The different regulatory properties and tissue distribution of the membranous
adenylyl cyclases suggest that each isoform may serve distinct purposes. In fact, the
physiological functions of individual adenylyl cyclase isoforms have been investigated in
studies employing knockout and overexpression animal models (Sadana and Dessauer,
2009).
The calcium stimulated adenylyl cyclases, AC1 and AC8, are highly expressed in
the hippocampus, which is a brain region associated with learning and memory (Ferguson
and Storm, 2004; Sadana and Dessauer, 2009). Studies suggest that learning and memory
result from enhanced connectivity between neurons, particularly in the hippocampus
(Lynch, 2004; Sacktor, 2011). Long-term potentiation (LTP) is a mechanism that
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strengthens the connections (i.e. synapses) between neurons (Lynch, 2004; Sacktor,
2011). Therefore, LTP is considered one of the main cellular mechanisms regulating
memory formation and maintenance (Lynch, 2004; Sacktor, 2011). Notably, LTP is
disrupted in the hippocampus of double-knockout mice lacking both AC1 and AC8
(Ferguson and Storm, 2004; Wong et al., 1999). And it was shown that LTP could be
rescued by forskolin, suggesting that cAMP is an essential component of LTP, and also
that there are additional adenylyl cyclase isoforms expressed in the hippocampus (Wong
et al., 1999). Even though the individual knockout of AC1 or AC8 causes a reduction in
hippocampal mossy fiber LTP, AC1 knockout mice display normal paired-pulse
facilitation (PPF - a form of short-term synaptic plasticity), whereas AC8 knockout mice
have impaired PPF (Villacres et al., 1998; Wang et al., 2003).
In behavioral assays it was observed that the double-knockout animals displayed
impaired long-term memory in both passive avoidance and contextual learning assays
(Wong et al., 1999). In contrast, mice lacking only AC1 or AC8 displayed wild-type-like
behaviors in both passive avoidance and contextual learning assays (Wong et al., 1999).
Notably, it has been shown that AC1 knockout mice lose remote contextual memories
faster than wild-type mice (Shan et al., 2008). These results suggest that loss of activity
of both AC1 and AC8 lead to memory impairments in mice; however, individual
knockout of either cyclase only causes modest effects in a subset of behavioral assays.
Calcium-stimulated adenylyl cyclases are also expressed in regions of the central
nervous system associated with pain and nociception. Specifically, AC1 is expressed in
the anterior cingulate cortex and in dorsal horn neurons of the spinal cord (Wei et al.,
2006; Xu et al., 2008; Zhuo, 2012). It has been hypothesized that the development of
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chronic pain shares some cellular mechanistic features with memory formation and
maintenance, that is, strengthening of synapses through LTP (Ferguson and Storm, 2004;
Zhuo, 2012). This hypothesis is supported by the fact that behavioral responses of AC1
knockout mice (but not AC8) to inflammatory and neuropathic pain are largely inhibited
compared to wild-type animals (Vadakkan et al., 2006; Zhuo, 2012). It was also shown
that a small molecule inhibitor of AC1 activity (i.e. NB001) has analgesic properties in
both inflammatory and neuropathic rodent models of pain (Wang et al., 2011). NB001
also inhibited LTP in neurons from the anterior cingulate cortex and spinal cord, but not
hippocampus (Wang et al., 2011). Genetic deletion of AC1 also results in neuroprotection
against N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity (Wang et al.,
2007).
Adenylyl cyclases may also play a role in drug tolerance and dependency. For
instance, chronic activation of the µ-opioid receptor leads to enhanced activity of
adenylyl cyclases (see discussion on heterologous sensitization below) (Bohn et al., 2000;
Duman et al., 1988; Nestler and Tallman, 1988; Watts and Neve, 2005). Moreover,
naloxone-induced morphine withdrawal behaviors in mice are markedly reduced in AC1
and AC8 knockout mice (Li et al., 2006; Zachariou et al., 2008). In agreement, genetic
deletion of AC5, which is the main adenylyl cyclase isoform co-expressed with the µopioid receptor in the striatum, significantly attenuates all main behavioral outcomes of
morphine treatment, including tolerance, dependence, withdrawal symptoms, reward,
analgesia, and locomotor activation (Kim et al., 2006; Sadana and Dessauer, 2009). Due
to its high expression in the striatum, AC5 also appears to be important for motor
coordination (Iwamoto et al., 2003). It has been shown that AC5 knockout mice display
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behaviors associated with Parkinson’s disease, such as locomotor impairment, abnormal
coordination, and bradykinesia (Iwamoto et al., 2003; Sadana and Dessauer, 2009).
Cyclic AMP signaling and adenylyl cyclases are involved in the olfactory system.
Specifically, AC3 is highly expressed in olfactory neurons (Sadana and Dessauer, 2009).
The regulatory properties of AC3 are consistent with its role in olfaction. AC3 is strongly
stimulated by Gαolf, conditionally activated by calcium/calmodulin, and inhibited by
calmodulin-dependent protein kinase III (CaMKIII) and regulator of G protein signaling
2 (RGS2) (Cooper and Crossthwaite, 2006; Sadana and Dessauer, 2009). Genetic deletion
of AC3 in mice causes significant impairments in olfaction-based behavioral tests and
olfactory-dependent learning (Wong et al., 2000). Moreover, AC3 knockout mice do not
perceive mouse pheromones or urine (Wang et al., 2006).
Cardiac function is also strongly associated with the activity of adenylyl cyclases
(Wang et al., 2009a). There are a number of GPCRs (e.g. adrenergic and muscarinic
receptors) expressed in the heart that can regulate the activity of adenylyl cyclases
(Sadana and Dessauer, 2009; Wang et al., 2009a). AC5 and AC6 are the main adenylyl
cyclase isoforms expressed in the heart (Sadana and Dessauer, 2009; Wang et al., 2009a).
It is somewhat surprising that overexpression and knockout studies with AC5 and AC6
report striking differences in the roles of these closely related adenylyl cyclases in cardiac
function (Wang et al., 2009a). Overexpression of AC6 enhances left ventricular function
in heart failure (Lai et al., 2004; Roth et al., 1999). It was also shown that in
cardiomyocytes AC6 expression leads to protective effects in cardiomyopathy and
improves heart function (Gao et al., 2004; Wang et al., 2009a). Studies employing AC6
knockout mice have shown that these animals display cardiac defects and impaired
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calcium uptake in left ventricular homogenates (Tang et al., 2008). In contrast, genetic
deletion of AC5 in mice is protective against cardiac pressure overload in a heart failure
model (Okumura et al., 2003). AC5 knockout mice also display increased longevity and
protection against age-related cardiomyopathies (Chester and Watts, 2007; Yan et al.,
2007).

1.1.6

Complex signaling pathways downstream of G protein-coupled receptors
Besides the activation of immediate signaling proteins, such as G proteins and β-

arrestins, GPCRs can also activate more complex signaling pathways that are
downstream of those immediate receptor effectors (Brust et al., 2015a). Activation of
ERK phosphorylation, heterologous sensitization, and dynamic mass redistribution
(DMR) by GPCRs are signaling events that may be mediated by one or more immediate
receptor effectors (Brust et al., 2015a; Lefkowitz and Shenoy, 2005; Oak et al., 2001;
Schroder et al., 2010; Watts and Neve, 2005; Zhu et al., 2013).

1.1.6.1 ERK phosphorylation
ERK phosphorylation is a signaling outcome typically associated with the
activation of receptor tyrosine kinases (RTKs) (McKay and Morrison, 2007). The core
pathway for ERK phosphorylation involves activation of RTKs leading to the activation
of Ras, which activates Raf; Raf phosphorylates and activates MEK, which in turn
phosphorylates ERK (figure 1.3) (McCubrey et al., 2007; McKay and Morrison, 2007).
There are proteins termed ERK scaffolds that function as docking platforms to bring
together members of the MAPK (mitogen-activated protein kinase) signaling cascade and
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facilitate ERK phosphorylation (McKay and Morrison, 2007). As discussed above, βarrestins can act as such scaffolding proteins and lead to GPCR-mediated ERK
phosphorylation (figure 1.3) (DeFea et al., 2000; Luttrell et al., 2001; Shenoy and
Lefkowitz, 2011). Furthermore, GPCRs may also trigger ERK phosphorylation through
the activation of G proteins (Rozengurt, 2007). The mechanism leading to ERK
phosphorylation is highly dependent on the receptor and on the tissue/cell line under
analysis (Luttrell and Luttrell, 2003).

Figure 1.3 Schematic of ERK phosphorylation through GPCRs. Gαi/o-coupled
receptors can cause ERK phosphorylation through transactivation of RTKs. β-arrestins
act as scaffolding proteins bringing together Raf, MEK, and ERK to induce ERK
phosphorylation. Gαq-coupled GPCRs can lead to ERK phosphorylation through the
activation of PKC. And Gαs-coupled receptors lead to ERK phosphorylation through
cAMP-dependent mechanisms (i.e. PKA and EPAC). Note that Gβγ subunits are not
included in the figure, however, as discussed in the text, they are also involved in GPCRmediated ERK phosphorylation.
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Activation of Gαq-coupled GPCRs can lead to ERK phosphorylation through the

activation of PKC (figure 1.3) (Luttrell and Luttrell, 2003; Rozengurt, 2007). In contrast,
Gαs-coupled receptors appear to drive ERK phosphorylation through cAMP-dependent
mechanisms. One proposed model is through PKA activation of Rap-1, which activates
B-Raf leading to ERK phosphorylation (figure 1.3) (Luttrell and Luttrell, 2003). In
contrast, it has also been suggested that it is exchange protein activated by cAMP
(EPAC) that activates Rap-1 to result in ERK phosphorylation (figure 1.3) (Rozengurt,
2007). Additional studies have suggested that cAMP accumulation can inhibit ERK
phosphorylation and lead to cell death (Dumaz and Marais, 2005; Zambon et al., 2005).
These data further corroborate the relevance of the model in studies of GPCR-mediated
ERK phosphorylation.
GPCRs coupled to Gαi/o appear to lead to ERK phosphorylation through a
different mechanism. The reports published to date suggest that there is a transactivation
of RTKs by GPCRs (Luttrell and Luttrell, 2003; Oak et al., 2001). However, it has also
been reported that in some tissues GPCRs coupled to inhibitory G proteins can lead to
ERK phosphorylation through PKC activation (Luttrell and Luttrell, 2003). The
mechanism for transactivation of RTKs has been associated with a stimulation of the
release of RTK ligands that are located in the cellular membrane (Luttrell and Luttrell,
2003). This phenomenon appears to be associated with activation of both Gαi/o and Gβγ
subunits, since in Chinese hamster ovary (CHO) cells sequestration of Gβγ subunits
partially inhibits dopamine D2 receptor-mediated ERK phosphorylation and inhibition of
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Gαi/o with pertussis toxin fully inhibits this response (Brust et al., 2015a; Oak et al.,
2001).

1.1.6.2 Heterologous Sensitization
Heterologous sensitization of adenylyl cyclase (also referred to as sensitization,
superactivation, or supersensitization of adenylyl cyclase) is a cellular adaptive response
that occurs following persistent activation of Gαi/o-coupled receptors (Watts and Neve,
2005). Heterologous sensitization is characterized by a marked enhancement in the
activity of adenylyl cyclases, which results in a paradoxical increase in cAMP production
(Watts and Neve, 2005). A number of Gαi/o-coupled GPCRs have been shown to cause
heterologous sensitization of adenylyl cyclase following chronic treatments with receptor
agonists, including the dopamine D2 receptor and the µ-opioid receptor (Bohn et al.,
2000; Brust et al., 2015a; Brust et al., 2015b; Clark et al., 2004; Watts and Neve, 2005).
The detailed molecular mechanism underlying heterologous sensitization is not
completely understood. However, recent studies have unveiled important mechanistic
features of heterologous sensitization. The different regulatory properties of adenylyl
cyclase isoforms suggest that there may be isoform specific mechanisms for heterologous
sensitization (Sadana and Dessauer, 2009; Watts and Neve, 2005). For instance, it has
been shown that Gαs is required for sensitization of AC5, but not for AC1 (Vortherms et
al., 2006; Vortherms et al., 2004). Moreover, group 2 adenylyl cyclases are not sensitized
to stimulation by Gαs, but chronic activation of the dopamine D2 receptor sensitizes AC2
to activation by PKC (Avidor-Reiss et al., 1997; Cumbay and Watts, 2001; Nevo et al.,
1998; Rhee et al., 2000; Thomas and Hoffman, 1996; Watts and Neve, 1996).
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Gβγ subunits also appear to play an important role in heterologous sensitization. It

has been shown that sequestration of Gβγ subunits with βARK-CT blunts dopamine D2
receptor-mediated sensitization of AC5 (Ejendal et al., 2012). Additionally, Gβγ subunits
can inhibit AC1 and conditionally activate AC2, suggesting that the roles of Gβγ subunits
in heterologous sensitization may be isoform-dependent (Cooper and Crossthwaite, 2006;
Sunahara and Taussig, 2002). The activity of adenylyl cyclase isoforms can also be
regulated by direct phosphorylation (Sadana and Dessauer, 2009; Watts and Neve, 2005).
Protein kinases such as PKA, PKC, and calmodulin kinases (CaMK) regulate the activity
of adenylyl cyclase isoforms through direct phosphorylation (Chen et al., 1997; Defer et
al., 2000; Sadana and Dessauer, 2009; Wayman et al., 1996). Therefore, it is possible that
the phosphorylation state of adenylyl cyclases may be regulated during heterologous
sensitization to enhance cAMP production.
Since it was first described, heterologous sensitization has been associated with
opioid tolerance and dependence (Sharma et al., 1975). However, for opioid receptors it
has been shown that the recruitment of β-arrestin appears to be linked to morphine
tolerance, while heterologous sensitization is associated with morphine dependence
(Bohn et al., 2000). It has also been shown that tissue injury in mice produces enhanced
µ-opioid receptor constitutive activity, which inhibits signaling events associated with
nociception in neurons of the spinal cord (Corder et al., 2013). Notably, in the injured
mice, inhibition of the constitutive activity of the µ-opioid receptor with naltrexone in the
post-hyperalgesia state results in pain reinstatement, induction of behaviors consistent
with opioid dependence, and also causes heterologous sensitization of AC1 in the spinal
cord (Corder et al., 2013). These results are consistent with previous reports and further
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strengthen the link between heterologous sensitization and physiological responses
observed following chronic treatment with agonists of Gαi/o-coupled receptors (e.g.
opioid dependence) (Bohn et al., 2000; Corder et al., 2013).

1.1.6.3 Dynamic Mass Redistribution
Dynamic mass redistribution (DMR) is a label-free platform that detects
phenotypic changes in a cell (Fang et al., 2006). Specifically, DMR refers to changes in
cell shape caused by movement of biomolecules within the cell (Fang et al., 2006;
Schroder et al., 2011). There are numerous cellular processes that induce movement of
biomolecules in a cell, including signaling events associated with GPCRs (Schroder et
al., 2011). Measurements of DMR in response to GPCR activation are accomplished by
temporally monitoring changes in the refractive index of the cells during receptor
activation (Brust et al., 2015a; Schroder et al., 2010; Schroder et al., 2011). A polarized
broadband light is directed at the bottom of a microplate, which contains a resonant
waveguide grating biosensor in contact with the cells. The interface between biosensor
and cells creates an optical system that propagates and reflects the specific wavelength
that is in resonance with the system (Schroder et al., 2011). Redistribution of cellular
mass towards the interface between cell and biosensor results in positive DMR, in
contrast, redistribution of mass away from the cell-biosensor interface results in negative
DMR values (Schroder et al., 2011). These DMR changes are calculated by normalizing
the reflected wavelength at the basal state to a value equal to zero. Increases in the
reflected wavelength are associated with positive DMR, and decreases with negative
DMR (Schroder et al., 2011).

!

25
Readouts from DMR and other cell phenotypic assays have clear advantages and

disadvantages when compared to other more traditional methods utilized to measure
activity of GPCRs. One advantage is that DMR is a label-free integrated cellular response
that for GPCRs, in theory, reflects the activation of multiple signaling pathways
(Schroder et al., 2010; Schroder et al., 2011). Therefore, DMR readouts should reflect a
generalized receptor response, which encompasses the multiple ways a ligand can induce
receptor signals. Nevertheless, measures of individual signaling pathways are also
important and may have notable clinical implications (Kenakin, 2012; Mailman, 2007;
Rominger et al., 2014). Further, it may be difficult and laborious to deconvolute the DMR
signals in order to define which components of the GPCR signaling cascade are depicted
in the DMR response. Recent efforts suggest that the main DMR peak reflects activation
of Gα proteins (Schroder et al., 2010). Further studies are needed to determine the role of
Gβγ subunits and β-arrestins in DMR.

1.2
1.2.1

Functional Selectivity

History and definition:
As mentioned above, GPCRs can activate multiple signaling pathways. These

pathways include immediate receptor effectors (i.e. Gα and Gβγ subunits, and βarrestins) and more complex pathways that are downstream of the immediate effectors
(e.g. ERK phosphorylation and heterologous sensitization) (Brust et al., 2015a). Notably,
there are ligands that upon interaction with a GPCR induce a receptor conformation that
favors the activation of one signaling pathway relative to another (figure 1.4) (Kenakin,
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2012; Kenakin and Christopoulos, 2013b; Liu et al., 2012a; Urban et al., 2007a;
Venkatakrishnan et al., 2013; Violin et al., 2014; Whalen et al., 2011). These ligands are
termed functionally selective or biased ligands (Kenakin, 2012). In extreme cases, biased
ligands can behave as both agonists and antagonists for different signaling pathways
downstream of the same receptor (Brust et al., 2015b; Free et al., 2014; Urban et al.,
2007a).

Figure 1.4 Functional selectivity downstream of GPCRs. a. A balanced ligand
interacts with the GPCR and equally activates signaling through G proteins and βarrestin. b. An antagonist interacts with the GPCR and inhibits signaling through G
proteins and β-arrestin. c. A G protein-biased ligand* interacts with the GPCR and
activates signaling through G proteins in the absence of β-arrestin activation. d. A βarrestin-biased ligand* interacts with the GPCR and activates signaling through β-arrestin
in the absence of G protein activation. *Note that, as discussed below, compounds that
display shifts in potency and/or efficacy in one pathway relative to another may also be
considered biased.
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Even though a large portion of the literature on functional selectivity is fairly

recent, examples and ideas of “functional mismatches” and “configurational selectivity”
have been presented decades ago (Jim et al., 1985; Kenakin et al., 1991; Portoghese,
1965; Roth and Chuang, 1987; Urban et al., 2007a). Portoghese (1965) described a
method to determine similarities and differences in the mode of binding of ligands of
“analgesic-receptors”. The differences in the activity of structurally related compounds
indicated the “configurational selectivity”, in which the interaction of the compound with
receptor would dictate the “discriminatory power” of the receptors associated with the
activity observed (Portoghese, 1965). Two decades later, Jim and colleagues (1985)
reported inconsistencies between molecular efficacies and functional physiological
responses of α1-adrenergic receptor agonists in venous smooth muscle (Jim et al., 1985).
And in 1987 Roth and Chuang hypothesized that it could be possible to design ligands of
serotonin receptors that would only activate or inhibit a subset of the receptor’s
responses, thus defining the basis of functional selectivity and biased signaling (Roth and
Chuang, 1987). Notably, it was not until 1998 that the term “biased agonist” was
introduced for [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P at neuropeptide receptors (Jarpe
et al., 1998).

1.2.2

Clinical relevance and examples of biased ligands
As discussed above, GPCRs are very important drug targets; and the activation of

these receptors is associated with propagation of signal through multiple pathways.
However, activation of all signaling pathways downstream of a GPCR may not be a
clinically desired feature of a drug. It has been hypothesized that for several GPCRs only
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a subset of receptor responses is associated with the therapeutic effects of drugs, while
the additional signaling pathways may be associated with undesired side effects
(Mailman, 2007; Rominger et al., 2014; Violin et al., 2014; Whalen et al., 2011).
Therefore, it has been hypothesized that the use of biased ligands may improve the safety
and specificity of drug therapies targeting GPCRs (Whalen et al., 2011).
Studies with several GPCRs have provided evidence that selective activation of
signaling pathways downstream of a GPCR may lead to safer and more effective drug
therapies. For instance, several studies suggest that a G protein-biased ligand (i.e. a
ligand that selectively activates G proteins over β-arrestin) for the µ-opioid receptor can
lead to enhanced analgesic effects and decreased tolerance (Bohn et al., 2004; Bohn et al.,
2000; Bohn et al., 1999). In mice lacking β-arrestin 2, morphine displays enhanced
analgesia with a robust reduction in behaviors associated with tolerance, respiratory
depression, and constipation (Bohn et al., 2004; Bohn et al., 2000; Bohn et al., 1999;
Raehal et al., 2005). Recently, a biased ligand that potently activates G proteins while
inducing minimal recruitment of β-arrestins to the µ-opioid receptor (TRV130) has been
described (DeWire et al., 2013). Notably, in comparison to morphine TRV130 causes
enhanced analgesia with reduced gastrointestinal dysfunction and respiratory depression
in mice (DeWire et al., 2013). Clinical trials are now being conducted with TRV130 and
may lead to the first rationally designed biased ligand that is used clinically (Soergel et
al., 2014; Violin et al., 2014).
Functional selectivity has also been studied at adrenergic receptors. It was
suggested that, in therapies for obstructive lung disease, G protein-biased ligands at the
β2-adrenergic receptor may lead to bronchodilation with reduced receptor tachyphylaxis
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(Deshpande et al., 2008; Wang et al., 2009b). These studies suggested that the activation
of G proteins is associated with bronchodilation and the recruitment of β-arrestins causes
receptor desensitization and also sterically prevent additional G protein activation cycles
(Rominger et al., 2014; Whalen et al., 2011). It has also been suggested that a β-arrestinbiased ligand for the β1-adrenergic receptor may provide the beneficial effects of βblockers along with increased cell survival (through β-arrestin-mediated ERK
phosphorylation), a desired outcome of patients with arrhythmia and hypertension
following myocardial infarctions (DeWire and Violin, 2011; Whalen et al., 2011).
Biased signaling has also been suggested to be a strategy for improving the safety
of antipsychotic drugs targeting the dopamine D2 receptor. Antipsychotic drugs are
antagonists (or partial agonist in the case of aripiprazole) of the dopamine D2 receptor
(Brust et al., 2015b; Mailman and Murthy, 2010; Shapiro et al., 2003). It has been shown
that clinically used antipsychotic drugs are also antagonists of β-arrestin recruitment to
the dopamine D2 receptor (Masri et al., 2008). A recent study suggested that ligands that
are inhibitors of Gαi/o signaling and activate β-arrestin recruitment to the dopamine D2
receptor lead to behaviors consistent with antipsychotic activity with reduced
extrapyramidal side effects in mice (Allen et al., 2011). These results combined with the
studies described above support the use and development of biased ligands as a path to
improve the safety and efficacy of drug therapies targeting GPCRs. The pursuit of
functionally selective compounds is quickly becoming a common strategy in rational
drug design for GPCR-associated drug discovery.
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Quantification of functional selectivity
Heightened awareness of the potential benefit of pathway-biased ligands has

created the need for methods to efficiently quantify and compare agonist-mediated
activity through multiple pathways. Drug-induced divergences in potency and/or efficacy
may also lead to biased signaling. However, methods to calculate the degree of bias of a
ligand were not available until recently (Kenakin and Christopoulos, 2013b). The new
quantitative methods incorporate efficacy and potency to calculate “bias factors”
(Kenakin and Christopoulos, 2013b; Kenakin et al., 2012; Rajagopal et al., 2011). The
values from these methods reflect the relative activities of a test ligand compared with
that of a reference compound for activating one effector pathway relative to another, such
as Gα versus β-arrestin signaling. All methods to quantify functional selectivity
determine bias as a relative measure (Kenakin and Christopoulos, 2013b; Rajagopal et
al., 2011). Therefore, functional selectivity is always relative to a reference compound.
Moreover, functional selectivity can also be dependent on the system (receptor reserve),
on the amplification of the response being measured, on the assay temperature, and on the
assay incubation time (Kenakin, 2014b; Kenakin et al., 2012; Pereira et al., 2014; Urban
et al., 2007b). In most scenarios, the quantitative methods of measuring ligand bias take
into account the system bias and signal amplification (Kenakin, 2009; Kenakin and
Christopoulos, 2013b; Kenakin et al., 2012). However, divergences in assay temperature
and incubation time may still cause conflicting results.
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1.2.3.1 Equimolar comparison
The equimolar comparison was first described in 2010 by Gregory and colleagues
(Gregory et al., 2010). It represents the simplest method of determining ligand bias. In the
equimolar comparison normalized responses of two signaling pathways for equal
concentrations of ligand are plotted against each other (Gregory et al., 2010; Rajagopal et
al., 2011). Shifts on the plots toward one of the axes in comparison with a reference
compound indicate bias for the pathway on that axis (Brust et al., 2015a; Gregory et al.,
2010; Rajagopal et al., 2011). Even though the equimolar comparison is simple and easy
to perform, it is only a qualitative measure and cannot quantify the degree of bias of a
ligand.

1.2.3.2 Equiactive comparison
The equiactive comparison is also relatively simple. However, in contrast to the
equimolar comparison, it is a quantitative method of determining ligand bias. The
equiactive comparison model compares the log of the ratios of the relative activity of the
test compounds with the reference compound (Brust et al., 2015a; Ehlert, 2008; Griffin et
al., 2007; Rajagopal et al., 2011). This quantitative method uses EC50 values and the
maximal effects of the compounds from standard sigmoid curve-fitting approaches to
generate a bias factor using the following equation:
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where Emax is the maximal effect of the compound, EC50 is the EC50 value of the
compound, lig is the compound being analyzed, ref is the reference compound, path1 is
one of the pathways being analyzed, and path2 is the other pathway being analyzed.

1.2.3.3 Black and Leff operational model
There are two methods of quantifying ligand bias that use the Black and Leff
operational model: the transduction coefficient and the sigma comparison (Black and
Leff, 1983; Kenakin et al., 2012; Rajagopal et al., 2011). The Black and Leff operational
model was originally developed as a quantitative pharmacological model that describes
ligand agonism using three parameters: the affinity of the ligand for the
receptor/signaling complex (KA), the receptor density (R0), and the transduction of the
agonist/receptor complex into a pharmacological effect (KE) (Black and Leff, 1983).
Therefore, in theory this method quantifies pharmacological responses regardless of
signal amplification and receptor reserve.
An easy and accurate way of defining and visualizing the Black and Leff
operational model is as a mathematical rearrangement of three distinct Hill equations:
concentration of agonist by effect, concentration of agonist by receptor occupancy, and
receptor occupancy by effect (figure 1.5) (Black and Leff, 1983).
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Figure 1.5 Graphical representation of the Black and Leff operational model. The
Black and Leff operational model is based on the rearrangement of three different Hill
equations: concentration of agonist (log [A]) by effect (E), concentration of ligands by
receptor occupancy (AR), and receptor occupancy by effect.
Arithmetical rearrangements of the Hill equations that express concentration of
agonist by receptor occupancy and receptor occupancy by effect with the introduction of
the term τ (τ = R0/ KE) that denotes the transduction ratio (i.e. efficiency of signal
transduction) lead to an equation that can be used to plot data from a third Hill equation
(concentration of agonist by effect):
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where Emax is the maximal effect of the compound, τ is the transduction ratio, [A] is the
concentration of ligand, KA is the functional affinity, and n is the transducer slope of the
curve. In this equation τ accounts for the ligand’s relative efficacy, which takes into
account the responsiveness of the system, and KA accounts for the ligand’s relative
potency (Black and Leff, 1983; Kenakin, 2004; Kenakin, 2014b). Note that these terms
are different from EC50 and maximal response (commonly used to denote potency and
efficacy, respectively) that are obtained by fitting pharmacological data into the Hill
equation (Goutelle et al., 2008).

1.2.3.4 Transduction coefficient
The transduction coefficient method uses functional data plotted in the Black and
Leff operational model to quantitatively determine ligand functional selectivity (Kenakin
et al., 2012). This method uses the calculated τ and KA values in the following equation to
generate a bias factor:
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where τ is the coupling efficiency and KA is the conditional affinity. Both are obtained by
fitting the data to the Black and Leff operational model. The use of the Black and Leff
operational model combined with the ratios of τ/KA allow for remarkable consistency of
results of the transduction coefficient regardless of the model system and signal
amplification (Kenakin and Christopoulos, 2013b; Kenakin et al., 2012). Notably, the
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transduction coefficient method is very similar to the equiactive comparison when the
slopes of the dose-response curves are close to one. In these cases, the ΔΔlog(τ/KA) from
the transduction coefficient would be proportional to the ΔΔlog(Emax/EC50) that is used
in the equiactive comparison (Brust et al., 2015a; Kenakin, 2014b).

1.2.3.5 Sigma comparison
The sigma comparison also uses the Black and Leff operational model for
calculating ligand bias. However, in contrast to the transduction coefficient method, in
the sigma comparison the KA is set to the ligands dissociation constant (Ki) obtained from
competitive binding assays (Rajagopal et al., 2011). Additionally, the sigma comparison
treats the data obtained from the Black and Leff operational model differently, and uses
the τ values in the following equations:
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where τ is the coupling efficiency and σ is the effective signaling. Even though the sigma
comparison and the transduction coefficient differ in at least two important aspects, if the
functional KA obtained in the transduction coefficient is similar to the affinity constants
obtained from competitive binding assays (Ki) the bias factors from these two analyses
should display good agreement (Kenakin and Christopoulos, 2013b).
In summary, the most used methods to quantify functional selectivity appear to
display marked similarities. When the Hill slope of the concentration-response curves of
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the compounds is equal to unity, the equiactive comparison and the transduction
coefficient become proportional and the results converge (Brust et al., 2015a; Kenakin
and Christopoulos, 2013b; Kenakin et al., 2012). The sigma comparison is similar to the
transduction coefficient in cases that the ligand’s binding affinity is equal to its functional
KA obtained from the Black and Leff equation (Kenakin and Christopoulos, 2013a;
Kenakin and Christopoulos, 2013b). Differences between those two parameters can lead
to striking inconsistencies in the bias factors (Brust et al., 2015a; Kenakin and
Christopoulos, 2013a). One limitation of all these methods is that the nature of the data
transformations precludes the traditional quantitative analyses from incorporating data
from antagonists or inverse agonists. The utility of the equimolar comparison is limited
by its qualitative nature; nevertheless, this method can be used to analyze data from
antagonists or inverse agonists (Brust et al., 2015a).

1.3
1.3.1

Dopamine receptors

Dopamine: neuroanatomy and function
Dopamine is a catecholaminergic neurotransmitter that exerts its actions through

different GPCRs in the central nervous system (figure 1.6). Dopamine was first
synthesized in 1910 by George Barger and James Ewens in England (Blum et al., 2012).
However, it was not until the late 1950’s that dopamine was discovered as a
neurotransmitter by Nobel laureate Dr. Arvid Carlsson (Carlsson et al., 1957; Carlsson et
al., 1958). Before Dr. Carlsson’s discovery, dopamine was thought to be only a precursor
of norepinephrine and epinephrine.
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Figure 1.6 Chemical structure of dopamine. 4-(2-aminoethy)benzene-1,2-diol.

The physiological synthesis of dopamine starts with the rate-limiting step, which
is the hydroxylation of L-Tyrosine by the enzyme tyrosine hydroxylase to generate Ldihydroxyphenylalanine (L-DOPA); next, DOPA decarboxylase removes the carboxylic
acid group from L-DOPA to generate dopamine (Beaulieu and Gainetdinov, 2011).
Because of dopamine’s lack of bioavailability, L-DOPA is commonly used in dopaminereplacement therapies.
There are four main dopaminergic pathways in the human brain. The
neurocircuitry of the projections ascending from the brainstem can be divided in three
main pathways (i.e. mesostriatal, mesolimbic, and mesocortical tracts) (Taber et al.,
2012). The mesostriatal pathway (i.e. nigrostriatal pathway) is mainly involved in the
control of voluntary movements and loss of these neurons results in Parkinson’s disease
(Hegarty et al., 2013). The mesolimbic pathway is associated with positive
reinforcement, including natural rewarding and drug abuse. Neurons from the mesolimbic
tracts project to the nucleus accumbens, as well as to the amygdala, olfactory tubercle,
and septum (Taber et al., 2012). Notably, all major classes of drugs of abuse activate the
mesolimbic dopaminergic pathway. The mesocortical pathway is thought to be mainly
associated with reward-processing (i.e. option assessment, comparative valuation, and
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hedonic evaluation). In humans this pathway projects to the entire cortical mantle (Taber
et al., 2012). Dysfunctions in the mesocortical pathway are associated with schizophrenia
(Masana et al., 2012). There is also the tubero-infundibular dopaminergic pathway, which
projects from the hypothalamus to the portal veins of the pituitary gland (Petty, 1999).
This pathway regulates the release of prolactin in the blood, and dysfunctions in this
pathway are associated with loss of libido and amenorrhea in women and loss of libido
and impotence in men (Petty, 1999).

1.3.2

Signaling properties and expression patterns of dopamine receptors
There are five different types of dopamine receptors in humans (i.e. D1, D2, D3,

D4, and D5) (Beaulieu and Gainetdinov, 2011). As previously mentioned, these receptors
belong to the large family of GPCRs (Fredriksson et al., 2003). The dopamine receptors
are divided into two different groups: the D1-like receptors (i.e. D1 and D5) and the D2like receptors (i.e. D2, D3, and D4) (Beaulieu and Gainetdinov, 2011). This classification
regards the general effects of these receptors on adenylyl cyclases (figure 1.7). The D1like receptors couple to stimulatory Gα subunits of G proteins and, thus, stimulate
adenylyl cyclases. Conversely, the D2-like receptors couple to inhibitory Gα subunits of
G proteins to inhibit adenylyl cyclases (Beaulieu and Gainetdinov, 2011).
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Figure 1.7 G protein signaling through dopamine receptors. D2-like receptors (D2,
D3, and D4) couple to inhibitory G proteins to inhibit adenylyl cyclases. In contrast, D1like receptors (D1 and D5) couple to stimulatory G proteins to stimulate adenylyl
cyclases.
Dopamine receptors can also recruit β-arrestins and mediate β-arrestin-dependent
signaling events, which also appear to differ for dopamine D1 and D2 receptors
(Del'guidice et al., 2011). In the basal ganglia dopamine D1 receptors lead to β-arrestinmediated ERK phosphorylation through the mechanisms described above (figure 1.8). In
contrast, signaling through β-arrestins by dopamine D2 receptors leads to Akt
dephosphorylation, which is accomplished by the formation of a protein complex
containing β-arrestin, protein phosphatase 2A (PP2A), and Akt (figure 1.8) (Beaulieu et
al., 2005; Beaulieu et al., 2007a; Del'guidice et al., 2011).
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Figure 1.8 β-arrestin-mediated signaling through dopamine receptors. Signaling
through β-arrestins by dopamine D2 receptors leads to Akt dephosphorylation through the
formation of a protein complex containing β-arrestin, PP2A, and Akt. In contrast,!
dopamine D1 receptors lead to β-arrestin-mediated ERK phosphorylation through the
formation of a signaling complex composed of β-arrestin, Raf, MEK, and ERK.
All dopamine receptors are expressed in the basal ganglia, which are the regions
of the brain that display the highest expression levels of dopamine receptors (Hurd et al.,
2001). Both dopamine D1 and D2 receptors are expressed at high levels in the striatum
(caudate and putamen) and nucleus accumbens, however, only the dopamine D2 receptor
is expressed in the substantia nigra and ventral tegmental area (Hurd et al., 2001; Jackson
and Westlind-Danielsson, 1994).
The dopamine D1 receptor also displays moderate levels of expression in the
cerebral cortical areas, and high levels of expression in the olfactory tubercle and septal
region (Hurd et al., 2001; Jackson and Westlind-Danielsson, 1994). The dopamine D2
receptor displays high levels of expression in the olfactory tubercle, thalamus,
hypothalamus, and pineal gland; moderate levels of expression in the hippocampus; and
low to moderate levels of expression in the cerebral cortex, and amygdala (Bouthenet et
al., 1987; Hurd et al., 2001; Jackson and Westlind-Danielsson, 1994). The dopamine D3
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receptor is found at higher levels in the thalamus and stria terminalis (Jackson and
Westlind-Danielsson, 1994). The dopamine D4 receptor is expressed at higher levels in
the frontal cortex, olfactory bulb, amygdala, and medulla oblongata (Jackson and
Westlind-Danielsson, 1994). And the dopamine D5 receptor is expressed at higher levels
in the cerebral cortex and hypothalamus (Jackson and Westlind-Danielsson, 1994).

1.3.3

Dysfunctions in the dopaminergic system
The dopaminergic system is targeted for several drug therapies. The dopamine D2

receptor, for instance, is the main target in therapies for Parkinson’s disease and
schizophrenia (Mailman and Murthy, 2010; Meissner et al., 2011). Disruptions of the
dopaminergic signaling have also been linked to other neurological dysfunctions, such as
depression, bipolar disorder, Tourette’s syndrome, drug abuse, Huntington’s disease, and
attention-deficit/hyperactivity disorder (ADHD) (Beaulieu and Gainetdinov, 2011).
Parkinson’s disease (PD) is a neurodegenerative disorder that directly affects the
supply of dopamine in the brain. Specifically, in PD there is a progressive loss of neurons
from the substantia nigra that compose the mesostriatal pathway (Dauer and Przedborski,
2003; Fahn, 2010; Wirdefeldt et al., 2011). As discussed above, the mesostriatal pathway
is involved in movement control, and, therefore, patients with PD display bradykinesia,
rigidity, and resting tremors (Meissner et al., 2011; Wirdefeldt et al., 2011). These
symptoms are commonly treated with dopamine-replacement therapies, the most
common of which is the dopamine precursor L-DOPA (Clarke, 2010; Meissner et al.,
2011). Further, dopamine D2 receptor agonists, such as pramipexole, ropinirole, and
rotigotine are also used (Meissner et al., 2011). However, the treatments with
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dopaminergic agents are limited by the onset of dyskinesias, which are involuntary
movements perturbing head, trunk, and limbs (Clarke, 2010; Meissner et al., 2011;
Wirdefeldt et al., 2011). Even though a cure for PD remains to be discovered, the
dopamine-replacement therapies (at least in the initial several years of treatment) provide
significant reductions of the symptoms caused by the disease and result in considerable
improvements in the quality of life of PD patients (Clarke, 2010; Meissner et al., 2011).
In contrast to the therapies for PD, the antipsychotic agents that are utilized to
treat schizophrenia are antagonists of dopamine receptors (specifically the dopamine D2
receptor) (Lieberman et al., 2008). According to the dopamine hypothesis of
schizophrenia, antagonists of dopamine receptors would decrease the positive symptoms
of schizophrenia (Creese et al., 1976). In agreement, the first generation of antipsychotic
drugs (e.g. haloperidol, fluphenazine) are antagonists of the dopamine D2 receptor, while
second generation antipsychotic drugs (e.g. clozapine, risperidone) display a more
complex pharmacology, antagonizing both the dopamine D2 and serotonin 5HT2A
receptors to yield their antipsychotic effects (Mailman and Murthy, 2010). The first
generation agents, and to some extent the second generation antipsychotic drugs, also
antagonize other GPCRs in the central nervous system (e.g. muscarinic and histamine as
well as other dopamine and serotonin receptors) resulting in a number of side effects
(Lieberman et al., 2008).
It has been hypothesized that in schizophrenia there is an enhancement in the
dopaminergic activity of the mesolimbic system that leads to the positive symptoms of
the disease (e.g. hallucinations, though disorders, delusions), and a decrease in
dopaminergic activity in the mesocortical pathway that is associated with the negative
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symptoms (e.g. poor self care, social withdrawal, blunted emotion) (Guillin et al., 2007;
Lieberman et al., 2008; Mailman, 2007). Therefore, it has been suggested that a partial
agonist of the dopamine D2 receptor would inhibit dopaminergic activity in the
mesolimbic system and enhance dopaminergic activity in the mesocortical pathway,
giving rise to the theory of “dopamine stabilizers” (Mailman and Murthy, 2010;
Tamminga and Carlsson, 2002).
Aripiprazole is a partial agonist of the dopamine D2 receptor and has been
proposed to be a prototype for third generation antipsychotics (Jones et al., 2009;
Mailman and Murthy, 2010). In clinical studies, aripiprazole was effective in acute and
maintenance treatments of schizophrenia (DeLeon et al., 2004). Aripiprazole was also
better than the second generation antipsychotic olanzapine for improving neurocognitive
symptoms and was efficacious for treatments of other behavioral and mental illnesses,
such as bipolar disorder and treatment-resistant anxiety and mood disorders (DeLeon et
al., 2004; Pae et al., 2011). Remarkably, in comparison to other antipsychotic drugs,
aripiprazole displays a significantly lower propensity of causing extrapyramidal
symptoms and other commonly observed side effects (Marder et al., 2003).
Notably, there are a few additional hypotheses besides “dopamine stabilization”
that have been suggested to explain aripiprazole’s improved clinical effects, including
functional selectivity (Allen et al., 2011; Brust et al., 2015b; Burris et al., 2002; Mailman
and Murthy, 2010; Shapiro et al., 2003; Urban et al., 2007b). The studies conducted to
examine the molecular pharmacology of aripiprazole report interesting and often
contrasting results. For instance, previous studies utilizing HEK and CHO cells have
demonstrated that aripiprazole is a partial agonist for recruitment of β-arrestin and
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inhibition of cAMP accumulation through the dopamine D2 receptor (i.e. Gα signaling)
(Allen et al., 2011; Burris et al., 2002; Lawler et al., 1999; Shapiro et al., 2003). In
contrast, it has also been reported that, in CHO cells, aripiprazole is an antagonist in
GTPγS binding assays with the dopamine D2 receptor, which may suggest some level of
G protein inhibition (Fell et al., 2009; Shapiro et al., 2003). It was also revealed that
aripiprazole failed to activate outward potassium currents following activation of the
dopamine D2 receptor in MES-23.5 cells, indirectly suggesting that it was inactive or
possibly an antagonist for Gβγ signaling through the dopamine D2 receptor (Shapiro et
al., 2003). Therefore, it appears that the molecular pharmacology of aripiprazole is
dependent on the model system (i.e. cell line) and the method used to measure dopamine
D2 receptor activity.
The functional selectivity studies previously performed with aripiprazole-like
compounds suggest somewhat opposing hypotheses. It has been proposed that
aripiprazole’s antagonist properties at β-arrestin signaling through the dopamine D2
receptor are key for antipsychotic activity (Beaulieu et al., 2007a; Del'guidice et al.,
2011; Masri et al., 2008). Inhibition of β-arrestin results in higher Akt activity and, thus,
glycogen synthase kinase 3 inhibition potentially leading to antipsychotic activity
(Beaulieu et al., 2008; Beaulieu et al., 2005; Urs et al., 2012). In contrast, it has been
shown by another group that aripiprazole is a partial agonist of β-arrestin through the
dopamine D2 receptor (Allen et al., 2011). They reported that aripiprazole analogs that
selectively activate β-arrestin cause behaviors consistent with antipsychotic activity with
decreased extrapyramidal symptoms in mice. These seemingly opposing hypotheses can
be merged by presuming that some level of β-arrestin agonism/antagonism (i.e. partial
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agonism) or dopamine D2 receptor stabilization of that pathway is important for
antipsychotic activity.

1.4
1.4.1

Opioid receptors

Neuroanatomy and function of opioid receptors
Opioid receptors are among the most studied GPCRs. To date, 4 different types of

opioid receptors have been described: µ- (for morphine), δ- (for vas deferens), and κ- (for
ketocyclazocine) opioid, and nociceptin/orphanin FQ receptors (Waldhoer et al., 2004).
All opioid receptors couple to inhibitory Gαi/o proteins, although coupling to additional G
proteins (i.e. Gs and Gz) has also been reported (Evans, 2004; Waldhoer et al., 2004). And
the structures of all opioid receptors have been determined through X-ray crystallography
studies (Granier et al., 2012; Manglik et al., 2012; Thompson et al., 2012; Wu et al.,
2012). Because opioids have been used for medical and recreational purposes since
antiquity, the analgesic and psychotropic effects that result from the activation of these
receptors (especially the µ-opioid receptor) are well known (Evans, 2004; Williams et al.,
2013). In general, µ- and δ-opioid receptors are associated with analgesia and reward, the
κ-opioid receptor is linked to dysphoria, and the nociceptin/orphanin FQ receptors are
linked to pain processing and anxiolytic actions (Evans, 2004; Meis, 2003; Raehal et al.,
2011; Waldhoer et al., 2004; Williams et al., 2013).
The µ-opioid receptor is widely distributed throughout the central nervous system
(Mansour et al., 1988). Brain regions such as the neocortex, dorsal horns of the spinal
cord, striatum, nucleus accumbens, thalamus, hippocampus, amygdala,!nucleus tractus
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solitaries,!inferior and superior colliculi, and spinal trigeminal nucleus express high levels
of the µ-opioid receptor (Mansour et al., 1995; Mansour et al., 1988). Among the cortical
regions, a high level of expression of the µ-opioid receptor in the anterior cingulate
cortex has been demonstrated in humans (Jones et al., 1991). The µ-opioid receptor is
commonly targeted for analgesic effects (Waldhoer et al., 2004). However, the onset of
tolerance, dependence, respiratory depression, and constipation limit the use of therapies
targeting this receptor (Evans, 2004; Waldhoer et al., 2004; Williams et al., 2013).
Notably, studies with knockout mice suggested that all physiological effects caused by
morphine result from the activation of µ-opioid receptors (Evans, 2004; Gaveriaux-Ruff
and Kieffer, 2002).
The δ-opioid receptor displays higher levels of expression in olfactory-related
neural areas, striatum, neocortex, amygdala, and nucleus accumbens (Mansour et al.,
1995; Mansour et al., 1988). Studies with knockout mice have suggested that the δ-opioid
receptor plays a role in pain processing and may also mediate anxiolytic effects
(Gaveriaux-Ruff and Kieffer, 2002). The δ-opioid receptor may also play a role in drug
tolerance, since mice lacking the receptor did not displays behaviors associated with
chronic morphine-mediated tolerance (Gaveriaux-Ruff and Kieffer, 2002; Zhu et al.,
1999).
κ-opioid receptors are highly expressed in the striatum, amygdala, nucleus
accumbens, neural lobe of the pituitary, hypothalamus, nucleus tractus solitarius, and
median eminence (Mansour et al., 1995; Mansour et al., 1988). The κ-opioid receptor is
commonly linked to dysphoria (Gaveriaux-Ruff and Kieffer, 2002; Waldhoer et al.,
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2004). Studies with knockout mice have suggested that κ-opioid receptor agonists may be
useful in treating visceral pain (Gaveriaux-Ruff and Kieffer, 2002; Simonin et al., 1998;
Waldhoer et al., 2004). Moreover, in κ-opioid receptor-deficient mice, behaviors
associated with naloxone-precipitated withdrawal following chronic morphine treatment
were significantly attenuated (Gaveriaux-Ruff and Kieffer, 2002; Simonin et al., 1998;
Waldhoer et al., 2004).
Nociceptin/orphanin FQ receptors display high levels of expression in the cortex,
hypothalamus, thalamus, substantia nigra, anterior olfactory nucleus, hippocampus,
amygdala, locus coeruleus, central gray, pontine nuclei, raphe complex, and spinal cord
(Meis, 2003). Originally considered to be an orphan receptor, the nociceptin/orphanin FQ
receptor was classified as an opioid receptor in 1995 with the discovery of its endogenous
ligand, the nociceptin/orphanin FQ peptide (Meunier et al., 1995; Reinscheid et al.,
1995). Studies have reported contradictory roles for the nociceptin/orphanin FQ receptor
in pain regulation. It has been previously shown that activation of nociceptin/orphanin
FQ receptor can lead to both hyperalgesia and analgesia depending on the experimental
methodologies employed (Chiou et al., 2007; Meis, 2003). Nociceptin/orphanin FQ
receptor agonists may also be useful to treat drug dependence, since activation of these
receptors has inhibitory effects on rewarding caused by morphine, cocaine, amphetamine,
and alcohol (Chiou et al., 2007). Moreover, activation of nociceptin/orphanin FQ
receptors causes anxiolytic effects, but also leads to learning and memory deficits (Chiou
et al., 2007; Meis, 2003).
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Ligands of the µ-opioid receptor as analgesics
As mentioned above, agonists of the µ-opioid receptor have been used for their

analgesic properties for thousands of years. Many of the µ-opioid receptor agonists are
currently clinically approved for treating pain (Evans, 2004; Waldhoer et al., 2004;
Williams et al., 2013). The endogenous ligands of the µ-opioid receptor include
endomorphin-1, endomorphin-2, β-endorphin, β-neoendorphin, and dermorphin
(Waldhoer et al., 2004). Peptide agonists, such as DAMGO and PL 017, as well as small
molecules, such as the clinically used morphine, fentanyl, and sufentanil can also activate
the µ-opioid receptor (Waldhoer et al., 2004).
Agonists of the µ-opioid receptor are very effective at relieving pain, however, a
number of side effects are also associated with these ligands, including sedation,
respiratory depression, nausea and vomiting, and constipation (DeWire et al., 2013;
Evans, 2004; Raehal et al., 2011). In addition, the use of these drugs is limited by the
onset of analgesic tolerance and physical dependence (DeWire et al., 2013; Evans, 2004;
Raehal et al., 2011). Therefore, it has long been a major goal in opioid research to find
ligands that would retain the analgesic properties in the absence of side effects (Evans,
2004; Raehal et al., 2011). Initial efforts focused on finding ligands that would be
selective for a specific type of opioid receptor (Evans, 2004). However, compounds that
are selective for the µ-opioid receptor also cause the commonly observed side effects
(Evans, 2004; Waldhoer et al., 2004). In fact, it has been suggested by studies with
knockout mice that both the desired analgesia as well as the side effects of morphine are
mediated by the µ-opioid receptor (Evans, 2004; Gaveriaux-Ruff and Kieffer, 2002). In
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addition, it has also been shown that selective activation of δ-opioid receptors can lead to
seizures and κ-opioid receptor-selective agonists cause dysphoria and hallucinations
(Bodnar and Klein, 2004; Evans, 2004; Killinger et al., 2010).
The relative failure of the opioid receptor type-selective ligands in eliminating the
side effects associated with opioid use and the discovery that GPCRs can activate
multiple signaling pathways have shifted the focus of opioid research towards the
discovery of biased ligands of opioid receptors, especially at the µ-opioid receptor
(Raehal et al., 2011; Violin et al., 2014). As discussed above, it appears that activation of
G proteins by the µ-opioid receptor is associated with analgesia, while recruitment of βarrestins to the receptor is linked to the side effects of opioids (Bohn et al., 2004; Bohn et
al., 2000; Bohn et al., 1999; Raehal et al., 2005). Accordingly, a ligand (TRV130) that
selectively activates Gαi/o signaling over β-arrestin recruitment to the µ-opioid receptor
displayed enhanced analgesia with a robust reduction in the opioid-associated side effects
in comparison to morphine (DeWire et al., 2013; Soergel et al., 2014).

1.4.2.1 Ligand-directed functional selectivity at the µ-opioid receptor and type 1 adenylyl
cyclase
The µ-opioid receptor and AC1 are co-expressed in areas of the central nervous
system that are linked to pain and nociception (i.e. dorsal horn neurons of the spinal cord
and anterior cingulate cortex) (Corder et al., 2013; Jones et al., 1991; Mansour et al.,
1995; Mansour et al., 1988; Wei et al., 2006; Xu et al., 2008; Zhuo, 2012). Besides direct
receptor modulation with biased ligands, another strategy to overcome the β-arrestin-
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mediated side effects of opioids and retain the desired analgesia is by targeting signaling
pathways that are downstream of the µ-opioid receptor. That µ-opioid receptors couple to
Gαi/o proteins to inhibit adenylyl cyclases suggests that direct inhibiting the adenylyl
cyclases co-expressed with the µ-opioid receptors (e.g. AC1) might be a good strategy for
the development of new classes of analgesic drugs (figure 1.9) (Corder et al., 2013;
Lamberts et al., 2011; Zhuo, 2012).

Figure 1.9 Inhibition of AC1 as a strategy to bias signaling through the µ-opioid
receptor. The µ-opioid receptor can activate several signaling pathways. Direct
inhibition of AC1 can simulate the outcomes of Gαi/o activation by the µ-opioid receptor
(related to analgesia) in the absence of the activation of additional signaling pathways
(that can lead to opioid side effects).
Activation of G proteins by the µ-opioid receptor can also cause activation of Gβγ
subunits, which have been also linked to analgesia through the modulation of GIRK
channels (Luscher and Slesinger, 2010). Activation of GIRK channels by the µ-opioid
receptor causes hyperpolarization of neurons leading to a reduction of pain perception
(Luscher and Slesinger, 2010). However, knockout of GIRK channel isoforms in mice
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causes only a reduction in the potency of opioid-induced analgesia, with no change in the
efficacy (Cruz et al., 2008; Mitrovic et al., 2003). Even though this may be because other
isoforms of GIRK channels are still expressed in those mice, it also indicates that there
may be additional mechanisms involved in µ-opioid receptor-mediated analgesia. For
instance, as discussed above, the development of chronic pain shares some cellular
mechanistic features with memory formation and maintenance, that is, strengthening of
synapses through LTP (Ferguson and Storm, 2004; Zhuo, 2012). Additionally, inhibition
of AC1 activity blocks the induction of LTP in neurons from the dorsal horn of the spinal
cord and anterior cingulate cortex (Wang et al., 2011). In thalamocortical synapses AC1stimulated PKA activity is required for trafficking of AMPA (α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid) receptors to synapses and, therefore, also to the
development of synaptic plastic changes, such as LTP and LTD (long-term depression)
(Lu et al., 2003). The inhibition of AC1 likely causes a reduction in PKA-phosphorylated
AMPA receptors that disrupts LTP in the spinal cord and anterior cingulate cortex,
resulting in a reduction of chronic pain. In addition, Gβγ subunits are also needed for
heterologous sensitization, which is a cellular mechanism linked to opioid dependence
(Watts and Neve, 2005).
It has been previously shown that AC1 knockout mice display behaviors
consistent with enhanced analgesia in comparison to wild-type mice for models of
chronic pain (Vadakkan et al., 2006). Additionally, inhibition of AC1 activity with a
small molecule (NB001) causes analgesic effects in rodent models of inflammatory and
neuropathic pain (Wang et al., 2011). Therefore, the development of AC1-selective
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inhibitors may lead to new drugs with pain relieving properties that lack the side effects
commonly associated with opioids.
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CHAPTER 2. NEW FUNCTIONAL ACTIVITY OF ARIPIPRAZOLE: ROBUST
ANTAGONISM OF D2 DOPAMINE RECEPTOR-STIMULATED Gβγ SIGNALING
As published in
Biochemical Pharmacology (2015) 93(1) 85-91.

2.1

Introduction

Functionally-selective or biased ligands distinctly activate different signaling
pathways through a single G protein-coupled receptor (GPCR) (Urban et al., 2007a).
Although classically, ligands of GPCRs have been classified as full, partial, or inverse
agonists, or antagonists; it is now accepted that the same ligand can display different
pharmacological profiles at different signaling pathways through the same GPCR
(Kenakin and Christopoulos, 2013b). Increasing evidence suggests that biased ligands
could provide safer and more effective drug therapies (Whalen et al., 2011).
The dopamine D2 receptor (DRD2) is a GPCR that is targeted in the therapies of
Parkinson’s disease and schizophrenia. The DRD2 couples to inhibitory heterotrimeric G
proteins leading to activation of Gα subunits that inhibit adenylyl cyclases, as well as
promoting Gβγ signaling. Additional adaptive signaling responses of the DRD2 include
β-arrestin recruitment and heterologous sensitization of adenylyl cyclase (Beaulieu and
Gainetdinov, 2011; Watts and Neve, 2005). The drugs used in the therapies for
Parkinson’s disease (e.g. pramipexole, ropinirole) are agonists of the Gα response of the
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DRD2, whereas those used for schizophrenia are either antagonists or partial agonists
(e.g. haloperidol, aripiprazole, respectively) (Meissner et al., 2011). The dopamine
hypothesis of schizophrenia suggests that antagonists of dopamine receptors would
decrease the positive symptoms of schizophrenia (Creese et al., 1976). Accordingly, the
first generation of antipsychotic drugs antagonizes the DRD2, while second generation
antipsychotic drugs have more complex pharmacology, antagonizing both the DRD2 and
5HT2A for their therapeutic effects. The first generation agents, and to some extent the
second generation antipsychotics, also antagonize other GPCRs in the central nervous
system (e.g. muscarinic and histamine as well as other dopamine and serotonin receptors)
resulting in a number of side effects (Lieberman et al., 2008). Aripiprazole has been
suggested to be a potential prototype for third generation antipsychotic drugs (Jones et
al., 2009; Mailman and Murthy, 2010). It has also been hypothesized that the unique
actions of aripiprazole involve functional selectivity or its partial agonist activity that
may stabilize dopaminergic signaling through the DRD2 (Allen et al., 2011; Burris et al.,
2002; Fell et al., 2009; Mailman and Murthy, 2010; Shapiro et al., 2003; Urban et al.,
2007b). Previous studies have demonstrated that aripiprazole is a partial agonist for
inhibition of cAMP accumulation through the DRD2 (i.e. Gα signaling) (Burris et al.,
2002; Lawler et al., 1999; Shapiro et al., 2003). In contrast, it has also been reported that
aripiprazole is an antagonist in GTPγS binding assays with the DRD2 (Fell et al., 2009;
Shapiro et al., 2003). It was also revealed that aripiprazole failed to activate outward
potassium currents following activation of the DRD2 in MES-23.5 cells, indirectly
suggesting that it was inactive or possibly an antagonist for Gβγ signaling through the
DRD2 (Shapiro et al., 2003).
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The observations highlighted above prompted us to further explore the molecular

pharmacology of aripiprazole at the DRD2 in comparison to a small subset of clinicallyrelevant DRD2 ligands. Specifically, we measured Gα signaling, Gβγ signaling,
heterologous sensitization of adenylyl cyclase, and dynamic mass redistribution (DMR).
Aripiprazole displayed a unique profile for activation of G protein signaling, behaving as
a robust antagonist of Gβγ subunits, while partially activating Gα. Additionally,
aripiprazole was a weak partial agonist/antagonist for heterologous sensitization of
adenylyl cyclase and in cell-based DMR experiments. The unique antagonist profile of
aripiprazole may provide additional opportunities for developing targeted antipsychotic
agents.

2.2
2.2.1

Methods

Compounds used:
The following compounds were purchased from Sigma-Aldrich (St. Louis, MO):

dopamine hydrochloride, (±) quinpirole dihydrochloride, pramipexole dihydrochloride,
ropinirole hydrochloride, rotigotine hydrochloride, clozapine, spiperone and 3-isobutyl-1methylxanthine (IBMX). Aripiprazole was purchased from Santa Cruz Biotechnology
(Dallas, TX). Forskolin was purchased from Tocris (Ellisville, MO). Haloperidol was a
gift from D. Nichols, Purdue University.
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Cell culture:
Human embryonic kidney (HEK) cells stably expressing the long isoform of the

DRD2 (HEK-D2) and adenylyl cyclase 2 (HEK-AC2/D2) or adenylyl cyclase 5 (HEKAC5/D2) were cultured in Dulbecco’s Modified Eagle Medium (Life Technologies,
Grand Island, NY) supplemented with 5% bovine calf serum (Hyclone, Logan, UT), 5%
fetal clone I (Hyclone, Logan, UT), and Antibiotic-Antimycotic (Life Technologies,
Grand Island, NY), and puromycin (Sigma-Aldrich, St. Louis, MO) (HEK-D2), or zeocin
(Life Technologies, Grand Island, NY) and G418 (Invivogen, San Diego, CA) (HEKAC2/D2), or puromycin and G418 (HEK-AC5/D2). Cells were grown to confluency in
15 cm dishes, harvested with Cell Dissociation Buffer (Life Technologies, Grand Island,
NY), and resuspended in 5 ml of fetal bovine serum (Hyclone, Logan, UT) containing
10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO), 1 ml was added to cryovials
that were incubated overnight at -80°C in a CoolCell device (BioCision, Larkspur, CA)
for cryopreservation. On the following day, cryovials were stored in liquid N2 until the
assay day.

2.2.3

Gαi/o assay:
Cryopreserved HEK-AC5/D2 cells were thawed in a 37°C water-bath,

resuspended in 10 ml optiMEM (Life Technologies, Grand Island, NY) and centrifuged
at 500 x g for 5 min. The cells were resuspended in 1 ml optiMEM, and counted using a
Countess automated cell counter (Life Technologies, Grand Island, NY). Cells were
plated in a white, flat bottom, low-volume, tissue culture-treated 384 well plate
(PerkinElmer, Shelton, CT) at a final density of 2 000 cells/well. The plate was
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centrifuged for 1 min at 100 x g and incubated in a 37°C humidified incubator for 1 h.
The DRD2 ligand was added followed by the addition of forskolin (3 µM final
concentration) containing IBMX (0.5 mM final concentration). Cells were incubated at
room temperature for 1 h and cAMP accumulation was measured using Cisbio’s dynamic
2 kit (Cisbio Bioassays, Bedford, MA) according to the manufacturer’s instructions.
Plates were analyzed for fluorescent emissions at 620 nm and 665 nm using 330 nm as
the excitation wavelength in a Synergy 4 (Biotek, Winooski, VT), and ratiometric
analysis was carried out by dividing the 665 nm emissions by the 620 nm emissions to
extrapolate the cAMP concentrations from a cAMP standard curve.

2.2.4

Gβγ assay:
The assays used to measure Gβγ activation by the DRD2 were done using the

specific properties of AC2, AC4, and AC7 (Cooper and Crossthwaite, 2006; Watts and
Neve, 1997). These AC isoforms are insensitive to inhibition by Gαi/o and potentiated by
Gβγ subunits from Gαi/o-coupled receptors in the presence of direct AC-activators
(Federman et al., 1992). HEK-AC2/D2 cells were thawed in a 37°C water-bath,
resuspended in 10 ml optiMEM and centrifuged at 500 x g for 5 min. The resuspension
and centrifugation steps were repeated. The cells were resuspended in 1 ml optiMEM and
counted. Cells were diluted to a concentration of 5 x 105 cells/ml and the cell suspension
was added to a white, low-volume, flat bottom, tissue culture-treated 384 well plate
resulting in a final density of 2 500 cells/well. The plate was centrifuged for 1 min at 100
x g and incubated in a 37°C humidified incubator for 1 h. The DRD2 ligand was added
and cAMP accumulation was initiated by the addition of phorbol 12-myristate 13-acetate
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(PMA) (Tocris, Ellisville, MO) (final concentration of 1 µM) in the presence of 0.5 mM
IBMX, to specifically stimulate AC2. Cells were incubated at room temperature for 1 h
and cAMP accumulation was measured as described above.

2.2.5

Heterologous sensitization of adenylyl cyclase:
Heterologous sensitization is a cellular adaptive response that occurs after

prolonged periods of stimulation of Gαi/o-coupled receptors (Watts and Neve, 2005). For
the sensitization assays, HEK-AC5/D2 cells were thawed in a 37°C water bath,
resuspended in 10 ml optiMEM and centrifuged at 500 x g for 5 min. The cells were
resuspended in 1 ml optiMEM and counted. Cells were diluted and added to a white, flatbottom, tissue culture-treated 384 well plate (PerkinElmer, Shelton, CT) resulting in a
final density of 2 000 cells/well. The plate was centrifuged for 1 min at 100 x g and
incubated in a 37°C humidified incubator for 1 h. To induce sensitization, the DRD2
ligand was added and cells were pre-incubated in a 37°C humidified incubator for 2 h.
Following the 2 h incubation (i.e. sensitization period), forskolin (300 nM final
concentration) containing 0.5 mM IBMX was added in the presence of 1 µM spiperone
(to inhibit acute ligand activation of the DRD2). Cells were incubated at room
temperature for 1 h and cAMP accumulation was measured as described above.

2.2.6

Dynamic Mass Redistribution:
For DMR assays, 20 µl per well of HEK-D2 growth medium was added to an

EnSpire-LFC 384 fibronectin coated plate (PerkinElmer, Waltham, MA). Plate was
centrifuged for 1 min at 500 x g and placed in 37°C humidified incubator while cell
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suspension was prepared. HEK-D2 cells were dissociated and collected using 0.25%
trypsin-EDTA (Life Technologies, Grand Island, NY), diluted to 10 ml with growth
media, centrifuged at 500 x g for 5 min, and resuspended in 10 ml growth medium. Cells
were counted and diluted to 5 x 105 cells/ml in growth medium, and 30 µl of this
suspension was added to wells of EnSpire plate to achieve a final density of 15 000
cells/well and a total volume of 50 µl/well. Cells were incubated in a humidified
incubator until 95% confluent, typically 16-24 h. One hour prior to assay, cell-containing
wells were washed twice with room temperature assay buffer, 20 mM HEPES (Fisher
Scientific, Pittsburg, PA) in HBSS (Life Technologies, Grand Island, NY) using a
JANUS MDT Mini liquid handling robot (PerkinElmer, Shelton, CT). Cells were then
incubated for 1 h at ambient temperature to allow development of stable DMR baseline.
In agonist-mode, cells were incubated for 1 h in 40 µl assay buffer, and in antagonist
mode cells were incubated for 1 h in 30 µl assay buffer supplemented with 10 µl of 5X
concentrated antagonist. After 1 h, 10 baseline reads were generated, 10 µl of 5X
concentrated agonist was added, and final DMR was measured for 200 reads using a
PerkinElmer EnSpire Multimode Plate Reader equipped with Corning EPIC label-free
technology (Waltham, MA). DMR responses were quantified by measuring both the total
area under the curve (AUC) as well as the maximal DMR peak amplitude using
GraphPad Prism (GraphPad Software Inc., San Diego, CA).
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Data collection and analysis:

All data reported represent the average of at least three independent experiments
conducted in duplicate. Analysis for EC50/IC50 values and 95% confidence intervals (C.I.)
were completed using GraphPad Prism.

2.3
2.3.1

Results

Aripiprazole is a partial agonist for Gα activation through the DRD2:
Previous studies have reported that aripiprazole is a partial agonist for inhibition

of cAMP and an antagonist in GTPγS binding assays through the DRD2 (Burris et al.,
2002; Fell et al., 2009; Lawler et al., 1999; Shapiro et al., 2003). The work presented here
examined DRD2-mediated inhibition of cAMP production in HEK cells stably expressing
the DRD2 and adenylyl cyclase 5 (AC5). AC5 is abundantly expressed in the striatum, a
region where the DRD2 is highly expressed and is thought to be essential for motor
effects associated with DRD2 antagonism (Chern, 2000; Lee et al., 2002). In agreement
to what was previously observed, aripiprazole was a partial agonist for inhibiting
forskolin-mediated cAMP production displaying 48% of dopamine’s response (figure
2.1). The prototypical DRD2 agonist, quinpirole resulted in 98% of dopamine’s response,
and clinically used DRD2 agonists pramipexole, ropinirole, and rotigotine also had
agonist responses with > 80% of dopamine’s response (table 2.1). The potency of
aripiprazole (ca. 4 nM) was comparable to that of dopamine and quinpirole (table 2.1).
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Figure 2.1 Inhibition of cAMP accumulation by aripiprazole and reference DRD2
ligands. Activation of Gαi/o was assessed by measuring inhibition of forskolin-stimulated
cAMP accumulation in HEK-AC5/D2 cells. Data shown represent the average and
S.E.M. of at least three independent experiments conducted in duplicate.
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Table 2.1 Activation of Gαi/o, Gβγ, heterologous sensitization, and DMR downstream of the DRD2. Gαi/o signaling and
heterologous sensitization were measured in HEK-AC5/D2 cells. Activation of Gβγ signaling was measured in HEK-AC2/D2
cells and DMR was measured in HEK-D2 cells. EC50 values are shown in nM with the 95% confidence interval. The maximal
effects are shown as percentages of dopamine’s response with standard errors. Data in the table represent the average of at
least three independent experiments. ND = not determined.

Compound

Gαi/o activation
Max
EC50 (nM)
effect
(%)

Gβγ activation
Max
EC50 (nM)
effect
(%)

Dopamine

1.5 (0.6-3.7)

100 (±3)

46 (28-75)

100 (±4)

Quinpirole

2.1 (1.0-4.5)

98 (±3)

74 (50109)

99 (±4)

Aripiprazole

4.1 (0.6-30)

48 (±9)

ND

-

Pramipexole

0.9 (0.4-1.9)

87 (±4)

17 (7.736)

98 (±5)

Ropinirole

2.6 (1.1-6.1)

81 (±6)

47 (25-89)

70 (±4)

Rotigotine

0.05 (0.010.11)

88 (±4)

0.7 (0.31.4)

79 (±4)

Sensitization
Max
EC50 (nM)
effect
(%)
8.2 (5.5100 (±3)
12.2)
8.2 (6.1124 (±3)
11.0)
1.6 (0.718 (±1)
3.9)
1.9 (1.2119 (±4)
3.0)
8.4 (6.1126 (±3)
11.5)
0.5 (0.3116 (±5)
0.7)

DMR (AUC)
Max
EC50 (nM)
effect
(%)
7.6 (6.7-8.6)

100 (±1)

37 (32-44)

104 (±1)

730 (4331231)

32 (±1)

8.3 (5.8-12)

98 (±2)

33 (26-41)

100 (±2)

ND

-
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Aripiprazole is an antagonist of Gβγ signaling through the DRD2:
To explore the ability of aripiprazole to modulate Gβγ signaling through the

DRD2 we measured Gβγ-mediated potentiation of AC2. AC2 is insensitive to direct Gαi/o
regulation, but is conditionally activated by Gβγ subunits (Federman et al., 1992). Thus,
the cAMP response of AC2 to stimulators such as Gαs or PKC can be potentiated by the
release of Gβγ subunits following DRD2 activation (Watts and Neve, 1997). HEK cells
stably expressing the DRD2 and AC2 were used, and DRD2-mediated potentiation of
PKC-stimulated AC2 activity was assessed. As expected, dopamine and quinpirole
elicited dose-dependent enhancements in PMA-stimulated cAMP accumulation in HEKAC2/D2 cells with EC50 values of 46 nM (95% CI [28 - 75 nM]) and 74 nM (95% CI [50
- 109 nM]), respectively (figure 2.2A). Pramipexole, ropinirole, and rotigotine also led to
dose-dependent enhancements of the cAMP response, resulting in 98%, 70%, and 79% of
dopamine’s response, respectively (table 2.1). In contrast, aripiprazole failed to enhance
PMA-stimulated AC2 activity in this assay (figure 2.2A).
Because aripiprazole did not activate Gβγ subunit signaling in our assay, we
explored its ability to antagonize dopamine’s Gβγ response. As shown in figure 2.2B,
aripiprazole fully inhibited dopamine’s response in a dose-dependent manner, with an
IC50 value of 2.8 nM (95% CI [1.3 - 5.9 nM]). These results are consistent with the lack
of GIRK channel activation observed by Shapiro et al. (2003) and demonstrate for the
first time that aripiprazole is a potent antagonist of Gβγ signaling through the DRD2. The
first generation antipsychotic drug haloperidol and the second generation antipsychotic
drug clozapine were also tested for antagonism of Gβγ signaling. Both compounds fully
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inhibited dopamine’s response, with IC50 values of 1.5 nM (95% CI [0.8 - 2.8 nM) and
575 nM (95% CI [270 - 1 226 nM]), respectively (figure 2.2B).
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Figure 2.2 Modulation of Gβγ subunit signaling by aripiprazole and reference
DRD2 ligands in HEK-AC2/D2 cells. A. Activation of Gβγ signaling was assessed by
measuring DRD2 potentiation of the AC2-stimulated cAMP accumulation in HEKAC2/D2 cells. B. Antagonism of dopamine’s Gβγ response through the DRD2. Cells
were treated with antagonists for 30 min, followed by a 1 h incubation with 300 nM
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dopamine in the presence of 1 µM PMA and 0.5 mM IBMX. Data shown represent the
average and S.E.M. of at least three independent experiments conducted in duplicate.

2.3.3

Aripiprazole’s effects on heterologous sensitization of AC5:
Because aripiprazole was a partial agonist for Gαi/o activation and an antagonist

for Gβγ subunits, a more complex G protein-dependent signaling pathway was analyzed.
Heterologous sensitization of adenylyl cyclase is a cellular adaptive response that occurs
following chronic activation of Gαi/o-coupled receptors (Watts and Neve, 2005). In this
phenomenon, prolonged Gαi/o agonist exposure results in a marked enhancement of
subsequent drug-stimulated cAMP accumulation. Mechanistically, it has been shown that
both Gα and Gβγ subunits of G proteins are involved in this cellular response (Watts and
Neve, 2005).
Heterologous sensitization of AC5 was measured in HEK cells stably expressing
AC5 and the DRD2 by pre-incubating the cells with the DRD2 ligands for 2 h before
stimulating cAMP accumulation with forskolin. Pretreatment with dopamine or
quinpirole resulted in dose-dependent enhancements in the forskolin-stimulated cAMP
accumulation with EC50 values of approximately 8 nM (figure 2.3A). Pramipexole,
ropinirole, and rotigotine also led to heterologous sensitization of AC5 and had maximal
responses greater than 100% (table 2.1). In contrast, aripiprazole displayed a weak partial
agonist response in this assay, resulting in only 18% of dopamine’s response (table 2.1).
Subsequent antagonist-mode studies revealed that aripiprazole was a potent partial
antagonist of dopamine-mediated heterologous sensitization of AC5 with an IC50 value of
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4.2 nM (95% CI [2.0 - 8.9 nM]) (figure 2.3B). Additional studies revealed that
haloperidol and clozapine were also antagonists of heterologous sensitization with IC50
values of 0.2 nM (95% CI [0.1 - 0.2 nM]) and 473 nM (95% CI [320 - 698 nM]),
respectively (figure 2.3B).
A

Heterologous sensitization
(% dopamine)

150

Dopamine
Aripiprazole
Quinpirole

125
100
75
50
25
0
-25
-14

-12

-10

-8

-6

-4

log [drug] (M)

B
Heterologous sensitization
(% dopamine)

125

Haloperidol
Aripiprazole
Clozapine

100
75
50
25
0
-25
-12

-10

-8

-6

-4

log [drug] (M)
Figure 2.3 Heterologous sensitization by aripiprazole and reference DRD2 ligands in
HEK-AC5/D2 cells. A. Heterologous sensitization of AC5 was measured by pre-treating
cells with the DRD2 ligand for 2 h, followed by the addition of forskolin in the presence
of IBMX and spiperone. B. Antagonism of heterologous sensitization of AC5 was
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measured by pre-incubating the cells with antagonists for 30 min, followed by a 2 h pretreatment with 100 nM dopamine. Cyclic AMP accumulation was then stimulated by
forskolin in the presence of IBMX and spiperone. Data shown represent the average and
S.E.M. of three independent experiments conducted in duplicate.

2.3.4

Aripiprazole’s effects on dynamic mass redistribution (DMR):
Another approach used to measure aripiprazole’s effects on the DRD2 employed

a label-free holistic approach. DMR responses reflect changes in cellular shape, which
are hypothesized to be caused by the intracellular movement of biomolecules due to
ligand-mediated signaling events (Schroder et al., 2011). These assays were conducted in
HEK cells stably expressing the DRD2. Dopamine, quinpirole, pramipexole, and
ropinirole displayed dose-dependent positive DMR responses with EC50 values ranging
from approximately 8 nM to 40 nM (table 2.1). All of these compounds elicited similar
maximal responses, ranging from 98% to 104% of dopamine’s response (table 2.1). In
contrast, aripiprazole was only a partial agonist, with a maximal effect of 32% (figure
2.4A). Aripiprazole was also the least potent compound tested with an EC50 value of 730
nM (95% CI [433 - 1 231 nM]), which could be due to its antagonism of Gβγ subunits
(table 2.1). In contrast, dopamine was the most potent compound (table 2.1).
Subsequent studies evaluated aripiprazole in antagonist mode. After pretreatment
with aripiprazole for 1 h, the DMR response of HEK-D2 cells to an EC90 concentration of
dopamine (100 nM) was completely abrogated (figure 2.4B). This also held true for the
DRD2 antagonists haloperidol and clozapine. Haloperidol was the most potent inhibitor
tested, possessing an IC50 of 5.5 nM (95% CI [4.0 - 7.7 nM]). Aripiprazole and clozapine
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exhibited IC50s of 316 nM (95% CI [230 - 434 nM]) and 2.2 µM (95% CI [1.4 - 3.6
µM]), respectively (figure 2.4B).
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Figure 2.4: Modulation of DMR by aripiprazole and reference DRD2 ligands in
HEK-D2 cells. A. Dynamic mass redistribution was measured during stimulation with
DRD2 ligands, and the AUC at each drug concentration was determined. B. Antagonism
of DMR was measured by pre-treating cells with antagonists for 1 h, followed by
incubation with 100 nM dopamine. Data shown represent the average and S.E.M. of at
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least three independent experiments conducted in duplicate. Experiments conducted by
Michael P. Hayes and David L. Roman.

2.4

Discussion

Aripiprazole is considered to be the prototypical third generation antipsychotic
drug. Clinical studies showed that aripiprazole was efficacious in acute and maintenance
treatments of schizophrenia (DeLeon et al., 2004). Aripiprazole was also superior to the
second generation antipsychotic drug olanzapine in improving neurocognitive symptoms.
Additionally, aripiprazole was effective as an adjunctive therapy for major depressive
disorder and in treating other behavioral and mental illnesses, such as bipolar disorder
and treatment-resistant mood and anxiety disorders (DeLeon et al., 2004; Pae et al.,
2011). Remarkably, in comparison to other antipsychotic drugs, aripiprazole displays a
significantly lower tendency to cause commonly observed side effects including
extrapyramidal symptoms (Marder et al., 2003).
One of the hypotheses for the improved clinical profile of aripiprazole is that it
acts as a “dopamine stabilizer”. This hypothesis proposes that because of aripiprazole’s
partial agonist activity, when there are high levels of dopamine, aripiprazole behaves as a
partial antagonist, inhibiting dopamine’s actions; however, in low levels of dopamine,
aripiprazole behaves as a partial agonist, increasing or normalizing dopaminergic
signaling (Tamminga and Carlsson, 2002). Though this seems to be a simple and logical
explanation, the unique pharmacological profile of aripiprazole in a variety of assays
suggests that additional molecular mechanisms may underlie aripiprazole’s improved
clinical effects.
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For example, aripiprazole also has high affinity for other GPCRs, such as the

dopamine D3 receptor, the 5HT2A 5HT1A, 5HT2B, and 5HT7 serotonin receptors, the H1
histamine receptor, and the α1-adrenergic receptor (Shapiro et al., 2003). The functional
effects of aripiprazole on serotonin receptors have been studied revealing partial agonist
activity in assays with 5HT1A, 5HT2A, 5HT3C, 5HT7 serotonin receptors, inverse agonism
of the 5HT2B serotonin receptor, and antagonism of the 5HT6 serotonin receptor (Shapiro
et al., 2003). These data suggest that the unique clinical profile of aripiprazole could be
due to its interactions with other GPCRs (see Shapiro et al., 2003).
Aripiprazole also displays a somewhat unique pharmacological profile in
functional assays with the DRD2. Consistent with our results, aripiprazole partially
inhibited forskolin-mediated cAMP accumulation in multiple cell lines (Burris et al.,
2002; Lawler et al., 1999; Shapiro et al., 2003). However, in GTPγS binding assays with
the DRD2 aripiprazole fully antagonized the responses to both dopamine and quinpirole
(Fell et al., 2009; Shapiro et al., 2003). These data examining Gα responses are
seemingly at odds and may be explained by some degree of functional selectivity for
downstream Gα responses or alternatively, signal sensitivity or the lack of amplification
in the GTPγS binding assays (Harrison and Traynor, 2003). In our model of Gαi/o
activation, the DRD2 was co-expressed with AC5 in HEK cells. AC5 was used because it
is the most abundant adenylyl cyclase in the striatum, a brain region in which the DRD2
is highly expressed (Chern, 2000; Lee et al., 2002). Another unique finding from Shapiro
et al. was that aripiprazole failed to increase the activity of GIRK channels (Shapiro et
al., 2003). Activation of GIRK channels by the DRD2 is a signaling event that is
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mediated by Gβγ subunits and has been associated with decreased synaptic activity in the
basal ganglia (Luscher and Slesinger, 2010). The lack of a GIRK response was not
explored further, however, we hypothesized that aripiprazole could potentially act as an
antagonist for this downstream Gβγ response. HEK cells stably expressing AC2 and the
DRD2 were employed to measure Gβγ activation in response to aripiprazole and control
ligands. Although AC2 was used as a reporter of Gβγ signaling in our model, AC2 is
widely expressed in the central nervous system (Chern, 2000). Consistent with our
hypothesis, aripiprazole dose-dependently antagonized dopamine’s ability to potentiate
AC2 activity. The potency for blocking this Gβγ response was similar to that observed
with the first generation antipsychotic drug, haloperidol. The results described above may
be explained by transducer-effector coupling efficiency (i.e. agonists showed greater
potency for Gα versus Gβγ), but also may suggest some level of pathway functional
selectivity at divergent signaling pathways downstream of the DRD2.
Heterologous sensitization of adenylyl cyclase is a cellular adaptive response that
occurs following prolonged periods of Gαi/o-coupled receptor activation (Watts and
Neve, 2005). DRD2-induced sensitization results in a marked enhancement of subsequent
cAMP signaling in both cellular and animal models (Chester et al., 2006; Culm et al.,
2004; Watts and Neve, 2005). Enhanced or persistent DRD2 activation has also been
implicated in schizophrenia (Beach et al., 2008; Kellendonk et al., 2006; Seeman et al.,
2006). Further, elevated brain adenylyl cyclase activity and cAMP levels in the
cerebrospinal fluid have been reported in schizophrenics (Kerwin and Beats, 1990; Muly,
2002). The weak partial agonist response as well as antagonist activities observed for
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aripiprazole in our heterologous sensitization assays suggest that prolonged treatments
with similar drugs will produce only modest adaptive effects on cAMP accumulation.
This outcome may be a beneficial feature for antipsychotic drugs like aripiprazole that
appear to stabilize or normalize DRD2 effects on intracellular second messengers both
acutely and chronically.
The novel responses we observed with aripiprazole in the G protein-mediated
assays prompted us to explore DMR as an unbiased readout for ligand-receptor signaling.
In DMR experiments, plane polarized light is passed through specialized biosensor
microtiter plates containing cells in the absence and presence of receptor ligand (Schroder
et al., 2010). Mass movement within the cell causes changes in the cellular index of
refraction, leading to altered resonance of polarized light. As mass moves towards the
bottom of the plate, longer wavelengths resonate, producing positive DMR signals.
Alternatively, as cellular mass moves away from the plate, shorter wavelengths resonate
and a negative DMR signal is observed. DMR is a label-free approach for measuring
integrated receptor responses in real time and has been used with a variety of G proteincoupled receptors. Previous work has characterized DMR signals mediated through Gαs,
Gαi/o-, Gαq/11-, and Gα12/13-coupled receptors including muscarinic M2 and M3 receptors,
α2- and β2-adrenergic receptors, and GPR55 (Ferrie et al., 2014; Schroder et al., 2010).
The DMR measurement profile of Gαi/o-coupled receptors presumably involves Gα
subunit activation because it is prevented by pertussis toxin (Schroder et al., 2010).
Consistent with this idea and similar to the heterologous sensitization results, aripiprazole
elicited a weak partial agonist response. Somewhat surprisingly, aripiprazole
pretreatment prevented the cellular DMR responses to an EC90 concentration of
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dopamine. This lack of observed partial agonist activity may reflect receptor
desensitization or more speculatively, altered receptor conformations leading to altered
functional affinity in the DMR experiments (i.e. altered affinity of aripiprazole for the
receptor-signaling protein complexes responsible for DMR changes) (Kenakin, 2014b).
Previous functional selectivity studies with aripiprazole-like drugs propose
somewhat opposing hypotheses. It has been posited that aripiprazole’s ability to
antagonize β-arrestin signaling through the DRD2 is key for antipsychotic activity
(Beaulieu et al., 2007a; Del'guidice et al., 2011; Masri et al., 2008). Antagonism of βarrestin leads to higher Akt activity and, thus, glycogen synthase kinase 3 inhibition
potentially yielding antipsychotic activity (Beaulieu et al., 2008; Beaulieu et al., 2005;
Urs et al., 2012). In contrast, another team has shown that aripiprazole is a partial agonist
of β-arrestin through the DRD2 (Allen et al., 2011). They reported that aripiprazole
analogs that selectively activate β-arrestin display behaviors consistent with antipsychotic
activity with reduced extrapyramidal symptoms in mice. These apparently opposing
hypotheses can be reconciled by assuming that some degree of β-arrestin
agonism/antagonism (i.e. partial agonism) or DRD2 receptor stabilization of that pathway
is important for antipsychotic efficacy.
The present results demonstrate a novel DRD2 modulation profile for aripiprazole
(i.e. antagonist for Gβγ signaling) that may suggest some level of functional selectivity or
signaling pathway specificity. In addition to aripiprazole, we showed that other clinically
used antipsychotic drugs (i.e. haloperidol and clozapine) also antagonized Gβγ signaling
through the DRD2. These results suggest that inhibition of Gβγ signaling through the

!

!

74

DRD2 may be a shared feature of clinically used antipsychotic drugs. Two recent studies
suggest that partial agonism of β-arrestin and inhibition of Gαi/o through the DRD2 may
provide antipsychotic activity with reduced motor side effects (Allen et al., 2011; Chen et
al., 2012). Unfortunately, the activity of the ligands identified by those studies at Gβγ
signaling effectors (e.g. AC2 or GIRK) was not examined. It would be interesting to
explore the activity of such ligands for Gβγ-dependent pathways. The physiological
responses to antagonism of DRD2 Gβγ signaling are anticipated to be diverse and involve
multiple effectors expressed throughout the central nervous system including multiple
AC isoforms (i.e. AC2, AC4, and AC7), GIRK and N-type calcium channels,
phospholipase C isoforms, phosphoinositide 3 kinase, glycine receptors, phosducin,
tubulin, and ERK (Khan et al., 2013; Lin and Smrcka, 2011). The potential number of
pathways involving the DRD2 Gβγ effectors may represent a new multi-pathway
approach versus a multi-receptor strategy in the “War on Mental Illness.”
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CHAPTER 3. BIAS ANALYSES OF PRECLINICAL AND CLINICAL D2
DOPAMINE LIGANDS: STUDIES WITH IMMEDIATE AND COMPLEX
SIGNALING PATHWAYS
As published in:
The Journal of Pharmacology and Experimental Therapeutics (2015) 352(3)
480-93.
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3.1

Introduction

G protein-coupled receptors (GPCRs) are coupled to multiple signaling pathways
(Lefkowitz and Shenoy, 2005), and different ligands can show unique profiles for
modulation of these individual pathways. Moreover, some ligands demonstrate functional
selectivity (or biased agonism) behaving as agonists for one signaling pathway while
acting as antagonists for another (Kenakin and Christopoulos, 2013b; Urban et al.,
2007a).
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Functional selectivity has been proposed as a strategy to improve the safety and

specificity of drug therapies targeting GPCRs (Whalen et al., 2011). For example,
several studies suggest that G protein-biased ligands for the µ-opioid receptor, which
selectively activate G proteins over β-arrestin, can lead to enhanced analgesic effects and
decreased tolerance (Bohn et al., 2004; Bohn et al., 2000; Bohn et al., 1999). It has also
been suggested that G protein-biased ligands for the β2-adrenergic receptor may lead to
reduced receptor tachyphylaxis in bronchodilation therapies for obstructive lung diseases
(Deshpande et al., 2008; Wang et al., 2009b). Additionally, β-arrestin-biased ligands for
the β1-adrenergic receptor may provide the beneficial effects of β-blockers along with
increased cell survival, a desired outcome in patients with arrhythmia and hypertension
following myocardial infarctions (DeWire and Violin, 2011).
The D2 dopamine receptor (DRD2) is the primary target in therapies for treating
schizophrenia and Parkinson’s disease, however, modulation of DRD2 activity is also
associated with a number of side effects including dysregulation of motor and pituitary
function. The DRD2 couples to Gαi/o subunits and leads to several signaling events
through the release/rearrangement of G proteins, such as inhibition/sensitization of
adenylyl cyclase, Gβγ potentiation of AC2, and ERK activation as well as β-arrestin
recruitment (Beaulieu and Gainetdinov, 2011; Watts and Neve, 2005). These diverse
signaling pathways make the DRD2 of great interest in studies of functional selectivity.
Several studies have demonstrated that agonists differ in their ability to activate various
pathways. For example, R(-)propylnorapomorphine (RNPA) and S()propylnorapomorphine (SNPA) differ in their ability to regulate activity of adenylyl
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cyclases compared to ion channels. RNPA and SNPA were reported as full agonists for
activation of Gαi/o, whereas both compounds displayed no detectable activity for the
activation of G protein-coupled inwardly-rectifying potassium channels (GIRK) through
the DRD2 (Gay et al., 2004). Notably, blockade of β-arrestin recruitment reportedly is a
shared property of antipsychotics that exhibit either antagonist (e.g. haloperidol), or
partial agonist (e.g. aripiprazole) activity through Gαi/o-cAMP pathways (Klewe et al.,
2008; Masri et al., 2008). This suggests that β-arrestin-biased D2 antagonists might
exhibit unique antipsychotic profiles (Masri et al., 2008). In contrast, a study with
analogs of the novel antipsychotic aripiprazole suggested that D2 ligands with Gαi/o
antagonist and β-arrestin agonist activity may have antipsychotic behavioral activity with
reduced extrapyramidal side effects in a mouse model (Allen et al., 2011).
Heightened awareness of the potential benefit of pathway-biased ligands has
created the need for methods to efficiently quantify and compare agonist-mediated
activity through multiple pathways. Recently described methods have been proposed as
tools to assess bias. The new quantitative methods incorporate efficacy and potency to
calculate “bias factors” (Kenakin and Christopoulos, 2013b; Kenakin et al., 2012;
Rajagopal et al., 2011). The values from these methods reflect the relative activities of a
test ligand with that of a reference compound for activating one effector pathway relative
to another, such as Gα versus β-arrestin signaling. Activation of more complex signaling
pathways downstream of GPCRs may require multiple effectors, and this suggests an
additional use of bias analyses. Specifically, comparisons of ligand bias profiles for more
immediate effectors versus complex pathways such as ERK phosphorylation,
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heterologous sensitization, and dynamic mass redistribution (DMR) could provide insight
on the relative contribution of the effectors toward the complex signaling pathway.
In the present study, the ability of reference or clinically-relevant ligands to activate
multiple signaling pathways coupled to the DRD2 was examined in a CHO cell line
stably expressing the human D2L receptor (CHO-D2L cells). Specifically, we analyzed
Gαi/o activation, Gβγ activation, β-arrestin recruitment, ERK phosphorylation,
heterologous sensitization, and DMR in response to a series of DRD2 ligands. The results
were analyzed using four of the most commonly used methods to measure ligand bias
(Kenakin and Christopoulos, 2013b; Rajagopal et al., 2011). The analyses revealed
general consistency across several bias models and highlight the utility of using a single
cell line in studies of functional selectivity. Additionally, the dependency of the complex
signaling pathways on the immediate effectors of the DRD2 was also explored by
comparing ligand bias profiles.

3.2
3.2.1

Methods

Compounds and other chemicals used:

The following compounds were purchased from Sigma-Aldrich (St. Louis, MO):
dopamine hydrochloride, (±) quinpirole dihydrochloride, pramipexole dihydrochloride,
R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride ((+)3-PPP), (+)bromocriptine methanesulfonate salt, R(-)propylnorapomorphine hydrochloride (RNPA),
ropinirole hydrochloride, pergolide mesylate, 3-isobutyl-1-methylxanthine (IBMX), and
rotigotine hydrochloride. Lisuride maleate and forskolin were purchased from Tocris
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(Ellisville, MO), and aripiprazole was purchased from Santa Cruz Biotechnology (Dallas,
TX). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and
ethylenediaminetetraacetic acid (EDTA) were purchased from Fisher Scientific
(Pittsburg, PA). MgCl2 and 2-Amino-2-(hydroxymethyl)-1,3-propanediol (TRIS) were
purchased from Sigma-Aldrich (St. Louis, MO).

3.2.2

Cell culture and cryopreservation:
Chinese hamster ovary (CHO) cells expressing the human dopamine D2L receptor

(CHO-D2L) in the PathHunter® β-Arrestin GPCR assay platform were purchased from
DiscoveRx (Freemont, CA). Cells were grown in Ham’s F12 media supplemented with 1
mM L-glutamine (Thermo Scientific, West Palm Beach – FL), 10% fetal bovine serum
(FBS) (Hyclone, Logan, UT), 50 U/ml penicillin, 50 µg/ml streptomycin (Life
Technologies, Grand Island, NY), 800 µg/ml G418 (Invivogen, San Diego, CA) and 300
µg/ml hygromycin B (Fisher Scientific, Pittsburg, PA). Confluent 15 cm dishes of cells
were harvested with Cell Dissociation Buffer (Life Technologies, Grand Island, NY) and
resuspended in 5 ml of FBS containing 10% dimethyl sulfoxide (Sigma-Aldrich, St.
Louis, MO), 1 ml was added to cryovials and frozen overnight at -80°C in a CoolCell
device (BioCision, Larkspur, CA). On the following day, cryovials were stored in liquid
N2 until the assay day.

3.2.3

Transient transfections:
CHO-D2L cells were plated in 15 cm dishes at a confluence of 2.6 x 106 cells/dish

with culture media without selection antibiotics, and incubated at 37°C in a humidified
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incubator overnight. On the following day, a 6 ml solution containing 30 µg of rat AC2
plasmid and 60 µl lipofectamine 2000 (Life Technologies, Grand Island, NY) in
optiMEM (Life Technologies, Grand Island, NY) was prepared and incubated at room
temperature for 45 min. The solution was added dropwise to the cells, and transfection
was carried out for 48 h. Cells were harvested, and cryopreserved as described above.

3.2.4

Gαi/o assay:
Cryopreserved CHO-D2L cells were thawed in a 37°C water-bath, resuspended in

10 ml optiMEM and centrifuged at 500 x g for 5 min. The supernatant was aspirated, the
cells were resuspended in 1 ml optiMEM and counted using a Countess automated cell
counter (Life Technologies, Grand Island, NY). Cells were diluted to reach a
concentration of 3 x 105 cells/ml. 10 µl/well of cell suspension was added to a white, flatbottom, tissue culture-treated 384 well plate (PerkinElmer, Shelton, CT) resulting in a
final density of 3000 cells/well. The plate was centrifuged for 30 sec at 100 x g and
incubated in a 37°C humidified incubator for 1 h. After incubation, 5 µl/well of DRD2
ligand was added followed by the addition 5 µl/well of forskolin (10 µM final
concentration) in 0.5 mM IBMX. Cells were incubated at room temperature for 1 h and
cAMP accumulation was measured using Cisbio’s dynamic 2 kit (Cisbio Bioassays,
Bedford, MA) according to the manufacturer’s instructions. Plates were analyzed for
fluorescent emissions at 620 nm and 665 nm using 330 nm as the excitation wavelength
in a Synergy 4 (Biotek, Winooski, VT), and ratiometric analysis was carried out by
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dividing the 665 nm emission by the 620 nm emission to extrapolate the cAMP
concentration from a cAMP standard curve.

3.2.5

β-arrestin assay:
Cryopreserved CHO-D2L cells were thawed in a 37°C water-bath, resuspended in

10 ml optiMEM and centrifuged at 500 x g for 5 min. The supernatant was aspirated, the
cells were resuspended in 1 ml optiMEM and counted. Cells were diluted to reach a
concentration of 2.5 x 105 cells/ml. 10 µl/well of cell suspension was added to a white,
flat bottom, low-volume, tissue culture-treated 384 well plate (PerkinElmer, Shelton, CT)
resulting in a final density of 2500 cells/well. The plate was centrifuged for 30 sec at 100
x g and incubated in a 37°C humidified incubator overnight. On the following day 2.5
µl/well of DRD2 ligands or vehicle/buffer control was added to the cells. Following drug
addition, cells were incubated in a 37°C humidified incubator for 1.5 h. Recruitment of βarrestin to the DRD2 was assessed using the PathHunter® assay (DiscoveRx, Freemont,
CA) according to the manufacturer’s instructions. The PathHunter® assay utilizes an
enzyme complementation platform in which the GPCR is tagged with ProLinkTM and βarrestin 2 is tagged with an enzyme acceptor, upon interaction between the GPCR and βarrestin 2, the two fragments complement to generate a functional β-galactosidase that
converts substrate to a chemiluminscent signal (Zhao et al., 2008) that was measured in a
Synergy 4.
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Gβγ assay:
The Gβγ assay uses a regulatory characteristic that is specific for AC2, AC4, and

AC7 (Cooper and Crossthwaite, 2006; Watts and Neve, 1997). These isoforms of AC are
insensitive to inhibition by Gαi/o and conditionally activated by Gβγ subunits from Gαi/olinked receptors in the presence of direct AC2 activators (Federman et al., 1992). CHOD2L cells transiently transfected with AC2 as described above were thawed in a 37°C
water-bath, resuspended in 10 ml optiMEM and centrifuged at 500 x g for 5 min. The
supernatant was aspirated and the resuspension and centrifugation steps were repeated.
The supernatant was aspirated, the cells were resuspended in 1 ml optiMEM and counted.
Cells were diluted to reach a concentration of 4 x 105 cells/ml and 5 µl/well of cell
suspension was added to a white, low-volume, flat bottom, tissue culture-treated 384 well
plate resulting in a final density of 2000 cells/ well. The plate was centrifuged for 30 sec
at 100 x g and incubated in a 37°C humidified incubator for 1 h. Plates were removed
from the incubator, and 2.5 µl/well of DRD2 ligand was added. Cyclic AMP
accumulation was initiated by the addition of 2.5 µl/well of phorbol 12-myristate 13acetate (PMA) (final concentration of 1 µM) in the presence of 0.5 mM IBMX, to
specifically stimulate AC2 (Watts and Neve, 1997). Cells were incubated at room
temperature for 1 h and cAMP accumulation was measured as described above.

3.2.7

Heterologous sensitization assay:
Heterologous sensitization assays were carried out as previously described

(Conley et al., 2014). Briefly, cryopreserved CHO-D2L cells were thawed in a 37°C
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water-bath, resuspended in 10 ml optiMEM and centrifuged at 500 x g for 5 minutes. The
supernatant was aspirated, the cells were resuspended in 1 ml optiMEM and counted.
Cells were diluted to reach a concentration of 3 x 105 cells/ml. 10 µl/well of cell
suspension was added to a white, flat-bottom, tissue culture-treated 384 well plate
resulting in a final density of 3000 cells/well. The plate was centrifuged for 30 sec at 100
x g and incubated in a 37°C humidified incubator for 1 h. After incubation, 5 µl/well of
DRD2 ligand was added to the cells, and the cells were incubated in a 37°C humidified
incubator for 2 h to accomplish sensitization. Following sensitization, 5 µl/well of
forskolin in IBMX and spiperone was added to the cells at final concentrations of 10 µM,
0.5 mM, and 1 µM, respectively. Cells were incubated at room temperature for 1 h, and
cAMP accumulation was measured as described above.

3.2.8

ERK assay:
Cryopreserved CHO-D2L cells were thawed in a 37°C water-bath, resuspended in

10 ml optiMEM and centrifuged at 500 x g for 5 min. The supernatant was aspirated and
resuspension and centrifugation steps were repeated. The supernatant was aspirated, the
cells were resuspended in 1 ml optiMEM and counted. Cells were diluted to reach a
concentration of 2 x 106 cells/ml. 8 µl/well of cell suspension was added in a white, lowvolume, flat bottom, tissue culture-treated 384 well plate resulting in a final density of
16,000 cells/well. The plate was centrifuged for 30 sec at 100 x g and incubated in a 37°C
humidified incubator for 2 h. Following incubation, 4 µl/well of DRD2 ligand was added
to the cells. Cells were incubated for 10 minutes at room temperature and ERK
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phosphorylation was measured using the Cellul’erk assay (Cisbio Bioassays, Bedford,
MA) according to the manufacturer’s instructions. Plates were read for fluorescent
emissions at 620 nm and 665 nm using 330 nm as the excitation wavelength in a Synergy
4.

3.2.9

Dynamic mass redistribution (DMR) assay:
DMR assays were performed as described previously (Schroder et al., 2011).

Briefly, 20 µl optiMEM was added to each well of one quadrant of a fibronectin-coated
EnSpire LFC-384 plate (PerkinElmer, Shelton, CT) and centrifuged at 500 x g for 30 sec.
Cryopreserved CHO-D2L cells were thawed, centrifuged, and counted as described above.
Cells were diluted to achieve 3.3 x 105 cells/ml. 30 µl/well of this dilution was added to
the plate for a final volume of 50 µl, and plate was incubated for 16-24 h in a 37°C
humidified incubator. 1-1.5 h prior to assay, media was aspirated and cells were washed
twice with room temperature HBSS (Life Technologies, Grand Island, NY) supplemented
with 20 mM HEPES, which served as assay buffer, using a JANUS MDT Mini
(PerkinElmer, Shelton, CT). Cells were incubated in 40 µl/well assay buffer for 1-1.5 h at
ambient temperature. 10 baseline DMR reads were performed, 10 µl/well of DRD2
ligand dissolved in assay buffer was added, and DMR was measured for 200 reads. All
DMR measurements were made using an EnSpire plate reader according to
manufacturer’s protocols (PerkinElmer, Shelton, CT). Following assay, wells were
visually inspected for confluency, and wells with significantly reduced cellular density
(<60%) were excluded from further analysis. Receptor activation was quantified by
calculating the maximum DMR peak intensity achieved during 40 reads, approximately
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20 min, following ligand addition. Receptor activation was also quantified by calculating
area under the curve (AUC) of the initial DMR peak that occurred during the first 40
reads, with resultant concentration response curves being indistinguishable from
maximum DMR peak intensity curves (data not shown).

3.2.10 Membrane preparations:
Cells were grown to confluency in 15 cm dishes. Culture media was aspirated,
replaced with 10 ml ice-cold lysis buffer (1 mM HEPES, 2 mM EDTA, pH 7.4) and
incubated on ice for 10 min. Cells were scraped using a sterile cell scraper, suspended in
the lysis buffer, triturated by pipetting up and down, and centrifuged at 30,000 x g for 20
min at 4°C. The supernatant was discarded. The pellet was resuspended in receptor
binding buffer (4 mM MgCl2, 50 mM TRIS, pH 7.4), homogenized using a Kinematica
homogenizer (Kinematica, Switzerland) and aliquoted in 1 ml fractions. The aliquots
were centrifuged at 12,000 x g for 10 min at 4°C, the supernatant was decanted, and the
pellet was frozen and stored in a -80°C freezer until the assay day.

3.2.11 Isotherm binding assay:
The isotherm binding assays were done using [3H] methylspiperone (PerkinElmer,
Shelton, CT) as described previously (Vidi et al., 2008). Membrane aliquots were thawed
on ice and resuspended in receptor binding buffer at a final concentration of
approximately 30 ng/µl of membrane protein. Total binding reactions were carried out in
receptor binding buffer containing increasing concentrations of [3H] methyspiperone and
membrane suspension in a total volume of 500 µl. Non-specific binding was assessed in
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the presence of 5 µM butaclamol. Reactions were incubated for 30 minutes at 37°C and
then harvested in a 96-well Packard Filtermate harvester (PerkinElmer, Shelton, CT) to
type B glass fiber filter plates (Millipore, Billerica, MA). Concentration of radioligand
was determined by pipetting [3H] methylspiperone directly onto the wells of the filter
plates for “total radioactivity”. The plates were dried overnight, and 40 µl/well of
MicroScint 0 scintillation fluid (PerkinElmer, Shelton, CT) was added. Radioactivity was
measured in a Packard TopCount scintillation detector (PerkinElmer, Shelton, CT).

3.2.12 Competitive binding assay:
Competitive binding assays were conducted in the presence of 0.4 nM [3H]
methylspiperone. Total and non-specific binding were determined as described for the
isotherm binding assay, except that the competitive binding reactions were carried out in
the presence of 75 µM 5’-guanylyl-imidodiphosphoate (GppNHp ; Sigma-Aldrich, St.
Louis, MO) (Kent et al., 1980). Competitive binding reactions contained increasing
concentrations of test compound, [3H] methylspiperone, GppNHp, membrane suspension,
and receptor binding buffer. The reactions were incubated, harvested, and radioactivity
was quantified as described above.

3.2.13 Bias and data analyses:
All data were analyzed using GraphPad Prism 6 (GraphPad Software Inc., San
Diego, CA). Ligand bias was assessed using four different methods. The equimolar
comparison was done by plotting normalized responses of two signaling pathways for
equal concentrations of ligand against each other. Shifts on the plots toward one of the
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axes in comparison with the reference compound (dopamine) indicated bias for the
pathway on that axis.
The equiactive comparison was done using the ratios of relative activity as
previously described (Ehlert, 2008; Griffin et al., 2007; Rajagopal et al., 2011) using the
following equation:
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Where Emax is the maximal effect of the compound, EC50 is the EC50 value of
the compound, lig is the compound being analyzed, ref is the reference compound, path1
is one of the pathways being analyzed, and path2 is the other pathway being analyzed.
For the transduction coefficient method, functional data was plotted in the Black
and Leff operational model (Black and Leff, 1983) and the analysis was done as
previously described (Kenakin et al., 2012), except for the standard errors, which were
calculated individually for each compound. The following equation was used for this
analysis:
!"#$!!"#$%& = ΔΔ!"#
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Where τ is the coupling efficiency and KA is the conditional affinity. Both were

obtained by fitting the data to the Black and Leff operational model.
The compounds were also analyzed using the sigma comparison, which was done
by fitting the functional data in the Black and Leff operational model (Black and Leff,
1983) setting the KA to the ligands’ dissociation constant (Ki) obtained from the
competitive binding assays carried in the same CHO-D2L cells used for the functional
studies. Data were analyzed as previously described (Rajagopal et al., 2011) using the
following equations:
!!"# = !"#

!!"#
!!"#

!"#!!

!"#$!!"#$%& =

!!"#

!"#!!

− !!"#
2

Where τ is the coupling efficiency and σ is the effective signaling.
For all methods the natural ligand, dopamine was used as the reference
compound. Statistical analyses were done in GraphPad Prim 6 using one-way ANOVA
followed by Dunnett’s post hoc test with a p value < 0.05.

3.3 Results
3.3.1

β-arrestin recruitment and Gαi/o activation:
The first pathway downstream of the DRD2 examined was the recruitment of β-

arrestin using the PathHunter® assay from DiscoveRx (figure 3.1A and table 3.1).
Rotigotine and lisuride potently stimulated recruitment of β-arrestin with EC50 values of
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0.2 nM and 0.4 nM, respectively. (+)-3-PPP was the least potent compound with an EC50
value of 925 nM. Aripiprazole and lisuride displayed partial agonist activity for the
recruitment of β-arrestin with maximal effects lower than 80% of the effect of dopamine.
The second signaling pathway examined was the canonical DRD2 activation of
Gαi/o by measuring inhibition of forskolin-stimulated cAMP accumulation. These studies
were performed in the same line of CHO-D2L cells used for the β-arrestin assay. As seen
in table 2.1 from chapter 2, the ProLinkTM tag at the DRD2 did not cause any significant
changes in ligand-induced DRD2-stimulated Gαi/o activation (table 1). The compounds
displayed a wide range of potencies for activation of Gαi/o (figure 3.1B and table 1) with
the most potent compounds being rotigotine, pergolide, and lisuride with EC50 values of
20 pM, 40 pM, and 70 pM, respectively. The least potent compound was (+)-3-PPP with
an EC50 value of 8.6 nM. Aripiprazole displayed partial agonist activity with efficacy
equal to 65% of the maximal effect of dopamine. The majority of the compounds were
more potent at inhibition of cAMP accumulation than recruitment of β-arrestin.
Alternatively, RNPA was more potent in stimulating recruitment of β-arrestin (table 3.1),
suggesting that this compound displays bias for the β-arrestin pathway.
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Figure 3.1 Activation of three signaling pathways downstream of the DRD2 in
CHO-D2L cells. A. Recruitment of β-arrestin to the DRD2 was measured using the
PathHunter assay from DiscoveRx. B. Activation of Gαi/o by the DRD2 was measured by
assessing inhibition of forskolin-mediated cAMP production. C. Activation of Gβγ by the
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DRD2 was assessed by measuring potentiation of PMA-stimulated cAMP accumulation
in CHO-D2L cells transiently transfected with AC2. Data represent the average and
S.E.M. of at least three independent experiments.
More detailed bias analyses for Gαi/o and β-arrestin were completed employing
the previously described methods of measuring ligand bias using dopamine as the
reference compound. The equimolar comparison identified apparent biased agonists
through qualitative analyses (figure 3.2A). For example, the data points of rotigotine are
shifted toward the β-arrestin recruitment axis in comparison to data points from
dopamine (figure 3.2A). The qualitative nature of this method precludes statistical
analyses. However, in comparison with the current quantitative analyses, the equimolar
comparison may be useful for comparing compounds that are antagonists or inverse
agonists for one or more of the signaling pathways under investigation.
The results from the Gαi/o and β-arrestin assays were then analyzed using three
recently described quantitative methods that incorporate functional data from
concentration response curves. The equiactive comparison model compares the log of the
ratios of the relative activity of test compounds to the reference compound (Ehlert, 2008;
Griffin et al., 2007; Rajagopal et al., 2011). When functional data were compared using
the equiactive comparison, five compounds (lisuride, bromocriptine, aripiprazole,
rotigotine, and RNPA) displayed statistically significant bias for the recruitment of βarrestin compared to Gαi/o with RNPA displaying the greatest degree of bias (figure
3.2B). The bias patterns observed here generally reflect the patterns seen in the potency
ratios for β-arrestin activity versus Gαi/o (table 3.1).
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Table 3.1 Potency and maximal effects of the compounds tested for downstream effectors of the DRD2. Data is an
average of at least three individual experiments conducted in duplicate. EC50 values are in nM and the 95% confidence interval
is shown in parentheses. Maximal effects are shown as a percentage of dopamine’s maximal response, standard errors are
shown in parentheses. Potency ratios of β-arrestin recruitment/ Gαi/o activation were also included. ND – not determined.
β-arrestin 2 recruitment
Compound

Max effect
EC50 (nM)

(%dopamine)

Gβγ activation

Max effect
EC50 (nM)

(%dopamine)

Max effect
EC50 (nM)

Potency (EC50) ratio
β-arrestin/Gαi/o

(%dopamine)

100 (±2)

1.2 (0.7-2.1)

100 (±3)

171 (72-407)

100 (±8)

103

64 (59-70)

96 (±1)

1.2 (0.9-1.6)

100 (±2)

145 (89-236)

103 (±4)

53

Lisuride

0.4 (0.3-0.6)

66 (±2)

0.07 (0.04-0.14)

106 (±5)

2.2 (0.4-12.0)

30 (±6)

9

Bromocriptine

2.9 (1.9-4.4)

101 (±4)

1.9 (0.9-4.3)

104 (±3)

0.5 (0.1-2.1)

34 (±5)

2

Aripiprazole

3.6 (2.5-5.2)

19 (±1)

1.3 (0.5-3.1)

65 (±4)

ND

-19 (±5)

3

Rotigotine

0.2 (0.1-0.3)

111 (±4)

0.02 (0.007-0.03)

95 (±3)

1.5 (0.3-6.9)

54 (±9)

10

(+)-3-PPP

925 (809-1058)

92 (±1)

8.6 (4.9-15.1)

108 (±4)

518 (136-1973)

57 (±9)

108

RNPA

1.9 (1.5-2.5)

101 (±2)

13 (3-57)

95 (±13)

360 (210-619)

110 (±11)

0.1

Pramipexole

12 (10-15)

94 (±2)

0.2 (0.1-0.3)

108 (±3)

20 (9-46)

86 (±5)

60

Ropinirole

49 (37-63)

92 (±2)

0.5 (0.3-0.8)

111 (±4)

100 (34-290)

56 (±6)

98

Pergolide

7.2 (5.9-8.9)

90 (±2)

0.04 (0.02-0.07)

101 (±4)

2.3 (0.6-9.5)

38 (±7)

180

Dopamine
Quinpirole

124 (100-153)
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Figure 3.2 Bias analyses of β-arrestin recruitment in comparison to Gα i/o activation
by the DRD2. A. Equimolar comparison. B. Equiactive comparison. C. Transduction
coefficient. D. Sigma comparison. Dopamine was used as the reference compound for all
the analyses. For the quantitative analyses positive values indicate bias for β-arrestin;
negative values indicate bias for Gαi/o. Data represent the average and S.E.M. of at least
three independent experiments. *p < 0.05.
The recently described transduction coefficient was then used to assess bias
(Kenakin et al., 2012). The functional data were plotted in the Black and Leff operational
model (Black and Leff, 1983) in order to calculate values for coupling efficiency (τ) and
conditional affinity (KA ). The Δlog (τ/KA) ratios for the reference compound were
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calculated and subtracted from the Δlog (τ/KA) ratios of test compounds at each
respective pathway to calculate bias (Kenakin et al., 2012). In agreement with the
equiactive comparison, this approach identified the same five compounds as biased for
recruitment of β-arrestin (figure 3.2C). In contrast to the equiactive model, the
transduction coefficient model identified pergolide as biased for Gαi/o in comparison to
β-arrestin recruitment. An inspection of the potency ratios also identifies pergolide as the
most Gαi/o-selective compound (table 3.1).
A third quantitative model also uses the Black and Leff operational model (Black
and Leff, 1983) with the notable requirement for dissociation constants (Ki) for each
ligand (Rajagopal et al., 2011). For this analysis we performed competitive binding
assays in membranes prepared from the same CHO-D2L cell line that was used for the
functional studies. The affinity values (Ki) of the compounds for the DRD2 were
measured using [3H]methylspiperone (table 3.2). Competitive binding experiments were
carried out in the presence of GppNHp to uncouple receptors from G proteins and
provide a more homogenous receptor state (Kent et al., 1980). The bias factors from the
sigma model were very similar to the bias factors obtained from the other quantitative
analyses (figure 3.2D). Four of the five compounds that were identified as biased for βarrestin recruitment using the other methods were also identified using the sigma model
(lisuride, bromocriptine, aripiprazole, and RNPA). In all three quantitative models,
RNPA was identified as the most biased compound for recruitment of β-arrestin.
Notably, in each of the quantitative bias analyses above aripiprazole was identified as
significantly biased for β-arrestin recruitment. These findings appear inconsistent with
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simple pharmacological inspection. For example, aripiprazole was a partial agonist for
Gαi/o activation and β-arrestin recruitment with relative efficacies of 65% and 19%,
respectively. Furthermore, the EC50 values of aripiprazole were 1.3 nM for Gαi/o
activation versus 3.6 nM for β-arrestin recruitment. Taken together, these values imply
aripiprazole is biased for Gαi/o activation in comparison to β-arrestin recruitment due to
increased efficacy and potency. This discrepancy can be accounted for by considering
that dopamine, the reference compound, is nearly 100 times more potent for Gαi/o
activation than β-arrestin recruitment. This highlights the importance of the choice and
activity of the reference compound in bias analysis and interpretation. Measures of bias
are always considered relative to the activity of the reference compound.
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Table 3.2 Affinity constants of the compounds for the DRD2. Log Ki values and
standard errors are shown in the table. The results are an average and S.E.M. of at least
three independent experiments.
Compound
Dopamine

Log Ki
-4.83 (±0.04)

Quinpirole

-5.03 (±0.09)

Aripiprazole

-7.40 (±0.08)

Lisuride

-9.27 (±0.17)

Bromocriptine

-8.02 (±0.10)

Rotigotine

-7.10 (±0.06)

(+)-3-PPP

-4.61 (±0.05)

RNPA

-7.89 (±0.04)

Pramipexole

-5.53 (±0.08)

Ropinirole

-5.28 (±0.14)

Pergolide

-6.49 (±0.15)

3.3.2

Activation of Gβγ:
The next signaling pathway downstream of the DRD2 that was analyzed was the

activation of Gβγ subunits. Activation of Gβγ by GPCRs can lead to several different
cellular responses, including activation of GIRKs, phospholipase C β2, modulation of Ntype calcium channels, and potentiation of AC2 (Lin and Smrcka, 2011). DRD2-mediated
Gαi/o activation and the subsequent release/rearrangement of Gβγ produce a conditional
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enhancement of cAMP production by AC2 when the enzyme is activated by PKC via
PMA (Watts and Neve, 1997). In order to examine Gβγ activation by the DRD2, CHOD2L cells were transiently transfected with AC2, and the potentiation of PMA-stimulated
cAMP accumulation by agonists was examined.
Consistent with activation of Gβγ, most of the compounds tested elicited an
enhanced cAMP response to PMA (figure 3.1C and table 3.1). Several compounds ((+)3-PPP, bromocriptine, ropinirole, pergolide, lisuride, and rotigotine) displayed partial
agonist profiles for Gβγ signaling with maximal activities that were lower than 80% of
dopamine’s maximal response. Aripiprazole did not display an agonist response in this
assay. The most potent compounds were bromocriptine and rotigotine, with EC50 values
of 0.5 nM and 1.5 nM, respectively, whereas the least potent compound was (+)-3-PPP
with an EC50 value of 518 nM. Dopamine and quinpirole were full agonists with EC50
values of 171 nM and 145 nM, respectively. The majority of the compounds were an
order of magnitude (>25-fold) less potent for Gβγ signaling compared to the Gαi/omediated response (table 3.1). Alternatively, bromocriptine was about 6-fold more potent
for Gβγ activity suggesting that this compound may be biased for Gβγ activation.
Bias analyses were carried out to compare Gβγ activation with Gαi/o signaling
through the DRD2. The equimolar comparison resulted in apparent bias of aripiprazole
for Gαi/o, due to the lack of response for Gβγ activation (figure 3.3A). The quantitative
methods were unable to analyze the results from aripiprazole given the lack of efficacy.
The equiactive comparison and the transduction coefficient identified bromocriptine as
biased for Gβγ activation in comparison with Gαi/o activation (figures 3.3B and 3.3C).
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Conversely, the sigma comparison suggested that pergolide was biased for Gαi/o
activation (figure 3.3D). Bias analyses for activation of Gβγ were also carried out in
comparison to β-arrestin recruitment (figure 3.4). In the equiactive comparison and
transduction coefficient, RNPA was the only compound that displayed significant bias for
β-arrestin recruitment (figures 3.4B and 3.4C). The sigma comparison identified
rotigotine as significantly biased for β-arrestin recruitment (figure 3.4D).
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Figure 3.3 Bias analyses of Gβγ in comparison to Gα i/o activation by the DRD2. A.
Equimolar comparison. B. Equiactive comparison. C. Transduction coefficient. D. Sigma
comparison. Dopamine was used as the reference compound for all the analyses. For the
quantitative analyses positive values indicate bias for Gβγ; negative values indicate bias
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for Gαi/o. Data represent the average and S.E.M. of at least three independent
experiments. *p < 0.05.
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Figure 3.4 Bias analyses of Gβγ activation in comparison to β-arrestin recruitment
to the DRD2. A. Equimolar comparison. B. Equiactive comparison. C. Transduction
coefficient. D. Sigma comparison. Dopamine was used as the reference compound for all
the analyses. For the quantitative analyses positive values indicate bias for Gβγ
activation; negative values indicate bias for β-arrestin recruitment. Data represent the
average and S.E.M. of at least three independent experiments. *p < 0.05.
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100
Heterologous sensitization of adenylyl cyclases:
After measuring the activation of immediate effectors of the DRD2, more

complex signaling pathways were analyzed. Heterologous sensitization is a cellular
adaptive response that is observed following persistent activation of Gαi/o-coupled
GPCRs (Watts, 2002). It has been shown that both Gα (which can be blocked by
pertussis toxin treatment) and Gβγ subunits (prevented by the expression of βARK-CT)
are required for this response (Ejendal et al., 2012; Watts and Neve, 2005). To explore
the potential relationship and apparent requirement for both Gα and Gβγ, sensitization
studies were completed in the CHO-D2L cells used above.
Heterologous sensitization was induced by pretreating the cells with the DRD2
ligands for two hours followed by measuring forskolin-stimulated cAMP accumulation in
the presence of spiperone. This prolonged pre-treatment results in an enhancement in
cAMP production when compared to vehicle-treated cells (figure 3.5A). The responses
observed for heterologous sensitization displayed diversity among the compounds tested
(table 3.3). Quinpirole and RNPA were more efficacious than dopamine. In contrast,
aripiprazole had no detectable response in this assay, and lisuride was an inverse agonist.
Most compounds displayed EC50 values that were comparable to those obtained for Gαi/o
activation.
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Figure 3.5 Activation of complex signaling pathways downstream of the DRD2. A.
Heterologous sensitization was assessed by pre-treating the cells with the DRD2 ligand
for two hours and then, stimulating them with forskolin. B. ERK phosphorylation was
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measured after treating the cells with the DRD2 ligand for 10 min using Cisbio’s
Cellul’erk kit. C. Dynamic mass redistribution was measured during stimulation with D2
ligands, which resulted in positive DMR. The maximal peak height was determined and
used to plot the curves. Data represent the average and S.E.M. of at least three
independent experiments. The DMR experiments (C) were conducted by Michael P.
Hayes and David L. Roman.

Ligand bias analyses were employed to compare heterologous sensitization with
activation of the immediate DRD2 effectors. The initial contrast between the methods
was that aripiprazole and lisuride could only be analyzed using the qualitative equimolar
comparison. The bias analyses for sensitization versus Gαi/o were model dependent and
identified only one biased compound (figures 3.6A and 3.6D, and 3.7A). Specifically, the
transduction coefficient method and the sigma comparison revealed no bias, whereas the
equiactive comparison identified RNPA as biased for heterologous sensitization. When
heterologous sensitization was compared to Gβγ activation, none of the compounds
displayed significant bias in any of the methods used (figures 3.6B and 3.6E, and 3.7B).
Heterologous sensitization was then compared with β-arrestin recruitment. These bias
comparisons revealed that RNPA was biased for β-arrestin recruitment and pergolide was
biased for heterologous sensitization in each of the quantitative models (figures 3.6C and
3.6F, and 3.7C). Additionally, the equiactive comparison identified rotigotine as
significantly biased for β-arrestin recruitment (figure 3.6C).
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Table 3.3 Potency and maximal effects of the compounds tested for the complex signaling pathways of the DRD2. Data
is an average of at least three individual experiments conducted in duplicate. EC50 values are in nM and the 95% confidence
interval is shown in parentheses. Maximal effects are shown as a percentage of dopamine’s maximal response, standard errors
are shown in parentheses. ND – not determined.
Heterologous sensitization
Compound

ERK phosphorylation

Max effect
EC50 (nM)

(%dopamine)

DMR (max peak height)

Max effect
EC50 (nM)

(%dopamine)

Max effect
EC50 (nM)

(%dopamine)

Dopamine

3.3 (0.9-11.6)

100 (±8)

53 (32-86)

100 (±5)

11 (8.6-15)

100 (±2)

Quinpirole

3.3 (2.3-4.7)

147 (±3)

44 (24-81)

95 (±5)

8.7 (5.8-12.9)

97 (±3)

0.09 (0.04-0.18)

-73 (±3)

1.5 (0.7-3.4)

53 (±5)

12 (7.5-19)

95 (±4)

ND

-13 (±13)

19 (3-112)

12 (±2)

593 (323-1090)

57 (±3)

0.06 (0.02-0.22)

98 (±9)

1.4 (0.7-2.9)

80 (±5)

6.4 (4.4-9.5)

120 (±3)

14 (11-18)

183 (±8)

216 (107-433)

84 (±6)

13 (9.0-17)

111 (±3)

0.05 (0.02-0.18)

105 (±9)

1.6 (0.7-3.7)

57 (±4)

14 (8.5-25)

106 (±5)

Lisuride
Aripiprazole
Rotigotine
RNPA
Pergolide
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Figure 3.6 Bias analyses using the equiactive comparison and transduction
coefficients of heterologous sensitization in comparison to effectors of the DRD2. A.
Equiactive comparison of heterologous sensitization and Gαi/o activation. B. Equiactive
comparison of heterologous sensitization and Gβγ activation. C. Equiactive comparison
of heterologous sensitization and β-arrestin recruitment. D. Analyses using the
transduction coefficients of heterologous sensitization in comparison to Gαi/o activation.
E. Analyses using the transduction coefficients of heterologous sensitization in
comparison to Gβγ activation. F. Analyses using the transduction coefficients of
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heterologous sensitization in comparison to β-arrestin recruitment. Dopamine was used
as the reference compound for all the analyses. Positive values indicate bias for
heterologous sensitization; negative values indicate bias for the DRD2 effector under
analysis. Data represent the average and S.E.M. of at least three independent
experiments. *p < 0.05.
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Figure 3.7 Bias analyses using the sigma comparison of heterologous sensitization in
comparison to effectors of the DRD2. A. Heterologous sensitization in comparison to
Gαi/o activation. B. Heterologous sensitization in comparison to Gβγ activation. C.
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Heterologous sensitization in comparison to β-arrestin recruitment. Dopamine was used
as the reference compound for all the analyses. Positive values indicate bias for
heterologous sensitization; negative values indicate bias for the immediate DRD2 effector
under analysis. Data represent the average and S.E.M. of at least three independent
experiments. *p < 0.05.

3.3.4

ERK phosphorylation:
The next complex signaling pathway analyzed was DRD2-mediated ERK

phosphorylation. β-arrestins are involved in ERK phosphorylation downstream of several
GPCRs (Lefkowitz and Shenoy, 2005; Zhu et al., 2013). However, it has been suggested
that DRD2-mediated ERK phosphorylation is a G protein-mediated event that is not
dependent on β-arrestins (Quan et al., 2008). Moreover, both G protein inactivation with
pertussis toxin and sequestration of Gβγ with βARK-CT inhibited DRD2-mediated ERK
phosphorylation in CHO cells (Oak et al., 2001). For this signaling pathway a subset of
the DRD2 ligands was tested that included dopamine and quinpirole, commonly used
reference compounds, and ligands that displayed functional selectivity for the immediate
effectors of the DRD2, such as aripiprazole, lisuride, rotigotine, RNPA, and pergolide
(figure 3.5B and table 3.3).
The quantitative bias analyses were then carried out comparing ERK
phosphorylation with the activation of the immediate effectors of the DRD2. Notably,
none of the quantitative methods identified significantly biased compounds in the
comparisons of ERK phosphorylation with Gαi/o or Gβγ activation (figures 3.8A, 3.8B,
3.8D, 3.8E, and 3.9). In contrast, the comparisons with β-arrestin recruitment using the
equiactive comparison identified aripiprazole, lisuride, rotigotine, and RNPA as
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significantly biased for β-arrestin recruitment (figure 3.8C). The transduction coefficient
and the sigma comparison were generally consistent revealing bias trends for
aripiprazole, rotigotine, and RNPA for β-arrestin recruitment (figures 3.8F and 3.9C).
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Figure 3.8 Bias analyses using the equiactive comparison and transduction
coefficients of ERK phosphorylation in comparison to effectors of the DRD2. A.
Equiactive comparison of ERK phosphorylation and to Gαi/o activation. B. Equiactive
comparison of ERK phosphorylation and Gβγ activation. C. Equiactive comparison of
ERK phosphorylation and β-arrestin recruitment. D. Analyses using the transduction
coefficients of ERK phosphorylation in comparison to Gαi/o activation. E. Analyses using
the transduction coefficients of ERK phosphorylation in comparison to Gβγ activation. F.
Analyses using the transduction coefficients of ERK phosphorylation in comparison to βarrestin recruitment. Dopamine was used as the reference compound for all the analyses.
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Positive values indicate bias for ERK phosphorylation; negative values indicate bias for
the immediate DRD2 effector under analysis. Data represent the average and S.E.M. of at
least three independent experiments. *p < 0.05.
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Figure 3.9 Bias analyses using the sigma comparison of ERK phosphorylation in
comparison to effectors of the DRD2. A. ERK phosphorylation in comparison to Gαi/o
activation. B. ERK phosphorylation in comparison to Gβγ activation. C. ERK
phosphorylation in comparison to β-arrestin recruitment. Dopamine was used as the
reference compound for all the analyses. Positive values indicate bias for ERK
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phosphorylation; negative values indicate bias for the immediate DRD2 effector under
analysis. Data are the average and S.E.M. of at least three independent experiments. *p <
0.05.

3.3.5

Dynamic mass redistribution (DMR):
The final measure of complex signaling following stimulation with DRD2 ligands

employed in this study was DMR. DMR is a label free phenotypic measure of ligandreceptor signaling that temporally monitors changes in intracellular mass via the optical
characteristics of the cells, namely the refractive index (Fang et al., 2006). DMR has been
used previously to study and characterize a number of GPCRs (Schroder et al., 2011).
Ligands characterized using this assay were dopamine and quinpirole as reference
compounds and the immediate effector biased compounds lisuride, pergolide, rotigotine,
RNPA, and aripiprazole. Of the compounds tested, only aripiprazole’s responses were
markedly different than that of dopamine (figure 3.5C and table 3.3). Rotigotine was the
most potent compound tested with an EC50 value of 6.4 nM. Aripiprazole was the only
compound tested that exhibited significantly lower efficacy as it only elicited 57% of
dopamine’s response. Aripiprazole was also the least potent compound tested with an
EC50 value of 593 nM (table 3.3).
DMR was then compared with the immediate effectors of the DRD2 using the
quantitative bias analyses. Notably, in contrast to the other complex signaling pathways,
the comparisons against all immediate DRD2 effectors resulted in significantly biased
compounds (figures 3.10 and 3.11). The equiactive comparison identified aripiprazole,
lisuride, rotigotine, and pergolide as significantly biased for Gαi/o; and RNPA as
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significantly biased for DMR in comparison to Gαi/o (figure 3.10A). The transduction
coefficient resulted in a similar pattern, except that RNPA was not significantly biased
(figure 3.10D). The sigma comparison resulted in only one significantly biased
compound in the analyses against Gαi/o. Pergolide was biased for Gαi/o (figure 3.11A).
The analyses of DMR versus Gβγ activation also resulted in significantly biased
compounds. The equiactive comparison identified lisuride, rotigotine, and pergolide as
biased for Gβγ (figure 3.10B). The transduction coefficient identified only lisuride as
biased for Gβγ (figure 3.10E). And the sigma comparison did not result in any
significantly biased compounds (figure 3.11B). All quantitative methods of analyzing
ligand bias resulted in significantly biased ligands in the comparisons between DMR and
β-arrestin recruitment. The equiactive comparison identified aripiprazole, lisuride,
rotigotine, RNPA, and pergolide as significantly biased for β-arrestin recruitment (figure
3.10C). A similar pattern was found in the analyses using the transduction coefficient,
except that pergolide was not significantly biased (figure 3.10F). The analyses using the
sigma comparison identified rotigotine, aripiprazole, and RNPA as significantly biased
for β-arrestin recruitment (figure 3.11C).
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Figure 3.10 Bias analyses using the equiactive comparison and transduction
coefficients of DMR in comparison to effectors of the DRD2. A. Equiactive
comparison of DMR and Gαi/o activation. B. Equiactive comparison of DMR and Gβγ
activation. C. Equiactive comparison of DMR and β-arrestin recruitment. D. Analyses
using the transduction coefficients of DMR in comparison to Gαi/o activation. E.
Analyses using the transduction coefficients of DMR in comparison to Gβγ activation. F.
Analyses using the transduction coefficients of DMR in comparison to β-arrestin
recruitment. Dopamine was used as the reference compound for all the analyses. Positive
values indicate bias for DMR; negative values indicate bias for the immediate DRD2
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effector under analysis. Data represent the average and S.E.M. of at least three
independent experiments. *p < 0.05.
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Figure 10.11 Bias analyses using the sigma comparison of DMR in comparison to
effectors of the DRD2. A. DMR in comparison to Gαi/o activation. B. DMR in
comparison to Gβγ activation. C. DMR in comparison to β-arrestin recruitment.
Dopamine was used as the reference compound for all the analyses. Positive values
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indicate bias for DMR; negative values indicate bias for the immediate DRD2 effector
under analysis. Data are the average and S.E.M. of at least three independent
experiments. *p < 0.05.

3.4

Discussion

Ligand bias is increasingly appreciated as a potential strategy for development of
drugs with improved efficacy and/or reduced side effects. However, debate currently
exists with regard to the most appropriate methods for assessing bias (Kenakin and
Christopoulos, 2013a; Rajagopal, 2013). In the present study, the ability of several
agonists to activate multiple signaling pathways coupled to the DRD2 was examined. The
most commonly used methods to measure ligand bias were employed and evaluated.
Bias analyses may be influenced by variability in cell-to-cell expression levels of
receptors and other signaling proteins that may lead to inconsistent results. For instance,
the potency and efficacy of aripiprazole, a DRD2 partial agonist, for activation of Gαi/o
are very cell line-dependent (Burris et al., 2002; Lawler et al., 1999; Shapiro et al., 2003)
making the choice of an appropriate cellular model an important first step. In the present
CHO-D2L model, factors such as receptor expression levels and the expression level of
immediate signaling transduction proteins, such as Gα, Gβγ, and β-arrestin, were
constant in an effort to ensure that the observed bias only reflects interactions between
ligand and receptor signaling complex.
Each of the methods used to assess ligand bias was effective in identifying
pathway-biased ligands. Although the equimolar comparison is logical and easy to
perform, its qualitative nature limits its use when comparing multiple compounds in
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structure activity relationships or screening studies (Kenakin and Christopoulos, 2013b;
Rajagopal et al., 2011). The relative merits and limitations of quantitative approaches to
measure ligand bias have been reviewed (Kenakin and Christopoulos, 2013b; Rajagopal
et al., 2011). The equiactive method uses EC50 values and the maximal effects of the
compounds from standard 4-parameter sigmoid curve-fitting approaches to calculate
relative activities (Ehlert, 2008; Griffin et al., 2007; Rajagopal et al., 2011). Both the
sigma comparison and transduction coefficient methods fit agonist data according to the
Black-Leff operational model, however, they differ in defining the agonist affinity
parameter KA. The sigma comparison utilizes affinity values derived from radioligand
binding experiments. This analysis, therefore, requires additional experiments or
literature mining to obtain the affinity constants of the drug for the receptor. Furthermore,
debate exists as to the design and appropriateness of using binding assay-derived affinity
values, as agonists often have different affinity values for multiple conformational states
of the receptor (Kenakin, 2014b; Kenakin and Christopoulos, 2013a; Nygaard et al.,
2013). The transduction coefficient model utilizes functionally-derived KA values which
incorporates the interaction between ligand, receptor, and transducer (Kenakin et al.,
2012), although the meaningfulness of these KA values has also been questioned
(Rajagopal, 2013).
Despite the differences in the analyses, the present results revealed similar trends
between the quantitative models, especially the equiactive and transduction coefficient
comparisons. The relationship between the equiactive and transduction coefficient results
was expected because the methods become nearly identical when the slopes of the
concentration response curves are close to unity (Kenakin and Christopoulos, 2013b).
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Similarly, if the experimentally determined affinity constants obtained from competitive
binding assays (Ki) are the same as the conditional affinities obtained in the transduction
coefficient method (KA), the bias factors from the sigma comparison and the transduction
coefficient would also show good agreement (Kenakin and Christopoulos, 2013b). In
contrast, poor agreement between the measured Ki value and calculated KA value lead to
inconsistent bias results. For example, bromocriptine was not biased for Gβγ signaling in
comparison to Gαi/o activation in the sigma comparison, however, it was identified as
biased in both the equiactive comparison and the transduction coefficient (figure 3.3).
This inconsistency can be explained by the constraint added by the measured Ki value to
the fit of the data in the Black and Leff operational model (Kenakin and Christopoulos,
2013b). Specifically, the Ki value of the compound was nearly 10 times larger than the
KA value obtained from the transduction coefficient yielding a sub-optimal fit (R2 = 0.56),
resulting in the lack of bias in the sigma comparison. It also appears that suboptimal
fitting of the data can also increase the noise in the calculated bias factors. This was
illustrated by examining RNPA in the analyses of Gβγ signaling using the sigma
comparison (figure 3.4B). The added constraint to the sigma comparison by the use of the
measured Ki value (which for this example was nearly 100 times lower that the KA value
and 28 times lower than the EC50 value) resulted in a poor fit (R2 = 0.49) of the data
increasing the noise in the bias analysis. One limitation of all these methods is that the
nature of the data transformations precludes the traditional quantitative analyses from
incorporating data from antagonists or inverse agonists. Furthermore, weak partial
agonists may have poor fits when using the Black and Leff equation, limiting their
analysis by these methods. For example, due to the lack of a significant agonist response
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for aripiprazole in the Gβγ activation assay, a bias factor could not be determined using
the quantitative models.
The studies presented identified several biased compounds via both quantitative
and qualitative measures. For example, aripiprazole had no agonist response for Gβγ
activation while retaining partial agonist activity for all the other immediate receptor
effectors analyzed (figure 3.1 and table 1). These results can be explained by differences
in stimulus-response coupling efficiencies (i.e. most ligands were more potent for Gαi/o
activation and β-arrestin recruitment than they were for Gβγ activation). Nevertheless,
these data are in agreement with a previous study demonstrating that aripiprazole was
inactive for stimulation of GIRK channels in MES-23.5 cells stably expressing the DRD2
(Shapiro et al., 2003). Both the activation of GIRK channels and the potentiation of AC2
result from the activation of Gβγ (Cooper and Crossthwaite, 2006; Lin and Smrcka, 2011;
Watts and Neve, 1997). Furthermore, we have recently demonstrated in HEK cells that
aripiprazole fully antagonizes dopamine’s Gβγ response through the DRD2 (Brust et al.,
2015b). In contrast, RNPA was an agonist for Gβγ activation in our assays, while it has
been shown that the compound does not activate GIRK-mediated K+-currents in CHO
cells stably expressing the DRD2 (Gay et al., 2004). Aripiprazole also failed to display
any detectable responses for heterologous sensitization. This finding is consistent with
the requirement of Gβγ activation for heterologous sensitization (Ejendal et al., 2012).
Furthermore, lisuride was an apparent inverse agonist for heterologous sensitization and
an agonist for all the other signaling pathways. This apparent functional selectivity
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profile may be due to pseudoirreversible binding as a result of the high affinity of lisuride
for the receptor (i.e. the inverse agonism observed is likely caused by continuous lisuridestimulated Gαi/o activity) (see table 3.2) (Watts and Neve, 1996).
Rotigotine, a dopamine agonist approved for treatment of Parkinson’s disease,
was among the most potent compounds for all signaling pathways, while (+)3-PPP was
the least potent compound. The remaining compounds showed similar rank orders across
the assays (table 3.1). The maximal effects of the compounds for the different signaling
pathways also varied, however, this was not specifically associated with bias. For
instance, although lisuride was a full agonist for Gαi/o and a partial agonist for β-arrestin
recruitment, the quantitative analyses indicated bias for β-arrestin recruitment. This can
be explained, in part by the reference compound used for the bias analyses. The EC50
value of dopamine for activation of Gαi/o was nearly 100 fold lower than its EC50 value
for β-arrestin recruitment, a profile that is similar to that of the prototypical DRD2
agonist quinpirole (table 3.1). However, for lisuride the magnitude of the change in the
EC50 values from Gαi/o to β-arrestin was about 10 fold (table 3.1). A similar bias profile
was attributed to aripiprazole, which had a relative efficacy of 65% for Gαi/o activation
and 19% for β-arrestin recruitment. These results highlight the strong influence that
potency has in these analyses compared with fairly large differences in efficacy
(approximately 40%).
Bias analyses may also be useful in providing mechanistic insight underlying the
activation of more complex signaling pathways downstream of a GPCR. Specifically, the
comparisons of heterologous sensitization and ERK phosphorylation with the immediate
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effectors of the DRD2 suggest that the recruitment of β-arrestin is not an essential event
for the activation of those two signaling pathways. This is consistent with the results from
assays using pertussis toxin, in which pertussis treatment fully inhibited quinpirolemediated heterologous sensitization and ERK phosphorylation (figure 10.12). For
heterologous sensitization none of the analyses found significant bias in the comparisons
with Gβγ activation. The comparisons with Gαi/o resulted in only one biased compound,
RNPA, in the equiactive comparison. In contrast, the analyses comparing heterologous
sensitization with β-arrestin recruitment resulted in several significantly biased
compounds in all of the quantitative bias analyses. This is consistent with previous
studies suggesting that G proteins but not β-arrestins are associated with heterologous
sensitization (Bohn et al., 2000; Watts and Neve, 2005). For ERK phosphorylation, none
of the compounds analyzed were significantly biased in the comparisons with Gαi/o or
Gβγ activation. However, all the quantitative bias analyses resulted in significantly biased
compounds in the comparisons with β-arrestin recruitment. These results suggest that in
our model ERK phosphorylation is mediated by G proteins and not by β-arrestins. These
results are in agreement with previous studies that suggested that DRD2-mediated ERK
phosphorylation was not dependent on β-arrestins, and that inhibition of G protein
signaling with pertussis toxin or βARK-CT also inhibited ERK phosphorylation (Oak et
al., 2001; Quan et al., 2008). The comparisons of DMR with the immediate effectors
revealed multiple biased compounds for all comparisons, except for the comparisons
between DMR and Gβγ activation in the sigma comparison. These results could be
interpreted to suggest that the immediate effectors have only limited contributions to the
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DMR response for those biased compounds. Alternatively, it is probably more reasonable
to propose that multiple effectors have significant contributions to DMR. This is
consistent with the idea that DMR is an integrated cellular response. However, there is
evidence that the most intense DMR peak is caused by activation of Gα (Ferrie et al.,
2014; Schroder et al., 2011) and treatment with pertussis toxin fully inhibited our
quinpirole-mediated DMR response (figure 3.12D).
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Figure 3.12 Effects of pertussis toxin pretreatment on Gα i/o activation, heterologous
sensitization, ERK phosphorylation, and DMR. Cells were treated overnight (16-18 h)
with 50 ng/ml pertussis toxin before the functional assays were initiated. Pertussis
treatment inhibited quinpirole-mediated inhibition of cAMP production (A.),
heterologous sensitization (B.), DRD2-mediated ERK phosphorylation (C.), quinpiroleinduced DMR changes (D.). Data are the average and S.E.M. of at least three
independent experiments. *p < 0.05 (t test with Holm-Sidak method comparing 10 µM
forskolin with 10 µM forskolin + 1 µM quinpirole [A.], buffer with 1 µM quinpirole [B.
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and D.], and basal with 1µM PMA or 1 µM quinpirole [C.]. The DMR experiments (D)
were conducted by Michael P. Hayes and David L. Roman.

Biased ligands have the potential of becoming very important tools to improve the
safety and specificity of current drug therapies. Many studies have already suggested
scenarios where biased ligands are desired (DeWire and Violin, 2011; Whalen et al.,
2011). Quantification of ligand bias is a key parameter to guide medicinal chemists in the
design of new pathway biased/functionally-selective compounds. Here a single cellular
model was used to measure activation of each signaling pathway and the different
equations used to quantify ligand bias were used and compared (Kenakin and
Christopoulos, 2013b; Rajagopal et al., 2011). We observed that there was good overall
consistency between the equiactive and transduction coefficient bias analyses when they
were used in a single cellular model. Additionally, the present studies suggest that
quantitative bias analyses can be used to offer mechanistic insight on complex GPCR
signaling pathways.
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CHAPTER 4. SMALL MOLECULE INHIBITORS OF TYPE 1 ADENYLYL
CYCLASE AS A POTENTIAL NEW FAMILY OF ANALGESIC AGENTS

4.1

Introduction

Adenylyl cyclases (ACs) are integrators of signaling through G protein-coupled
receptors (GPCRs). ACs catalyze the production of cAMP (cyclic adenosine
monophosphate) from ATP (adenosine triphosphate) (Cooper and Crossthwaite, 2006). In
general, GPCRs coupled to inhibitory G proteins (i.e. Gαi/o) inhibit ACs, while GPCRs
coupled to stimulatory G proteins (i.e. Gαs) activate ACs. Moreover, due to their
regulatory properties, AC isoforms can also be modulated by Gαq-coupled receptors and
ion channels (Cooper and Crossthwaite, 2006; Sunahara and Taussig, 2002). There are
nine isoforms of membrane-bound ACs, each of which presents different regulatory
properties and expression patterns (Sadana and Dessauer, 2009).
All membrane-bound ACs are activated by Gαs, however, based on their
additional regulatory properties these ACs can be divided into four different groups
(Cooper and Crossthwaite, 2006; Sadana and Dessauer, 2009). AC1, AC3, and AC8
belong to group 1 ACs. This group of ACs is activated by calcium/calmodulin. Group 2
ACs is composed of AC2, AC4, and AC7, which are conditionally activated by Gβγ
subunits. AC5 and AC6 represent group 3 ACs and these isoforms are inhibited by
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calcium. And AC9 is the lone AC in group 4 due to its relative insensitivity to the small
molecule AC-activator forskolin (Cooper and Crossthwaite, 2006; Sadana and Dessauer,
2009; Sunahara and Taussig, 2002).
The different regulatory properties and tissue distribution of the membranous ACs
suggest that each isoform may serve distinct purposes. In fact, the physiological functions
of individual AC isoforms have been investigated in studies employing knockout and
overexpression animal models (Sadana and Dessauer, 2009). The calcium stimulated
adenylyl cyclases, AC1 and AC8, are highly expressed in the hippocampus, which is a
brain region associated with learning and memory (Ferguson and Storm, 2004; Sadana
and Dessauer, 2009). In behavioral assays it was observed that double-knockout mice
lacking both AC1 and AC8 displayed impaired long-term memory in both passive
avoidance and contextual learning assays (Wong et al., 1999). In contrast, mice lacking
only AC1 or AC8 displayed wild-type-like behaviors (Wong et al., 1999). Notably, it has
been shown that AC1 knockout mice lose remote contextual memories faster than wildtype mice (Shan et al., 2008). These studies suggest that loss of activity of both AC1 and
AC8 lead to memory impairments in mice; however, individual knockout of either AC
only causes modest effects in a subset of behavioral assays.
Additional studies with mice lacking AC1 suggest that inhibitors of AC1 may be
useful for treating neuropathic/inflammatory pain and opioid dependence (Li et al., 2006;
Vadakkan et al., 2006; Zachariou et al., 2008). Besides the hippocampus, AC1 is also
expressed in regions of the central nervous system associated with pain and nociception,
such as the anterior cingulate cortex (ACC) and dorsal horn neurons of the spinal cord
(Wei et al., 2006; Xu et al., 2008; Zhuo, 2012). It has been hypothesized that the
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development of chronic pain shares some cellular mechanistic features with memory
formation and maintenance, that is, strengthening of synapses through LTP (long-term
potentiation) (Ferguson and Storm, 2004; Zhuo, 2012). The behavioral responses of AC1
knockout mice to inflammatory and neuropathic pain are largely inhibited compared to
wild-type animals (Vadakkan et al., 2006; Zhuo, 2012).
Consistent with those animal studies, a small molecule inhibitor of AC1 activity
(i.e. NB001) was shown to have analgesic properties in both inflammatory and
neuropathic rodent models of pain (Vadakkan et al., 2006; Wang et al., 2011). NB001
also inhibited LTP in neurons from the ACC and spinal cord, but not hippocampus
(Wang et al., 2011). The observations described above support the development and
characterization of selective AC1 inhibitors for potential use as analgesic agents. The
present study used a screening platform for identification of new selective AC1 inhibitors
from a commercially-available natural products-derived small molecule library. This was
facilitated by our previous structure-activity relationship (SAR) efforts involved with
discovering selective inhibitors of AC2 (Conley et al., 2013). One of the compounds
identified represents the most potent and selective small molecule AC1 inhibitor reported
to date. We have also examined the effects of our best compound (W001) on signaling
events mediated through the µ-opioid receptor (MOR) including AC inhibition, β-arrestin
recruitment, and heterologous sensitization of AC. Moreover, we report that W001 has
significant analgesic properties in a mouse model of inflammatory pain.
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4.2
4.2.1

Materials and Methods

Compounds and other chemicals used:

Forskolin and phorbol 12-myristate 13-acetate (PMA) were purchased from Tocris
(Ellisville, MO). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and
ethylenediaminetetraacetic acid (EDTA) were purchased from Fisher Scientific
(Pittsburg, PA). NKY80 was purchased from EMD Millipore (Temecula, CA).
Isoproterenol, A23187, adenosine monophosphate (ATP), ethyleneglycol-bis(2aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), 3-isobutyl-1-methylxanthine
(IBMX), 5’-guanylyl-imidodiphosphoate (GppNHp), TWEEN 20, MgCl2, and 2-Amino2-(hydroxymethyl)-1,3-propanediol (TRIS) were purchased from Sigma-Aldrich (St.
Louis, MO). 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(1-hydroxy-1-phenyl-4,5dihydro-1H-benzo[d]azepin-3(2H)-yl)propan-1-one (6264), 2-bromo-1-(1-phenyl-4,5dihydro-1H-benzo[d]azepin-3(2H)-yl)ethanone (W400), 6-chloro-2-(trichloromethyl)4H-chromen-4-one (W001), 2-(trichloromethyl)-4H-chromen-4-one (W002), 2-(1-(4chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(1-phenylethyl)acetamide
(W003), 4-chloro-1-methyl-3-nitroquinolin-2(1H)-one (W004), (E)-3-(3-(((1Hbenzo[d]imidazol-2-yl)thio)methyl)-4-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1one (W005), and 6-amino-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-1,4dihydropyrano[2,3-c]pyrazole-5-carbonitrile (W006) were purchased from TimTec
(Newark, DE).
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4.2.2

Cell culture:
Human embryonic kidney (HEK) cells stably expressing AC1, AC8, or AC1 with

the MOR were cultured in Dulbecco’s Modified Eagle Medium (Life Technologies,
Grand Island, NY) supplemented with 5% bovine calf serum (Hyclone, Logan, UT), 5%
fetal clone I (Hyclone, Logan, UT), and Antibiotic-Antimycotic (Life Technologies,
Grand Island, NY), and G418 (Invivogen, San Diego, CA) (HEK-AC1), or hygromycin
B (Fisher Scientific, Pittsburg, PA) (HEK-AC8), or G418 and puromycin (SigmaAldrich, St. Louis, MO) (HEK-AC1/MOR). Chinese hamster ovary (CHO) cells
expressing the MOR (CHO-MOR) in the PathHunter® β-Arrestin GPCR assay platform
were purchased from DiscoveRx (Freemont, CA). Cells were grown in Ham’s F12 media
supplemented with 1 mM L-glutamine (Thermo Scientific, West Palm Beach – FL), 10%
fetal bovine serum (Hyclone, Logan, UT), 50 U/ml penicillin, 50 µg/ml streptomycin
(Life Technologies, Grand Island, NY), G418 and hygromycin B. Cells were grown and
frozen as previously described (Conley et al., 2014).

4.2.3

Transient transfections:
HEK cells were plated in 15 cm dishes at a confluence of 9.0 x 106 cells/dish and

incubated at 37°C in a humidified incubator overnight. On the following day, a 6 ml
solution containing 9 µg of AC plasmid or venus fluorescent protein (venus) control
plasmid and 60 µl lipofectamine 2000 (Life Technologies, Grand Island, NY) in
optiMEM (Life Technologies, Grand Island, NY) was prepared and incubated at room
temperature for 45 min. The solution was added dropwise to the cells, and transfection
was carried out for 48 h. Cells were harvested, and cryopreserved as described above. For
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AC9, HEK cells were plated in 10 cm dishes at a confluence of 3.5 x 106 cells/dish and
incubated at 37°C in a humidified incubator overnight. On the following day, a 3 ml
solution containing 3 µg of AC9 plasmid or venus plasmid control plus 0.3 µg of Gαs
plasmid or venus plasmid control and 24 µl lipofectamine 2000 in optiMEM was
prepared and incubated at room temperature for 45 min. The solution was added
dropwise to the cells, transfection was carried out for 48 h, and cells were harvested and
cryopreserved.

4.2.4

Cyclic AMP accumulation in cells:
Cyclic AMP accumulation was measured as previously described (Brust et al.,

2015a). Briefly, cryopreserved cells were thawed, resuspended in optiMEM (Life
Technologies, Grand Island, NY), and plated in white, flat bottom, low-volume, tissue
culture-treated 384 well plates (PerkinElmer, Shelton, CT). Plates with cells were
incubated in a 37°C humidified incubator for 1 h. Inhibitors were added and plates were
incubated at room temperature for 30 min followed by the addition of AC stimulants in
the presence of 500 µM IBMX. Cells were incubated at room temperature for 1 h and
cAMP accumulation was measured using Cisbio’s dynamic 2 kit (Cisbio Bioassays,
Bedford, MA) according to the manufacturer’s instructions. Additional assays measured
cAMP accumulation using the HitHunter® cAMP Assay Platform from DiscoveRx
(Freemont, CA) according to the manufacturer’s instructions. Luminescence (HitHunter®
cAMP Assay) and fluorescence (Cisbio’s dynamic 2 kit) counts were measured using a
Synergy 4 (BioTek, Winooski, VT).
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4.2.5

Drug screening:
Cryopreserved HEK-AC1 cells were thawed, washed, resuspended in optiMEM

and plated into white, flat bottom, tissue culture-treated 384 well plates (PerkinElmer,
Shelton, CT) at 15 µl/well using a MultiFlo dispenser (BioTek, Winooski, VT). Cells
were incubated in a 37°C humidified incubator for 1 h. Next, test compounds from the
NDL-3000 Natural Derivatives library (TimTec, Newark, DE) were added (70 nl/well)
using a MultiPette-mounted 384 well pin tool and incubated at room temperature for 30
min. Following the incubation with test compounds, 5 µl/well of 3 µM A23187 in the
presence of 30 nM forskolin and 500 µM IBMX (final concentrations) was added to the
cells using a MultiFlo dispenser. Cells were incubated at room temperature for 1 h and
cAMP accumulation was measured as described above using a MultiFlo dispenser to
sequentially add 10 µl/well of cAMP-d2 and anti-cAMP cryptate conjugate working
solutions (Cisbio Bioassays, Bedford, MA) to the cells. Test compounds were screened in
singlet and a Z’ factor of 0.55 ± 0.22 (n = 10) was obtained using 30 µM W400 as a
positive control (Conley et al., 2013; Zhang, 1999).

4.2.6

Cell viability assays:
Cell viability assays were conducted with HEK-AC1 cells following plating and

drug incubation protocols identical to the procedures described above in “Cyclic AMP
assays in cells”. Cell viability was measured as a percentage of vehicle using 2% Triton
X-100 (Sigma-Aldrich, St. Louis, MO) as a control. The CellTiter-Glo® Luminescent
Cell Viability Assay kit from Promega (Madison, WI) was employed to assess cell
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viability according to the manufacturer’s instructions. Luminescence counts were
measured using a Synergy 4.

4.2.7

Cyclic AMP accumulation in cellular membranes:
Cellular membranes from HEK-AC1 cells were isolated and frozen as previously

described in the presence of 1 mM EGTA (Brust et al., 2015a). On the assay day
membranes were thawed on ice and resuspended in membrane buffer (33 mM HEPES,
0.1% TWEEN 20, 1 mM EGTA, pH 7.4). Protein concentration was measured using the
Pierce BCA Protein Assay kit (Thermo Scientific, West Palm Beach – FL) and 2.0 – 3.5
µg/well was plated in a white, flat bottom, tissue culture-treated 384 well plate. Inhibitors
(diluted in a 33 mM HEPES, 0.1% TWEEN 20 solution) were added and incubated for
20 min at room temperature. Next, 3 µM calmodulin or 30 µM forskolin (final
concentrations) was added in stimulation buffer (33 mM HEPES, 0.1% TWEEN 20, 1.5
mM MgCl2, 250 µM ATP, 1 µM GppNHp, 500 µM IBMX, and 500 µM CaCl2 – 10 µM
free Ca2+) and incubated at room temperature for 45 min. Cyclic AMP accumulation was
measured using Cisbio’s dynamic 2 kit according to the manufacturer’s instructions.

4.2.8

β-arrestin recruitment assay:
Recruitment of β-arrestin 2 to the MOR was measured as previously described

(Brust et al., 2015a). Briefly, CHO-MOR cells were plated in white, flat bottom, lowvolume, tissue culture-treated 384 well plates. Plates with cells were incubated in a 37°C
humidified incubator overnight. Following the incubation, AC1 inhibitors or vehicle was
added to the cells, which were incubated at room temperature for 30 min. Next, DAMGO
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or vehicle was added to cells, which were then incubated in a 37°C humidified incubator
for 1.5 h. β-arrestin 2 recruitment to the MOR was assessed using the PathHunter® assay
(DiscoveRx, Freemont, CA) according to the manufacturer’s instructions. Luminescence
counts were measured using a Synergy 4.

4.2.9

Heterologous sensitization assays:
Heterologous sensitization assays were conducted as previously described (Brust

et al., 2015b). Briefly, HEK-AC1/MOR cells were thawed and plated in white, flat
bottom, tissue culture-treated 384 well plates. Plates with cells were incubated in a 37°C
humidified incubator for 1 h. For inhibition of the development of sensitization, inhibitors
were added and plates were incubated at room temperature for 30 min, followed by
addition of DAMGO and incubation at 37°C for 2 h (to achieve sensitization). For the
assays to measure inhibition of the expression of sensitization the order of previous steps
was inverted. Next, cells were treated with 3 µM A23187 in the presence of 500 µM
IBMX and 1 µM naloxone (final concentrations) and incubated at room temperature for 1
h. Cyclic AMP accumulation was measured using Cisbio’s dynamic 2 kit according to the
manufacturer’s instructions.

4.2.10 Animals and housing:
Wild-type C57BL/6 mice, were obtained from Taconic (Cambridge City, IN).
Male mice age 5 weeks (18-23gr) were grouped housed in single grommet ventilated
plexiglass cages at ambient temperature (21ºC) in a room maintained on a reversed
12L:12D cycle (lights off at 10:00, lights on at 22:00) in our animal facility that has
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Association for Assessment and Accreditation of Laboratory Animal Care approval. Food
and water was provided ad libitum. The mice were given ~7 days to acclimatize to the
housing conditions and reverse light cycle before the start of the experiments. Mice were
then habituated to the containment boxes for the Von Frey assay. All animal procedures
were pre-approved by our Institutional Animal Care and Use Committee and were in
accordance with National Institutes of Health Guide for the Care and Use of Laboratory
Animals. Mice were not deprived of food or water at any time.

4.2.11 Assays with hippocampal homogenates:
C57BL/6 mice (13 weeks old) were decapitated, their brains were quickly
removed, and 2-mm slices encompassing the hippocampus were collected on ice. The
hippocampal region was dissected and immediately frozen in a -80°C freezer, where they
were stored until the assay day. Dissected hippocampal tissue was thawed on ice,
weighted, and homogenized in membrane buffer (2 ml/mg – wet weight) with ten manual
strokes using a Wheaton-Teflon glass homogenizer. Homogenates were added to a white,
flat bottom, tissue culture-treated 384 well plate and inhibitors (diluted in a 33 mM
HEPES, 0.1% TWEEN 20 solution) were added and incubated for 20 min at room
temperature. Next, 3 µM calmodulin (final concentration) was added in stimulation
buffer and incubated at room temperature for 45 min. Cyclic AMP accumulation was
measured using Cisbio’s dynamic 2 kit according to the manufacturer’s instructions.
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4.2.12 Inflammatory pain behavioral assays:
C57BL/6 mice were placed in suspended rectangular plastic chambers on a wire
mesh grid to habituate for 1 h. Next, a baseline measurement of mechanical sensitivity to
Von Frey filaments was performed as previously described (Corder et al., 2013; van Rijn
et al., 2012). Immediately after baseline measurements, the mice were injected with
Complete Freund's adjuvant (CFA – 10 µl, non-diluted) into the intraplantar surface of
the left hindpaw to induce inflammation (Corder et al., 2013). On the following day,
inflammatory hypersensitivity was measured using Von Frey filaments. Next, drugs were
injected intrathecally as previously described (van Rijn et al., 2012). Drug-induced
analgesia was measured 10 min after intrathecal injections using Von Frey filaments.
Data are represented as a percentage of the average baseline response.

4.3
4.3.1

Results

Screening of the NDL-3000 Natural Derivatives library:
Studies with AC-knockout mice have suggested that AC1 inhibitors may be

useful for treating neuropathic and inflammatory pain as well as opioid dependence (Li et
al., 2006; Vadakkan et al., 2006; Zachariou et al., 2008). To date there is only one small
molecule inhibitor of AC1 activity (NB001) reported in the literature that appears to be
selective in comparison to other AC isoforms (Wang et al., 2011). However, there is
evidence that NB001 is not a direct AC1 inhibitor and may act through a distinct
mechanism to inhibit AC1 activity in cells (Brand et al., 2013). Therefore, the initial
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objective of this work was to develop a screening platform that would allow the
identification of novel small molecule inhibitors of AC1.
The first step taken toward that goal was to find a robust inhibitor of AC1 activity
that would be used as a positive control in our screen. A previous study from our group
identified small molecule inhibitors of AC2 through drug library screening (Conley et al.,
2013). In follow-up assays with compounds identified by that study a ligand (6264) was
found that inhibited calcium-stimulated AC1 activity (Conley and Watts, unpublished
observations). The chemical structure of 6264 (figure 4.1) was used to conduct a small
SAR study with commercially available compounds, which ultimately led to the
identification of W400 as a robust AC1 inhibitor (figure 4.1). The use of W400 allowed
for a signal window that was amenable for screening purposes (nearly 20-fold against a
combination of 3 µM A23187 + 30 nM forskolin in HEK-AC1 cells) and, therefore, was
used as a positive control for inhibition in our screen.
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Figure 4.1 Chemical structures of AC1 inhibitors.
The robustness of our screening platform was assessed by conducting a Z’ factor
analysis using 3 µM A23187 + 30 nM forskolin as the maximal response and 30 µM
W400 (in the presence of 3 µM A23187 + 30 nM forskolin) as the minimum response
(Zhang, 1999). Our screening resulted in a Z’ factor equal to 0.55 ± 0.02 (n = 10),
confirming that our platform was amenable to drug library screening (National Institutes
of Health Chemical Genomics Center Assay Guidance Manual,
www.ncbi.nlm.nih.gov/books/NBK53196/).
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The NDL-3000 Natural Derivatives library (TimTec), which is composed of 3040
natural/natural derivative compounds with diverse chemical structures, was employed in
our screen. That forskolin (which is likely the most widely used compound that interacts
with ACs) is a natural compound (Seamon and Daly, 1981), suggests that the NDL-3000
Natural Derivatives library was a suitable choice for our screening efforts. The library
was screened (3.5 mg/l) for compounds that inhibit 3 µM A23187 + 30 nM forskolinstimulated cAMP accumulation in HEK-AC1 cells. The screen identified 35 hit
compounds (1.15%) that inhibited AC1’s response with 80% or more of W400’s
response.

4.3.2

Confirmation of inhibitory activity:
A subset of the hit compounds was tested in subsequent assays to confirm that the

inhibitors were truly AC1 inhibitors and to determine their potency at inhibiting AC1.
One of the first steps of theses follow-up assays was to determine if the inhibitors tested
were toxic to the cells. For that purpose the CellTiter-Glo® Luminescent Cell Viability
Assay kit was employed to measure cell viability (table 1). Compounds that resulted in
less than 80% cell viability of the vehicle-treated cells at 30 µM were excluded from
further experiments.
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Table 4.1 – Inhibition of A23187-stimulated AC1 activity and cell toxicity of hit compounds. Compounds were tested for
inhibition of 3 µM A23187-stimulated cAMP accumulation in HEK-AC1 cells. In the table IC50 values with 95% confidence
intervals and percent inhibition (with 100% being equal to the basal cAMP levels) with S.E.M. are reported. We also report the
cell toxicity results as a percentage of the vehicle treated cells. The data in the table represent the average of at least three
independent experiments conducted in duplicate.

Compound

Cisbio cAMP Dynamic 2 kit
IC50 - µM
% inhibition
(95% C.I.)
(SEM)

DiscoveRx cAMP HitHunter kit
IC50 - µM
% inhibition
(95% C.I.)
(SEM)

Cell viability
% vehicle
(SEM)

W001
W002
W003
W004
W005

1.1 (0.8 - 1.7)
2.8 (1.5 - 5.1)
0.6 (0.4 - 1.1)
0.4 (0.2 - 0.5)
0.8 (0.5 - 1.1)

105 (±5)
101 (±9)
108 (±6)
117 (±10)
114 (±5)

3.4 (1.8 - 6.7)
3.3 (1.7 - 6.7)
1.0 (0.5 - 1.9)
0.3 (0.1 - 0.8)
0.8 (0.4 - 1.9)

114 (±4)
118 (±16)
99 (±6)
140 (±22)
103 (±11)

85 (±6)
94 (±9)
93 (±0.1)
97 (±3)
82 (±9)

W006

10.9 (2.7 - 44)

116 (±6)

4.2 (1.2 - 14)

100 (±7)

90 (±2)

136
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Dose-response curves were then conducted to determine their IC50 values for
inhibiting A23187-stimulated cAMP accumulation in HEK-AC1 cells. A23187 is a
calcium ionophore and was chosen for these assays because it selectively activates the
overexpressed AC1 in this cellular system (Conley et al., 2013). Two different methods
of measuring cAMP accumulation were employed and resulted in overlapping results
(table 1). The potency of the compounds discovered in the screen for inhibition of
calcium-stimulated AC1 activity ranged from high nM to low µM IC50 values (figure 2a,
table 1). These data indicate that these compounds are the most potent inhibitors of AC1
reported to date.
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Figure 4.2 Dose-response curves of compounds for inhibition of cAMP production in
HEK cells stably expressing AC1 or AC8. A. Inhibition of 3 M A23187-stimulated
cAMP accumulation in HEK-AC1 cells. 6264 was used as a control. B. Inhibition of 3
M A23187-stimulated cAMP accumulation in HEK-AC8 cells. 6264 was used as a
control. All data shown represent the average and S.E.M. of at least three independent
experiments conducted in duplicate.
4.3.3

Selectivity of hit compounds against additional AC isoforms
The selectivity profile of the hit compounds was initially determined by testing

the activity of these compounds against AC8. AC8 is another calcium-stimulated AC, and
studies with double-knockout mice lacking both AC1 and AC8 suggest that non-selective
inhibition of these AC isoforms can result in significant memory impairments (Ferguson
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and Storm, 2004; Wang et al., 2011; Wong et al., 1999). HEK cells stably expressing
AC8 were also stimulated with A23187, and 6264 was used as a control in these studies,
since the compound also inhibited A23187-stimulated AC8 activity. Most compounds
tested were partial inhibitors of AC8 activity, however, W001 and W002 did not result in
any significant inhibition of AC8 at the doses tested in our cellular model (figure 4.2b).
Additional insight on the selectivity profile of W001 (the most potent selective
AC1 inhibitor) and W004 (the most potent non-selective AC1/AC8 inhibitor) was
achieved by employing HEK cells transiently transfected with each of eight different
isoforms of membrane-bound ACs (figure 4.3a). Stimulation of the AC-transfected cells
caused a marked increase in cAMP accumulation when compared to the same stimulation
paradigms in the venus-transfected control cells (figure 4.3b). As shown in figure 4.3a,
W001 appears to be selective for inhibition of AC1 in comparison to the other AC
isoforms tested. It was also observed that W001 caused a potentiation of the PMAstimulated cAMP production in HEK-AC2 cells, a phenomenon that was also observed
for 6264 (Conley and Watts, unpublished observations). W004 inhibited all ACs, except
for AC5 under the conditions tested. The non-selective AC inhibitor NKY80 was used as
a control.
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Figure 4.3 Inhibition of AC isoforms by W001, W004, and NKY80 in transiently
transfected HEK cells. A. Inhibition of cAMP accumulation in HEK transiently
transfected with venus control plasmid or AC isoforms. Venus- and AC3-transfected cells
were stimulated with 30 µM forskolin; AC1- and AC8-transfected cells were stimulated
with 3 µM A23187; AC2-transfected cells were stimulated with 1 µM PMA; AC4trasfected cells were stimulated with 10 µM isoproterenol; AC5- and AC6-transfected
cells were stimulated with 1 µM forskolin; AC9-transfected cells were stimulated with
100 nM isoproterenol in the presence of transfected Gαs. NKY80 was used as a control.
B. Stimulation of the transfected cells with the above mentioned drugs caused a marked
increase in cAMP accumulation when compared to the same stimulation in the venus
transfected control cells. All data shown represent the average and S.E.M. of at least three
independent experiments conducted in triplicate.
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4.3.4

Inhibition of forskolin- and Gαs-stimulated AC1 activity:
After determining the IC50 values of the compounds for inhibiting AC1 activity

and the selectivity profile against the other AC isoforms, W001 was tested in additional
assays employing different stimulation paradigms. The assays conducted included
inhibition of AC1 activation by forskolin and Gαs-coupled receptors. To induce
stimulation of AC1 through Gαs-coupled receptors, the β-adrenergic receptors that are
endogenously expressed in HEK cells were activated with isoproterenol. W001
significantly inhibited both the forskolin- and the isoproterenol-stimulated AC1 activity

Forskolin- or isoproterenol-stimulated
cAMP accumulation (% of vehicle)

(figure 4.4). In contrast, W001 had no effects in the wild type cells (figure 4.4).
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Figure 4.4 Inhibition of forskolin- and Gα s-stimulated AC1 activity by W001. HEKAC1 and HEK wild-type cells were treated with 30 µM W001 and stimulated with 300
nM forskolin or 10 µM isoproterenol (Gαs-coupled β-adrenergic receptors). All data
shown represent the average and S.E.M. of at least three independent experiments
conducted in duplicate. One-way analysis of variance (ANOVA) with Dunnett’s test was
carried out for statistical analyses. **p<0.01 versus vehicle. ****p<0.0001 versus
vehicle-treated cells.
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4.3.5

Inhibition of AC1 in in vitro assays and hippocampal homogenates:
The mechanism of action through which NB001 inhibits AC1 activity in cells has

been questioned because the compound failed to inhibit AC1 activity in in vitro assays
with cellular membranes that express AC1 (Brand et al., 2013). Therefore, in vitro assays
for AC1 inhibition were carried out using cellular membranes isolated from HEK cells
stably expressing AC1. AC1 activity in membranes was stimulated using purified
calmodulin or forskolin; and NKY80 was used as a control (Brand et al., 2013; Conley et
al., 2013). As shown in figure 4.5a, W001 significantly inhibited both the calmodulinand the forskolin-stimulated AC1 activity in the membranes.
The activity of W001 was further examined in a more physiologically relevant
model. Hippocampal homogenates prepared from C57BL/6 mice were stimulated with
purified calmodulin in the presence of 10 µM free Ca2+. Ca2+/calmodulin treatments
caused a significant increase in cAMP accumulation in these neuronal homogenates,
supporting the expression of calcium-stimulated ACs. Notably, treatment with W001
caused a significant inhibition of the Ca2+/calmodulin-stimulated cAMP accumulation in
the hippocampal homogenates (figure 4.5b). That the hippocampus expresses both AC1
and AC8 (as well as additional AC isoforms) at high levels (Ferguson and Storm, 2004;
Sadana and Dessauer, 2009), presumably explains the modest (but still significant)
inhibition of Ca2+/calmodulin-stimulated cAMP accumulation by W001 in comparison to
the non-selective AC inhibitor NKY80 (Brand et al., 2013).
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Figure 4.5: Inhibition of AC1 activity in cellular membranes and in hippocampal
homogenates. a) Cellular membranes from HEK-AC1 cells were isolated and cAMP
accumulation was stimulated with either 30 µM forskolin or 3 µM calmodulin in the
presence of 10 µM free Ca2+. b) Mouse hippocampal homogenates were stimulated with
3 µM calmodulin in the presence of 10 µM free Ca2+. All data shown represent the
average and S.E.M. of at least three independent experiments conducted in duplicate or
triplicate. One-way ANOVA with Dunnett’s test was carried out for statistical analyses.
**p<0.01, ***p<0.001, ****p<0.0001 all compared to vehicle-treated (i.e. in the absence
of inhibitor).

4.3.6

Effects of W001 on MOR signaling:
Agonists of the MOR have been used for their analgesic properties for thousands

of years. Nowadays, there are numerous MOR agonists that are clinically approved for
alleviating pain (Evans, 2004; Waldhoer et al., 2004; Williams et al., 2013). MOR
agonists are very effective at relieving pain, however, a number of side effects are also
associated with these ligands, including sedation, respiratory depression, nausea and
vomiting, and constipation (DeWire et al., 2013; Evans, 2004; Raehal et al., 2011). In
addition, the use of these drugs is limited by the onset of analgesic tolerance and physical
dependence (DeWire et al., 2013; Evans, 2004; Raehal et al., 2011).
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The MOR is a GPCR that couples to inhibitory G proteins (Gαi/o) to inhibit ACs,
moreover, the receptor also couples to β-arrestins, which can lead to additional signaling
or cause receptor desensitization (Raehal et al., 2011). Several studies suggest that
activation of G proteins by the MOR is associated with analgesia, while recruitment of βarrestins to the receptor is linked to the side effects of opioids (Bohn et al., 2004; Bohn et
al., 2000; Bohn et al., 1999; DeWire et al., 2013; Raehal et al., 2005; Violin et al., 2014).
Even though it is generally thought that MOR activation of Gβγ is responsible for opioid
analgesia, the requirement of cAMP for neuronal adaptations linked to chronic pain (i.e.
LTP) suggests that inhibition of the ACs co-expressed with the MOR may lead to new
drugs to treat chronic pain that lack the side effects commonly associated with opioids.
The MOR and AC1 are co-expressed in areas of the central nervous system that
are linked to pain and nociception (i.e. dorsal horn of the spinal cord and ACC) (Corder
et al., 2013; Jones et al., 1991; Mansour et al., 1995; Mansour et al., 1988; Wei et al.,
2006; Xu et al., 2008; Zhuo, 2012). Thus, the effects of the selective AC1 inhibitor
(W001) on both acute and chronic MOR signaling were investigated. Our results suggest
that W001 has an additive effect on MOR-mediated inhibition of AC1 (figure 4.6a). In
contrast, W001 had no effects on recruitment of β-arrestins to the MOR (figure 4.6b).
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Figure 4.6 Effects of W001 on acute MOR signaling. A. Inhibition of A23187stimulated cAMP accumulation in HEK-AC1/MOR cells. Both W001 (W) and DAMGO
(D) inhibit cAMP accumulation. When combined, W001 and DAMGO cause an added
response that reflects the sum of the individual inhibition of those two compounds. B.
W001 has no effects on the recruitment of β-arrestin 2 to the MOR. W001 caused no
changes in basal or DAMGO-stimulated β-arrestin 2 recruitment to the MOR. The data
shown represent the average and S.E.M. of at least three independent experiments
conducted in duplicate. One-way ANOVA with Dunnett’s test was carried out for
statistical analyses. *p<0.05, ***p<0.001 compared to respective D+W column.

Chronic activation of the MOR leads to a cellular adaptive response termed
heterologous sensitization (Bohn et al., 2000; Clark et al., 2004; Watts and Neve, 2005).
Heterologous sensitization is characterized by a robust enhancement in the activity of
ACs (figure 4.7a) (Watts and Neve, 2005). This phenomenon has long been linked to
opioid dependence (Bohn et al., 2000; Corder et al., 2013; Sharma et al., 1975; Watts and
Neve, 2005). The effects of W001 on MOR-mediated sensitization of AC1 were
examined in two different paradigms. One in which W001 was added before activation of
the MOR (i.e. development of heterologous sensitization) and another that W001 was
added after activation of the MOR (i.e. expression of heterologous sensitization).
Notably, W001 dose-dependently inhibited both the development and the expression of
MOR-mediated sensitization of AC1 (figure 4.7b).
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Figure 4.7 Effects of W001 on chronic MOR signaling. a) Heterologous sensitization
of AC1 by the MOR was achieved by pre-treating the cells with 1 µM DAMGO for 2 h.
b) The effect of W001 on the development of DAMGO-stimulated heterologous
sensitization of AC1 was examined by treating the cells with W001 before DAMGO
sensitization. The effect of W001 on the expression of DAMGO-stimulated heterologous
sensitization of AC1 was examined by treating the cells with W001 after DAMGOinduced sensitization. The data shown represent the average and S.E.M. of at least three
independent experiments conducted in duplicate.

4.3.7

Analgesic properties of W001 in mice:
In order to determine if AC1 inhibition by W001 has analgesic properties, an

inflammatory pain mouse model was employed. As shown in figure 4.8a, intraplantar
injection of CFA to the hind paw of C57BL/6 mice induced inflammation and
hypersensitivity to Von Frey filaments. Notably, intrathecal injections with W001 at
doses as low as 0.25 µg caused a significant relief of CFA-induced inflammatory pain
(figure 4.8). Limited dose-response experiments were also conducted and revealed an
estimated EC50 value for analgesia equal to 0.27 µg (95% CI = 0.12 – 0.40 – n = 6)
(figure 4.8b).
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Figure 4.8 Analgesic properties of W001 in mice. A. On day 0, baseline (BL)
measurements of mechanical sensitivity of C57BL/6 mice to Von Frey filaments were
taken and inflammatory hypersensitivity was induced by injection of CFA to the
hindpaw. On day 1, inflammatory hypersensitivity was measured and intrathecal
injections with W001 (0.5 µg – n=6) or DAMGO (50 µg – n=6), but not saline (n=10)
caused a significant relief of CFA-induced inflammatory pain 10 min after injections. B.
Dose-response experiments with W001 (n=6 for each condition) revealed an estimated
EC50 value for analgesia equal to 0.27 µg (95% CI = 0.12 – 0.40 – n = 6). One-way
ANOVA with Tukey’s test was carried out for statistical analyses. *p<0.05, **p<0.01,
***p<0.001 all compared to the CFA-induced inflammatory hypersensitivity.
Experiments conducted by Doungkamol Alongkronrusmee and Richard M. van Rijn.

4.4

Discussion

Through the use of knockout animals, previous studies have indicated that
inhibitors of AC1 may be useful to treat chronic pain as well as opioid dependence (Li et
al., 2006; Vadakkan et al., 2006; Zachariou et al., 2008). However, there is only one
compound that inhibits AC1 activity with some selectivity (NB001) (Wang et al., 2011).
Moreover, it has been suggested that NB001 is not a direct inhibitor of AC1 (Brand et al.,
2013). Therefore, in the present study a drug library screen was carried out to identify
novel AC1 inhibitors. Our efforts resulted in the discovery of the most potent selective
AC1 inhibitor described to date (W001 – IC50 = 1.1 µM, 95% CI = 0.8 – 1.7 µM).
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Multiple types of models (i.e. HEK-AC1 and mouse hippocampal homogenates, as well
as cellular membranes) and stimulation paradigms (i.e. A23187, calmodulin, forskolin,
and Gαs-coupled receptor) were employed to confirm the activity of W001. We have
further examined the effects of W001 on signaling through the MOR, as well as
determined its ability to induce analgesia in a mouse inflammatory pain model.
The different regulatory properties and expression patterns of the AC isoforms
suggest that these proteins can become valuable drug targets. However, it has also been
suggested that non-selective inhibition of ACs can lead to serious side effects. For
instance, double knockout mice lacking both AC1 and AC8 present behaviors consistent
with severe memory impairments (Wong et al., 1999). Therefore, one main requirement
for the development of an AC1 inhibitor to treat chronic pain is that the compound must
be selective for AC1 versus AC8. While NB001 displays nearly 10-fold selectivity for
inhibition of AC1 versus AC8 (Wang et al., 2011), W001 did not display any inhibition
of AC8 at doses up to 30 µM, indicating that the compound is more than 30-fold selective
for inhibition of AC1 versus AC8. Further, W001 did not cause inhibition of AC2, AC3,
AC4, AC5, AC6, or AC9.
Even though NB001 inhibited AC1 activity in cell models; it was shown that the
compound did not inhibit AC1 in in vitro assays that were carried out with cellular
membranes (Brand et al., 2013; Wang et al., 2011). Those studies indicated that NB001 is
not a direct AC1 inhibitor and may act through a distinct mechanism to inhibit AC1
activity in intact cells (Brand et al., 2013). In order to obtain mechanistic insight on the
mode of action of W001, in vitro assays were carried out using cellular membranes from
HEK cells stably expressing AC1. In contrast to what was previously shown for NB001,
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W001 significantly inhibited both forskolin- and calmodulin-stimulated AC1 activity in
those assays. These results suggest that W001 likely acts through a mechanism that
involves membrane components to inhibit AC1 activity, which is consistent with a direct
interaction of W001 with AC1.
AC1 is co-expressed with the MOR in the dorsal horn of the spinal cord and in the
ACC (Corder et al., 2013; Jones et al., 1991; Mansour et al., 1995; Mansour et al., 1988;
Wei et al., 2006; Xu et al., 2008; Zhuo, 2012). Similar to numerous GPCRs, there are
several different signaling pathways activated by the MOR (Raehal et al., 2011; Violin et
al., 2014). The MOR couples to Gαi/o to inhibit ACs and can also lead to signaling events
through Gβγ subunits as well as β-arrestins (Luscher and Slesinger, 2010; Raehal et al.,
2011; Williams et al., 2013). A relatively recent field of research entitled GPCR
functional selectivity, or ligand bias, studies ligands that can selectively activate specific
signaling pathways downstream of a GPCR (Brust et al., 2015a; Urban et al., 2007a;
Whalen et al., 2011). Notably, several studies have suggested that activation of G
proteins by the MOR is linked to the therapeutic analgesia of opioids while activation of
β-arrestins is associated with most of the undesired side effects of these drugs (i.e.
tolerance, constipation, and respiratory depression) (Bohn et al., 2004; Bohn et al., 2000;
Bohn et al., 1999; Raehal et al., 2005). Accordingly, a ligand (TRV130 – now undergoing
clinical trials) that selectively activates G protein signaling over β-arrestin recruitment to
the MOR displayed enhanced analgesia with a robust reduction in the opioid-associated
side effects in comparison to morphine (DeWire et al., 2013; Soergel et al., 2014). Here
we have hypothesized that a type of functional selectivity could be achieved by directly
targeting proteins downstream of the MOR (i.e. by directly inhibiting AC1 only the
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outcome of Gαi/o activation will be observed). As expected, W001 and DAMGO
displayed additive effects for inhibition of AC1 when combined. Moreover, W001 had no
significant effects on β-arrestin recruitment to the MOR. These data suggest that W001
mimics the effects of Gαi/o activation by the MOR.
It has been previously suggested that part of the MOR-induced analgesia occurs
through a mechanism that involves Gβγ-mediated activation of GIRK (G protein-coupled
inwardly-rectifying potassium) channels (Luscher and Slesinger, 2010). Activation of
GIRK channels by the MOR causes hyperpolarization of neurons leading to a reduction
of pain perception (Luscher and Slesinger, 2010). However, knockout of GIRK channel
isoforms in mice causes only a reduction in the potency of opioid-induced analgesia, with
no change in the efficacy (Cruz et al., 2008; Mitrovic et al., 2003). Even though this may
be because other isoforms of GIRK channels are still expressed in those mice, it also
indicates that there may be additional mechanisms involved in MOR-mediated analgesia.
For instance, AC1 is also inhibited by Gβγ subunits (Cooper and Crossthwaite, 2006); in
addition, the development of chronic pain shares some cellular mechanistic features with
memory formation and maintenance, that is, strengthening of synapses through LTP
(Ferguson and Storm, 2004; Zhuo, 2012). It was previously shown that inhibition of AC1
activity blocks the induction of LTP in neurons from the dorsal horn of the spinal cord
and ACC, but not from the hippocampus (Wang et al., 2011). Notably, inhibition of AC1
activity with NB001 had no effects in a mouse model of contextual fear memory, which
is consistent with the absence of LTP inhibition in the hippocampus (Wang et al., 2012).
In thalamocortical synapses AC1-stimulated protein kinase A (PKA) activity is required
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for trafficking of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
receptors to synapses and, therefore, also to the development of synaptic plastic changes,
such as LTP and LTD (long-term depression) (Lu et al., 2003). The inhibition of AC1
likely causes a reduction in PKA-phosphorylated AMPA receptors that disrupts LTP in
the spinal cord and ACC, resulting in a reduction of chronic pain.
Activation of G proteins by the MOR is also linked to opioid dependence (Bohn
et al., 2000; Corder et al., 2013; Watts and Neve, 2005). Chronic activation of the MOR
leads to a cellular adaptive response termed heterologous sensitization (Watts and Neve,
2005). Heterologous sensitization has long been linked to opioid dependence and is
characterized by a marked increase in AC activity (Bohn et al., 2000; Sharma et al., 1975;
Watts and Neve, 2005). Notably, it has been shown that in AC1 knockout mice the
behaviors associated with morphine dependence are largely inhibited (Li et al., 2006;
Zachariou et al., 2008). That W001 inhibited both the development and the expression of
MOR-mediated heterologous sensitization of AC1, suggests that AC1 inhibitors can
suppress the cellular outcomes of chronic activation of the MOR, and may be useful to
prevent or treat opioid dependence. Perhaps a combination of an AC1 inhibitor with a G
protein biased ligand for the MOR will lead to enhanced analgesia in the absence of both
acute and chronic opioid side effects.
The activity of W001 was also measured in more physiologically relevant
contexts. First, mouse hippocampal homogenates were employed and W001 caused a
significant inhibition of the Ca2+/calmodulin-stimulated cAMP accumulation. The
significance of these results is that they strongly support the capability of W001
inhibiting endogenous AC1 in a neuronal population. The final measure of W001 activity
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was an in vivo assay that was carried out in order to determine the ability of the
compound to inhibit chronic pain. A mouse inflammatory pain model was employed, in
which intraplantar injection of CFA to the mouse’s hindpaw induced an intense
inflammatory reaction. Remarkably, following induction of inflammation, intrathecal
injections of W001 at doses as low as 0.25 µg induced significant relief of CFA-mediated
inflammatory pain. These results demonstrate that W001 is a potent analgesic agent and
also illustrate that inhibitors of AC1 can be useful for treating chronic pain. The studies
conducted herein corroborate the utility of ACs as potential drug targets. Further, we
have identified the most potent and selective small molecule AC1 inhibitor reported to
date, and this compound displays analgesic properties in an in vivo model of chronic pain.
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS

That nearly 36% of all FDA-approved drugs directly target GPCRs (Overington et
al., 2006; Rask-Andersen et al., 2011) illustrates the remarkable relevance of this family
of proteins for drug discovery and development. The appreciation that GPCRs can
activate multiple signaling pathways took GPCR drug discovery to a new level. A recent
burst of research focused on finding ligands that can selectively activate one signaling
pathway over another downstream of the same GPCR. These considerable efforts rely on
(1) the fact that GPCRs are such a relevant drug target and (2) the hypothesis that
functional selectivity can lead to safer and more effective drugs. TRV130, for example,
binds to the µ-opioid receptor and represents the first rationally designed biased ligand to
reach clinical trials (DeWire et al., 2013; Soergel et al., 2014). It is expected that TRV130
will have enhanced analgesia with reduced tolerance, constipation, and respiratory
depression in comparison to morphine (Violin et al., 2014).
We have shown in chapter 2 that perhaps there are already drugs in the market
that display functional selectivity. As suggested by our studies, aripiprazole (a drug
clinically used to treat schizophrenia) is a partial agonist for most signaling pathways
downstream of the dopamine D2 receptor, but appears to be an antagonist for Gβγ
activation. This unique mechanism of action of aripiprazole may explain the drug’s
improved clinical profile in comparison to the other classes of antipsychotic drugs, which
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are antagonists of all dopamine D2 receptor-mediated signaling events. Gβγ subunits
activate GIRK channels (Luscher and Slesinger, 2010); therefore, inhibition of Gβγ
subunits at striatal medium spiny neurons (MSNs) belonging to the indirect pathway
would facilitate LTP (Luscher and Slesinger, 2010; Morrison and Murray, 2009). Drugs
that promote LTD (or block LTP) in this specific population of neurons have propsychotic properties, while drugs that promote or facilitate LTP display antipsychotic
effects (Morrison and Murray, 2009). That aripiprazole still retains partial agonist activity
at the remaining signaling pathways downstream of the dopamine D2 receptor, suggests
that its off-target effects would be milder compared to drugs that antagonize all signaling
pathways. Recent studies indicate that partial agonism of β-arrestin and inhibition of Gαi/o
through the dopamine D2 receptor may result in antipsychotic activity with reduced
extrapyramidal symptoms (Allen et al., 2011; Chen et al., 2012). Unfortunately, the
effects of those compounds at Gβγ signaling effectors (e.g. AC2 or GIRK) were not
investigated. It would be of interest to determine the activity of such ligands at Gβγdependent pathways and also to examine the contribution of inhibition of Gαi/o versus
Gβγ signaling for antipsychotic activity.
Gβγ subunits can lead to multiple signaling outcomes, including potentiation of
adenylyl cyclase activity and activation of ion channels (Khan et al., 2013; Lin and
Smrcka, 2011). However, most of the research on dopamine D2 receptor-targeting
antipsychotic drugs has focused on Gαi/o or β-arrestin activation by the receptor. For
instance, analogs of aripiprazole were recently developed in an attempt to find ligands
that would display functional selectivity between Gαi/o and β-arrestin through the
dopamine D2 receptor (Chen et al., 2012). The ligands developed displayed diverse
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signaling profiles for those two signaling pathways, and included ligands that displayed
functional selectivity (Chen et al., 2012). One interesting and feasible approach to study
the roles of Gβγ subunits in antipsychotic activity would be to further characterize those
analogs of aripiprazole. In that study 44 aripiprazole analogs were developed that
presented diverse signaling profiles in assays measuring Gαi/o activation and β-arrestin
recruitment to the dopamine D2 receptor (Chen et al., 2012). Those compounds could be
further investigated for their abilities to induce Gβγ-dependent signaling. This approach
would likely identify the chemical moieties in aripiprazole that are linked to Gβγ
antagonism, and also has the potential of revealing compounds that have different levels
of bias against Gβγ signaling. The use of these compounds in animal models of
schizophrenia (see Allen et al. 2011 and Chen et al. 2012) may aid in determining the role
of Gβγ subunits in this mental disorder.
Another recent study used quantitative functional selectivity analyses to find
ligands that would display bias for Gαi/o activation in comparison to ERK
phosphorylation (Shonberg et al., 2013). That study developed a number of compounds
based on the structure of tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin-2(1H)yl)ethyl)cyclohexyl)carbamate, a potent dopamine D2 receptor partial agonist. Several
studies suggest that ERK phosphorylation by the dopamine D2 receptor is a signaling
outcome that is downstream of both Gαi/o and Gβγ subunits (Brust et al., 2015a; Oak et
al., 2001; Quan et al., 2008). Therefore, the compounds developed in that study are
expected to include ligands that display bias between G protein subunits. However, the
pharmacological characterization of those compounds is incomplete and provides
opportunities for additional studies. For instance, assays to measure Gβγ activation and β-
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arrestin recruitment could identify additional functionally selective compounds.
Furthermore, following pharmacological profiling of those compounds, their
physiological responses could be tested in mouse models of schizophrenia. It is
hypothesized that compounds that antagonize Gβγ signaling will display antipsychotic
activity (Brust et al., 2015b; Luscher and Slesinger, 2010; Morrison and Murray, 2009).
These biased ligands may lead to antipsychotic drugs that, as aripiprazole, have lower
tendencies of causing side effects, especially extrapyramidal symptoms.
The dopamine D2 receptor is also targeted in antiparkinsonian therapies. Agonists
of the dopamine D2 receptor are used to alleviate the symptoms of Parkinson’s disease
(Beaulieu and Gainetdinov, 2011). However, the utility of biased ligands for improved
Parkinson’s disease therapies that target the dopamine D2 receptor has not yet been
explored. Among the four compounds (i.e. bromocriptine, pramipexole, ropinirole, and
rotigotine) analyzed in chapter 3 that are currently clinically used for treating Parkinson’s
disease, rotigotine and bromocriptine appear to be biased for β-arrestin 2 recruitment in
comparison to Gαi/ activation and bromocriptine was significantly biased for Gβγ
activation in comparison to Gαi/o activation.
It seems that the best connection of functional selectivity at dopamine D2
receptors with improved Parkinson’s disease therapies comes form a study that showed
that overexpression of GRK6 in primate and rodent models of Parkinson’s disease
alleviates the dyskinesia caused by long-term L-DOPA treatment (Ahmed et al., 2010).
Conversely, knockdown of GRK6 in rats caused an increase in dyskinesia (Ahmed et al.,
2010). These findings suggest that β-arrestin recruitment to the dopamine D2 receptor
may be beneficial and alleviate one of the main side effects of long-term antiparkinsonian
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therapies that target this receptor. Heterologous sensitization by the dopamine D2 receptor
has also been linked to the side effects of long-term antiparkinsonian therapies,
specifically the wearing off of their therapeutic actions (Fuxe et al., 2007). Therefore, it
seems that a ligand that displays bias for β-arrestin recruitment especially in comparison
to heterologous sensitization may lead to better therapies for the symptoms of
Parkinson’s disease.
An active field of study in functional selectivity is on the methods for identifying
biased ligands. Recently, several quantitative and qualitative methods were developed
and employed to identify biased ligands (Kenakin and Christopoulos, 2013b). In chapter
3 the most commonly used methods were studied and employed to identify biased ligands
at the dopamine D2 receptor. We observed that the quantitative methods yielded similar
results in our model. Most of the more dramatic differences were between the sigma
comparison and the other two methods studied (i.e. equiactive comparison and
transduction coefficient). These differences appear to be linked to the use of radioligand
binding constants in the sigma comparison, which are not always reflective of the
functional data and may result in sub-optimal fitting of the Black and Leff equation.
We have also noticed that potency is the major defining factor in the quantitative
bias analyses, while efficacy appears to have a minor role. However, studies with animal
models to determine the contribution of potency and efficacy for the physiological effects
of functionally selective compounds still remain to be conducted. It seems that currently
the ideal GPCR to conduct those studies is the µ-opioid receptor. The physiological
outcomes of G protein activation and β-arrestin recruitment to the µ-opioid receptor have
been studied thoroughly in the last two decades (Bohn et al., 2004; Bohn et al., 2000;
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Bohn et al., 1999; DeWire et al., 2013; Raehal et al., 2011; Raehal et al., 2005; Violin et
al., 2014). It is now well established that activation of G proteins leads to analgesia while
recruitment of β-arrestin to the receptor causes respiratory depression, constipation, and
tolerance. Compounds that display changes in potency or efficacy in molecular assays
can be employed in behavioral assays to determine the relative contribution of these
pharmacological parameters for the physiological outcomes of pathway activation.
Even though the above-mentioned studies may enlighten how the relative
contribution of potency and efficacy should be weighted in the quantitative bias analyses,
it is also possible that these factors will differ for different GPCRs and different target
tissues. This becomes evident when receptor reserve is considered, which has been shown
to change the relative efficacy of partial agonists (Watts et al., 1995). An interesting
approach to overcome the effects of receptor reserve would be to employ primary tissue
or stem cells in functional selectivity studies. These may be the most accurate models for
estimating ligand bias, however, signal amplification and incubation time and
temperature may still cause inconsistencies (Kenakin, 2014b; Kenakin et al., 2012;
Pereira et al., 2014; Urban et al., 2007b).
Another characteristic of the quantitative bias analyses is that compounds that are
antagonists or inverse agonists cannot be analyzed. This feature automatically excludes a
multitude of ligands from the bias analyses, including those that are termed “biased by
definition” (i.e. compounds that are neutral antagonists for one signaling pathway and
agonists for another) (Rajagopal et al., 2011). Therefore, methods that incorporate ligands
that display antagonist or inverse agonist responses are desired. A method was recently
developed based on the transduction coefficient to more accurately measure functional
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selectivity of weak partial agonists (Stahl et al., 2015). This method uses the inhibitory
partial antagonist curves to accurately determine the ligand’s KA (Stahl et al., 2015) and
may represent the first step towards developing methods that are capable of analyzing
data from antagonists and inverse agonists. Further exploring this method using
antagonist curves in conjunction with Schild analyses may lead to quantitative bias
analyses that can accommodate data from antagonists and inverse agonists (Stahl et al.,
2015).
The utility of bias analyses for providing mechanistic insight on the contribution
of immediate receptor effectors for the activation of the more complex signaling
pathways downstream of GPCRs was also examined. These studies suggested an
additional utility for biased ligands and methods of quantitatively measuring functional
selectivity. The hypothesis behind those studies was that if a ligand was biased for
pathway A vs. pathway B, it would also be biased for a signaling pathway that depends
on pathway A vs. pathway B. Our results support this hypothesis and suggest that the
quantitative bias analyses can be employed to yield mechanistic insight on the activation
of more complex signaling pathways downstream of GPCRs.
Targeting signaling components downstream of GPCRs may be an alternative
approach to achieve functional selectivity. For instance, activation of Gαi/o-coupled
receptors results in inhibition of adenylyl cyclases. Therefore, direct inhibition of
adenylyl cyclases can potentially mimic the outcomes of Gαi/o activation. In chapter 4 we
have shown that inhibition of AC1 with a small molecule mimics the cellular outcomes of
Gαi/o activation by the µ-opioid receptor with no effects on the recruitment of β-arrestins
to the receptor. These results support that the cellular actions of W001 (AC1 inhibitor)
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simulate the effects of a biased ligand that would selectively activate Gαi/o downstream
of the µ-opioid receptor. Furthermore, these studies suggested a new dimension in
functional selectivity. We suggest that a compound that interacts with a downstream
effector of a GPCR can be used alone to mimic functional selectivity or even in
combination with unbiased or biased ligands to yield specific cellular and physiological
outcomes.
Adenylyl cyclases are enzymes that are modulated by GPCRs. Moreover, due to
their regulatory properties, adenylyl cyclase isoforms can also be modulated by ion
channels and protein kinases (Cooper and Crossthwaite, 2006). The different regulatory
properties and expression patterns of the adenylyl cyclase isoforms suggest that these
proteins can become valuable drug targets. There are several studies employing knockout
animals that suggest that inhibitors of AC1 may be useful to treat chronic pain as well as
opioid dependence (Li et al., 2006; Vadakkan et al., 2006; Zachariou et al., 2008).
However, it has also been suggested that non-selective inhibition of ACs can lead to
serious side effects. For example, double knockout mice lacking both AC1 and AC8
present behaviors consistent with memory impairments (Wong et al., 1999). In chapter 4
a drug library screen was carried out to identify novel AC1 inhibitors. Our efforts
resulted in the discovery of the most potent selective small molecule AC1 inhibitor
described to date (W001 – IC50 = 1.1 µM, 95% CI = 0.8 – 1.7 µM). Further, W001
displayed analgesic effects in a mouse model of inflammatory pain. These studies
illustrate the relevance and potential of adenylyl cyclases as drug targets.
As shown in chapter 4, the drug screen conducted identified 35 compounds that
inhibited AC1 activity with high efficacy. Follow-up assays with a subset of those hit
!
!

160
!
compounds indicated that while some compounds were selective for AC1, there were
also compounds that inhibited adenylyl cyclase isoforms non-selectively. The chemical
structures of the compounds identified were diverse and provide opportunities for
medicinal chemistry studies. Chemical modifications on the core structure of the
compounds identified may improve their potency and selectivity. These studies may
identify the chemical groups of those compounds that are linked to adenylyl cyclase
inhibition and also explore the chemical requirements for selective inhibition of different
adenylyl cyclase isoforms.
We have also explored a mouse model of inflammatory pain to demonstrate the
potential of W001 as an analgesic drug. Future behavioral studies should focus on
determining the possible side effects of W001. Because AC1 is highly expressed in the
hippocampus, animal models that examine learning and memory would be ideal. Assays
such as the conventional Morris water maze and the novel object recognition could aid in
defining the effects that W001 on learning and memory. Further, contextual learning and
passive avoidance tests may serve as platforms to determine the effects of AC1 inhibition
in long-term memory (Wong et al., 1999). That a small molecule that inhibits AC1
activity (NB001) did not inhibit LTP in the hippocampus and had no effects in a mouse
model of contextual fear memory (Wang et al., 2011), suggests that selective AC1
inhibitors would not cause significant memory impairments. However, additional
behavioral assays to examine the effects of small molecule inhibitors of AC1 on learning
and memory should be conducted.
Additional behavioral assays can also enlighten the potential of W001 to treat
opioid dependence. It was shown that in AC1 knockout mice the behaviors associated

!
!

161
!
with morphine dependence are largely inhibited (Li et al., 2006; Zachariou et al., 2008).
Those same morphine treatment paradigms and behavioral assays could be conducted in
the presence of W001 in wild type mice to determine the potential of this compound for
treating opioid dependence. In addition to the behavioral assays, pharmacokinetic studies
could provide substantial support to taking these ligands to clinical trials. Ultimately, the
pharmacology of W001 could be further improved, resulting in an even more potent
inhibitor of AC1 that can be used to treat chronic pain in the absence of the side effects
commonly associated with opioids.
Drugs that target GPCRs have been used for thousands of years. The possibility
that functional selectivity can improve the current therapies that target this family of
receptors has added another level of complexity to the molecular pharmacology of the
compounds that target GPCRs. Moreover, proteins that are downstream effectors of
GPCRs, such as adenylyl cyclases, can also become attractive drug targets. The studies
presented herein embodied three levels of research in GPCR signaling: first by providing
mechanist insight on a clinically used antipsychotic drug (i.e. aripiprazole) that targets
GPCRs and is superior to other classes of antipsychotic drugs; second by studying and
comparing the different methods to measure ligand bias and determining their utility in
more basic GPCR research; and third by identifying novel small molecule inhibitors of
AC1, which can potentially induce functional selectivity and be used as analgesic drugs.
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